<html lang="en" class="pb-page js" data-request-id="94d6670fb4c0f1da-SJC"><head data-pb-dropzone="head"><style type="text/css" nonce="94d6670fb4c0f1da-SJC">@font-face {font-family: "Source Sans Pro";src: url(https://consent.trustarc.com/get?name=SourceSansPro-Regular.ttf) format("truetype"),url(https://consent.trustarc.com/get?name=SourceSansPro-Regular.woff) format("woff"),url(https://consent.trustarc.com/get?name=SourceSansPro-Regular.otf) format("opentype"),url(https://consent.trustarc.com/get?name=SourceSansPro-Regular.eot) format("embedded-opentype");}.truste_cursor_pointer {cursor: pointer;}.truste_border_none {border: none;}.truste_accessible_link {font-family: "Source Sans Pro", sans-serif;color: #1D4ED8;font-size: 14px;font-weight: 600;text-decoration: underline;}.truste_accessible_link:hover {color: #1D4ED8;text-decoration: none !important;}.truste_accessible_link:focus-visible {outline: none;border-radius: 4px;box-shadow: 0 0 0 1px #FFFFFF, 0 0 0 4px #3699F1;}</style><script src="https://ssl-cdn.janraincapture.com/widget_data/flow.js:7h8bznq6j7bvyvzqcrwvyp8dfb:en-US:20240514181256512029:standard" type="text/javascript"></script><script src="https://cssjs.nejm.org/akamai/capture:login" type="text/javascript"></script><script src="https://ssl-widget-cdn.rpxnow.com/translations/login/en-US" type="text/javascript"></script><script type="text/javascript" id="janrainAuthWidget" src="https://cssjs.nejm.org/akamai/mms-prod.js"></script><script type="text/javascript" src="https://www.nejm.org/wlmO44FEqHJL9ZjVy1hdGsSxrpb6fAclKrOmT1lkfi_f9f8shujAoZASu68niJzWb1aLhbyQSozt_3SaLv7Jjw=="></script>
            

<meta charset="UTF-8">






    
        
            
        
    
        
            
        
    
        
            
        
    
        
            
        
    
        
    
        
    
        
            
                
                
<title>REGN-COV2, a Neutralizing Antibody Cocktail, in Outpatients with Covid-19 | New England Journal of Medicine</title>





                
            
        
    







    
        
            
        
    
        
            
        
    
        
            
                
                



                
            
        
    
        
            
        
    
        
    
        
    
        
            
        
    











    








    

    
    

    
    
    
    
        
            
                <link rel="stylesheet" type="text/css" href="/wro/1125813~article-metrics.css">
            
            
            
        
    

    
    
        
            <link rel="icon" href="/products/mms-nextgen/mms/releasedAssets/images/favicon/fav_nejm_1-994b0160d1eb33dc79517ef0295aab1b.ico" type="image/x-icon">
        
        
            <link rel="icon" href="/products/mms-nextgen/mms/releasedAssets/images/favicon/fav_16-4aa032aa775940f725817b7ff42f0e2c.png" type="image/png" sizes="16x16">
        
        
            <link rel="icon" href="/products/mms-nextgen/mms/releasedAssets/images/favicon/fav_32-0a94fa44823476ffa0bb15bdb320fb34.png" type="image/png" sizes="32x32">
        
        
            <link rel="apple-touch-icon" href="/products/mms-nextgen/mms/releasedAssets/images/favicon/fav_152-d6c3522864a8e483996b7e9c132c901a.png" sizes="152x152">
        
        
            <link rel="apple-touch-icon" href="/products/mms-nextgen/mms/releasedAssets/images/favicon/fav_180-f2538afc53a365d4cd3f10ab73c56aad.png" sizes="180x180">
        
        
            <link rel="apple-touch-icon" href="/products/mms-nextgen/mms/releasedAssets/images/favicon/fav_167-8e888012bbdd31a00c3e54bc5b8ca5b6.png" sizes="167x167">
        
    

    
    
            <link rel="stylesheet" href="/products/mms-nextgen/mms/releasedAssets/css/build-5b89b331018866a4a965.css" media="all">
        <link rel="stylesheet" href="/products/mms-nextgen/mms/releasedAssets/css/print-5b89b331018866a4a965.css" media="print">
           <link rel="stylesheet" href="/products/mms-nextgen/mms/releasedAssets/css/build-article-5b89b331018866a4a965.css" media="all" id="article-style-sheet">
    
        <script nonce="94d6670fb4c0f1da-SJC">
        try {
            document.documentElement.classList.add('js');
        } catch (e) {
        }
    </script>
     
    

















    
        
            
                
                
                
                    
                    <!-- TrustArc Scripts -->
<script async="async" src="https://consent.trustarc.com/notice?domain=nejm.com&amp;c=teconsent&amp;js=nj&amp;noticeType=bb&amp;gtm=1&amp;text=true&amp;pcookie" crossorigin="" id="truste_0.5944638994102872"></script>
<script src="https://consent.trustarc.com/autoblockasset/core.min.js?domain=nejm.com"></script>
<script src="https://consent.trustarc.com/autoblockoptout?domain=nejm.com"></script>
<!-- /TrustArc Scripts -->
<!-- BlueConic Scripts -->
<script src="https://bc.nejm.org/script.js"></script>
    <!-- /BlueConic Scripts -->
<!-- Printing Meta Tags -->
    <meta name="articleType" content="Original Article">
<meta name="Specialties" content="Infectious Disease">
<meta name="topics" content="Viral Infections|Coronavirus">
<meta name="articleCategory" content="Research"><script type="text/javascript">var mmsData = {"access":{"isFreeCountry":"n"},"ad":{"category":"article"},"imageChallenge":{"id":null},"article":{"doi":"10.1056/NEJMoa2035002","title":"REGN-COV2, a Neutralizing Antibody Cocktail, in Outpatients with Covid-19","category":"Research","type":"Original Article","topics":"Viral Infections|Coronavirus","specialties":"Infectious Disease","seriesTitle":"","viewType":"Full","age":"2Years-1990","issueDate":"2021-01-21T00:00Z","isFree":"y","broadTopics":"","perspectiveTopics":"","granularTopics":"","methodologicalArea":"","isOnlineFirst":"n","isCurrentIssue":"n","metaTags":"\u003cmeta name\u003d\"articleType\" content\u003d\"Original Article\"/\u003e\n\u003cmeta name\u003d\"Specialties\" content\u003d\"Infectious Disease\"/\u003e\n\u003cmeta name\u003d\"topics\" content\u003d\"Viral Infections|Coronavirus\"/\u003e\n\u003cmeta name\u003d\"articleCategory\" content\u003d\"Research\"/\u003e"},"page":{"activity":"showFullText","url":"www.nejm.org/doi/full/10.1056/NEJMoa2035002","viewType":"desktop","journal":"NEJM"},"user":{"ucid":null,"audienceSegment":null,"specialtyGroupCode":null,"meterCountRemaining":null,"totalMeterCount":null},"object":[]};</script>
    <script type="text/javascript">var mmsDataAdd = {"user":{"customerType":"null","accessInstitutionID":"null"}};</script>
    <!-- Prehiding snippet for Adobe Target with asynchronous Launch deployment -->
    <!-- placeholder id=null, description=Adobe-Target-Prehiding-Snippet --><!--
  Adobe Target - Prehiding Snippet
  v2.0.0
-->
<script nonce="94d6670fb4c0f1da-SJC">
function tgtNoFlicker(e,n,t,o,i,c,l,r){function d(){return n.getElementsByTagName("head")[0]}function a(e,t){if(e){var o=n.getElementById(t);o&&e.removeChild(o)}}function f(e,o){!function(e,t,o){if(e){var i=n.createElement("style");i.id=t,i.innerHTML=o,e.appendChild(i)}}(d(),t,e),setTimeout(function(){a(d(),t)},o)}var m;n.location.href.indexOf(c)>-1?f(l,r):f(o,i),n.location.href.indexOf("mboxDisable")>-1?(a(d(),t),console.log("[TARGET] - Disabled, removing prehiding style")):(m=function(e){e&&(a(d(),t),console.log("[TARGET] - Blocked, removing prehiding style"))},fetch("//cdn.tt.omtrdc.net/cdn/target-vec.js",{method:"HEAD",mode:"no-cors"}).then(e=>m(!1)).catch(e=>m(!0)))}

tgtNoFlicker(window, document, 'at-body-style', 'div[data-location-name="Anonymous Module"], div[data-location-name="Anonymous Banner"], main > div.page-body > div > div > div > div.col-md-2-3.o-col.o-col--primary > div[class*="u-hide"], main > div.page-body > div > div > div > div.col-md-1-3.o-col.o-col--secondary > aside, header > h1#mainContent, a.m-article__link[href*="/10.1056/NEJMoa2116747"] > span.m-article__blurb > p, li.g-nejm-group__user-tool-secondary {opacity: 0 !important}', 3000);

tgtNoFlicker(window, document, 'at-mbox-style', '.N-ad-global-top-right, #N-ad-myNEJM-contextual-top, .N-ad-recentArticles, #N-ad-article-rightRail-1, #N-ad-siteWide-rightRail-1, #N-ad-imageChallenge-rightRail-2 {opacity: 0 !important}', 3000);
</script><!-- /Prehiding snippet for Adobe Target with asynchronous Launch deployment -->
    <!-- Launch Header Embed Code -->
    <script src="//assets.adobedtm.com/launch-ENcd6450fae3ae4870becbe6a2b01ab2e1.min.js" async="" type="ta-blocked" data-ta-blocked="1"></script>
    <!-- /Launch Header Embed Code -->

                    
                
            
        
    
        
            
                
                
                
                    
                    <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/"><meta name="citation_journal_title" content="New England Journal of Medicine"><meta name="dc.Title" content="REGN-COV2, a Neutralizing Antibody Cocktail, in Outpatients with Covid-19"><meta name="dc.Creator" content="David M. Weinreich"><meta name="dc.Creator" content="Sumathi Sivapalasingam"><meta name="dc.Creator" content="Thomas Norton"><meta name="dc.Creator" content="Shazia Ali"><meta name="dc.Creator" content="Haitao Gao"><meta name="dc.Creator" content="Rafia Bhore"><meta name="dc.Creator" content="Bret J. Musser"><meta name="dc.Creator" content="Yuhwen Soo"><meta name="dc.Creator" content="Diana Rofail"><meta name="dc.Creator" content="Joseph Im"><meta name="dc.Creator" content="Christina Perry"><meta name="dc.Creator" content="Cynthia Pan"><meta name="dc.Creator" content="Romana Hosain"><meta name="dc.Creator" content="Adnan Mahmood"><meta name="dc.Creator" content="John D. Davis"><meta name="dc.Creator" content="Kenneth C. Turner"><meta name="dc.Creator" content="Andrea T. Hooper"><meta name="dc.Creator" content="Jennifer D. Hamilton"><meta name="dc.Creator" content="Alina Baum"><meta name="dc.Creator" content="Christos A. Kyratsous"><meta name="dc.Creator" content="Yunji Kim"><meta name="dc.Creator" content="Amanda Cook"><meta name="dc.Creator" content="Wendy Kampman"><meta name="dc.Creator" content="Anita Kohli"><meta name="dc.Creator" content="Yessica Sachdeva"><meta name="dc.Creator" content="Ximena Graber"><meta name="dc.Creator" content="Bari Kowal"><meta name="dc.Creator" content="Thomas DiCioccio"><meta name="dc.Creator" content="Neil Stahl"><meta name="dc.Creator" content="Leah Lipsich"><meta name="dc.Creator" content="Ned Braunstein"><meta name="dc.Creator" content="Gary Herman"><meta name="dc.Creator" content="George D. Yancopoulos"><meta name="dc.Description" content="Recent data suggest that complications and death from coronavirus disease 2019 (Covid-19) may be related to high viral loads.In this ongoing, double-blind, phase 1–3 trial involving nonhospitalized..."><meta name="Description" content="Recent data suggest that complications and death from coronavirus disease 2019 (Covid-19) may be related to high viral loads.In this ongoing, double-blind, phase 1–3 trial involving nonhospitalized..."><meta name="dc.Publisher" content="Massachusetts Medical Society"><meta name="dc.Date" scheme="WTN8601" content="2021-01-21"><meta name="dc.Type" content="research-article"><meta name="dc.Format" content="text/HTML"><meta name="dc.Identifier" scheme="doi" content="10.1056/NEJMoa2035002"><meta name="dc.Identifier" scheme="publisher-id" content="NJ202101213840308"><meta name="dc.Language" content="EN"><meta name="dc.Relation" content="10.1056/NEJMoa2029849"><meta name="dc.Relation" content="10.1056/NEJMe2034495"><meta name="dc.Relation" content="YXQYoa2035002"><meta name="dc.Coverage" content="world"><meta name="dc.Rights" content="Copyright © 2020 Massachusetts Medical Society. All rights reserved.">




<link rel="meta" type="application/atom+xml" href="https://doi.org/10.1056%2FNEJMoa2035002">
<link rel="meta" type="application/rdf+json" href="https://doi.org/10.1056%2FNEJMoa2035002">
<link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1056%2FNEJMoa2035002">


                    
                
            
        
    
        
            
                
                
                
                
                
            
        
    
        
            
                
                
                
                    
                    





<meta name="robots" content="noarchive">





    





    
    
        
        <meta name="twitter:title" content="REGN-COV2, a Neutralizing Antibody Cocktail, in Outpatients with Covid-19 | NEJM">
        <meta property="og:title" content="REGN-COV2, a Neutralizing Antibody Cocktail, in Outpatients with Covid-19 | NEJM">
    


    <meta property="og:type" content="article">


    
    
        <meta property="og:url" content="https://www.nejm.org/doi/full/10.1056/NEJMoa2035002">
    
    


    
    
        <meta property="og:image" content="https://www.nejm.org/cms/asset/4eef3f7d-a00a-46f4-9759-44174e57e4cc/nejmoa2035002_f1.jpg">
        <meta name="twitter:image" content="https://www.nejm.org/cms/asset/4eef3f7d-a00a-46f4-9759-44174e57e4cc/nejmoa2035002_f1.jpg">
    



    <meta property="og:site_name" content="The New England Journal of Medicine">


    
    
        
        <meta property="og:description" content="Recent data suggest that complications and death from coronavirus disease 2019 (Covid-19)
may be related to high viral loads. In this ongoing, double-blind, phase 1–3 trial
involving nonhospitalize...">
        <meta name="twitter:description" content="Recent data suggest that complications and death from coronavirus disease 2019 (Covid-19)
may be related to high viral loads. In this ongoing, double-blind, phase 1–3 trial
involving nonhospitalize...">
    


    
    
        <meta property="og:image:width" content="2640">
    


    
    
        <meta property="og:image:height" content="2120">
    


    <meta name="twitter:card" content="summary">


    <meta name="twitter:site" content="@NEJM">


<meta name="viewport" content="width=device-width,initial-scale=1"><meta name="citation_fulltext_world_readable" content="">
    <meta name="publication_doi" content="10.1056/NEJMoa2035002">


    















                    
                
            
        
    
        
    
        
    
        
            
                
                
                
                
                
            
        
    




<meta name="format-detection" content="telephone=no">

<meta http-equiv="X-UA-Compatible" content="IE=edge">
    




    
        
        
        <link rel="canonical" href="https://www.nejm.org/doi/full/10.1056/NEJMoa2035002">
    
    







<meta name="pbContext" content=";requestedJournal:journal:nejm;page:string:Article/Chapter View;ctype:string:Journal Content;article:article:doi\:10.1056/NEJMoa2035002;issue:issue:doi\:10.1056/nejm_2021.384.issue-3;wgroup:string:MMS NextGen Website Group;pageGroup:string:Publication Pages;subPage:string:Full Text;website:website:mms-site;journal:journal:nejms">
        <script id="altmetric-embed-js" src="https://d1bxh8uas1mnw7.cloudfront.net/assets/altmetric_badges-288192a491f0ad9cc434f05ea175659426f5ab0cfd6befb3f3592f96bb90b0d1.js"></script><link rel="stylesheet" type="text/css" href="https://cssjs.nejm.org/custreg-933-8e181dff8b36ea01dc4c.css"><link rel="stylesheet" type="text/css" href="https://cssjs.nejm.org/custreg-34-6ea546d794fb7a1cea52.css"><link rel="stylesheet" type="text/css" href="https://cssjs.nejm.org/custreg-743-ddd329e1530654ec0846.css"><link rel="stylesheet" type="text/css" href="https://cssjs.nejm.org/custreg-305-9eee37798fdfe5196307.css"><link rel="stylesheet" type="text/css" href="https://cssjs.nejm.org/custreg-388-bb098c62445f518c0b46.css"><link rel="stylesheet" type="text/css" href="https://cssjs.nejm.org/custreg-556-8e58ca05fb5497e541ef.css"><script charset="utf-8" src="https://www.nejm.org/products/mms-nextgen/mms/releasedAssets/js/0-dfd243c732a07d3608f6.js"></script><script charset="utf-8" src="https://www.nejm.org/products/mms-nextgen/mms/releasedAssets/js/7-10d355ba95f7ec1fddf2.js"></script><script charset="utf-8" src="https://www.nejm.org/products/mms-nextgen/mms/releasedAssets/js/11-04bf2a0da30146b4a5d0.js"></script><script src="https://static.addtoany.com/menu/modules/core.pt5ow5lr.js" type="module"></script><link rel="preconnect" href="https://use.typekit.net"><style type="text/css">.a2a_hide{display:none}.a2a_logo_color{background-color:#0166ff}.a2a_menu,.a2a_menu *{-moz-box-sizing:content-box;-webkit-box-sizing:content-box;box-sizing:content-box;float:none;margin:0;padding:0;position:static;height:auto;width:auto}.a2a_menu{border-radius:6px;display:none;direction:ltr;background:#FFF;font:16px sans-serif-light,HelveticaNeue-Light,"Helvetica Neue Light","Helvetica Neue",Arial,Helvetica,"Liberation Sans",sans-serif;color:#000;line-height:12px;border:1px solid #CCC;vertical-align:baseline;overflow:hidden}.a2a_mini{min-width:200px;position:absolute;width:300px;z-index:9999997}.a2a_overlay{display:none;background:#616c7deb;backdrop-filter:blur(4px);-webkit-backdrop-filter:blur(4px);position:fixed;top:0;right:0;left:0;bottom:0;z-index:9999998;-webkit-tap-highlight-color:transparent;transition:opacity .14s,backdrop-filter .14s}.a2a_full{background:#FFF;border:1px solid #FFF;box-shadow:#2a2a2a1a 0 0 20px 10px;height:auto;height:calc(320px);top:15%;left:50%;margin-left:-320px;position:fixed;text-align:center;width:640px;z-index:9999999;transition:transform .14s,opacity .14s}.a2a_full_footer,.a2a_full_header,.a2a_full_services{border:0;margin:0;padding:12px;box-sizing:border-box}.a2a_full_header{padding-bottom:8px}.a2a_full_services{height:280px;overflow-y:scroll;padding:0 12px;-webkit-overflow-scrolling:touch}.a2a_full_services .a2a_i{display:inline-block;float:none;width:181px;width:calc(33.334% - 18px)}div.a2a_full_footer{font-size:12px;text-align:center;padding:8px 14px}div.a2a_full_footer a,div.a2a_full_footer a:visited{display:inline;font-size:12px;line-height:14px;padding:8px 14px}div.a2a_full_footer a:focus,div.a2a_full_footer a:hover{background:0 0;border:0;color:#0166FF}div.a2a_full_footer a span.a2a_s_a2a,div.a2a_full_footer a span.a2a_w_a2a{background-size:14px;border-radius:3px;display:inline-block;height:14px;line-height:14px;margin:0 3px 0 0;vertical-align:top;width:14px}.a2a_modal{height:0;left:50%;margin-left:-320px;position:fixed;text-align:center;top:15%;width:640px;z-index:9999999;transition:transform .14s,opacity .14s;-webkit-tap-highlight-color:transparent}.a2a_modal_body{background:0 0;border:0;font:24px sans-serif-light,HelveticaNeue-Light,"Helvetica Neue Light","Helvetica Neue",Arial,Helvetica,"Liberation Sans",sans-serif;position:relative;height:auto;width:auto}.a2a_thanks{color:#fff;height:auto;margin-top:20px;width:auto}.a2a_thanks>div:first-child{margin:0 0 40px 0}.a2a_thanks div *{height:inherit}#a2a_copy_link{background:#FFF;border:1px solid #FFF;cursor:pointer;margin-top:15%}label.a2a_s_link#a2a_copy_link_icon,label.a2a_w_link#a2a_copy_link_icon{background-size:48px;border-radius:0;display:inline-block;height:48px;left:0;line-height:48px;margin:0 3px 0 0;position:absolute;vertical-align:top;width:48px}#a2a_modal input#a2a_copy_link_text{background-color:transparent;border:0;color:#2A2A2A;cursor:pointer;font:inherit;height:48px;left:62px;max-width:initial;min-height:auto;padding:0;position:relative;width:564px;width:calc(100% - 76px)}#a2a_copy_link_copied{background-color:#0166ff;color:#fff;display:none;font:inherit;font-size:16px;margin-top:1px;padding:3px 8px}@media (forced-colors:active){.a2a_color_buttons a,.a2a_svg{forced-color-adjust:none}}@media (prefers-color-scheme:dark){.a2a_menu a,.a2a_menu a.a2a_i,.a2a_menu a.a2a_i:visited,.a2a_menu a.a2a_more,i.a2a_i{border-color:#2a2a2a!important;color:#fff!important}.a2a_menu a.a2a_i:active,.a2a_menu a.a2a_i:focus,.a2a_menu a.a2a_i:hover,.a2a_menu a.a2a_more:active,.a2a_menu a.a2a_more:focus,.a2a_menu a.a2a_more:hover,.a2a_menu_find_container{border-color:#444!important;background-color:#444!important}.a2a_menu:not(.a2a_thanks){background-color:#2a2a2a;border-color:#2a2a2a}.a2a_menu_find{color:#fff!important}.a2a_menu label.a2a_s_find svg{background-color:transparent!important}.a2a_menu label.a2a_s_find svg path{fill:#fff!important}.a2a_full{box-shadow:#00000066 0 0 20px 10px}.a2a_overlay{background-color:#373737eb}}@media print{.a2a_floating_style,.a2a_menu,.a2a_overlay{visibility:hidden}}@keyframes a2aFadeIn{from{opacity:0}to{opacity:1}}.a2a_starting{opacity:0}.a2a_starting.a2a_full,.a2a_starting.a2a_modal{transform:scale(.8)}@media (max-width:639px){.a2a_full{border-radius:0;top:15%;left:0;margin-left:auto;width:100%}.a2a_modal{left:0;margin-left:10px;width:calc(100% - 20px)}}@media (min-width:318px) and (max-width:437px){.a2a_full .a2a_full_services .a2a_i{width:calc(50% - 18px)}}@media (max-width:317px){.a2a_full .a2a_full_services .a2a_i{width:calc(100% - 18px)}}@media (max-height:436px){.a2a_full{bottom:40px;height:auto;top:40px}}@media (max-height:550px){.a2a_modal{top:30px}}@media (max-height:360px){.a2a_modal{top:20px}.a2a_thanks>div:first-child{margin-bottom:20px}}.a2a_menu a{color:#0166FF;text-decoration:none;font:16px sans-serif-light,HelveticaNeue-Light,"Helvetica Neue Light","Helvetica Neue",Arial,Helvetica,"Liberation Sans",sans-serif;line-height:14px;height:auto;width:auto;outline:0}.a2a_menu a.a2a_i:visited,.a2a_menu a.a2a_more{color:#0166FF}.a2a_menu a.a2a_i:active,.a2a_menu a.a2a_i:focus,.a2a_menu a.a2a_i:hover,.a2a_menu a.a2a_more:active,.a2a_menu a.a2a_more:focus,.a2a_menu a.a2a_more:hover{color:#2A2A2A;border-color:#EEE;border-style:solid;background-color:#EEE;text-decoration:none}.a2a_menu label.a2a_s_find{background-size:24px;height:24px;left:8px;pointer-events:auto;position:absolute;top:7px;width:24px}.a2a_menu label.a2a_s_find svg{background-color:#FFF}.a2a_menu label.a2a_s_find svg path{fill:#CCC}#a2a_menu_container{display:inline-block}.a2a_menu_find_container{border:1px solid #CCC;border-radius:6px;padding:2px 24px 2px 0;position:relative;text-align:left}.a2a_cols_container .a2a_col1{overflow-x:hidden;overflow-y:auto;-webkit-overflow-scrolling:touch}#a2a_modal input,#a2a_modal input[type=text],.a2a_menu input,.a2a_menu input[type=text]{display:block;background-image:none;box-shadow:none;line-height:100%;margin:0;outline:0;overflow:hidden;padding:0;-moz-box-shadow:none;-webkit-box-shadow:none;-webkit-appearance:none}#a2afeed_find_container input,#a2afeed_find_container input[type=text],#a2apage_find_container input,#a2apage_find_container input[type=text]{background-color:transparent;border:0;box-sizing:content-box;color:#2A2A2A;float:none;font:inherit;font-size:16px;height:28px;line-height:20px;left:38px;outline:0;margin:0;max-width:initial;min-height:initial;padding:2px 0;position:relative;width:99%}.a2a_clear{clear:both}.a2a_svg{background-repeat:no-repeat;display:block;overflow:hidden;height:32px;line-height:32px;padding:0;pointer-events:none;width:32px}.a2a_svg svg{background-repeat:no-repeat;background-position:50% 50%;border:none;display:block;left:0;margin:0 auto;overflow:hidden;padding:0;position:relative;top:0;width:auto;height:auto}a.a2a_i,i.a2a_i{display:block;float:left;border:1px solid #FFF;line-height:24px;padding:6px 8px;text-align:left;white-space:nowrap;overflow:hidden;text-overflow:ellipsis;width:132px}a.a2a_i span,a.a2a_more span{display:inline-block;overflow:hidden;vertical-align:top}a.a2a_i .a2a_svg{margin:0 6px 0 0}a.a2a_i .a2a_svg,a.a2a_more .a2a_svg{background-size:24px;height:24px;line-height:24px;width:24px}a.a2a_sss:hover{border-left:1px solid #CCC}a.a2a_more{border-bottom:1px solid #FFF;border-left:0;border-right:0;line-height:24px;margin:6px 0 0;padding:6px;-webkit-touch-callout:none}a.a2a_more span{height:24px;margin:0 6px 0 0}.a2a_kit .a2a_svg{background-repeat:repeat}.a2a_default_style a:empty,.a2a_flex_style a:empty,.a2a_floating_style a:empty,.a2a_overlay_style a:empty{display:none}.a2a_color_buttons a,.a2a_floating_style a{text-decoration:none}.a2a_default_style:not(.a2a_flex_style) a{float:left;line-height:16px;padding:0 2px}.a2a_default_style a:hover .a2a_svg,.a2a_floating_style a:hover .a2a_svg,.a2a_overlay_style a:hover .a2a_svg svg{opacity:.7}.a2a_overlay_style.a2a_default_style a:hover .a2a_svg{opacity:1}.a2a_default_style .a2a_count,.a2a_default_style .a2a_svg,.a2a_floating_style .a2a_svg,.a2a_menu .a2a_svg,.a2a_vertical_style .a2a_count,.a2a_vertical_style .a2a_svg{border-radius:4px}.a2a_default_style .a2a_counter img,.a2a_default_style .a2a_dd,.a2a_default_style .a2a_svg{float:left}.a2a_default_style .a2a_img_text{margin-right:4px}.a2a_default_style .a2a_divider{border-left:1px solid #000;display:inline;float:left;height:16px;line-height:16px;margin:0 5px}.a2a_kit a{cursor:pointer;transition:none}.a2a_floating_style{background-color:#fff;border-radius:6px;position:fixed;z-index:9999995}.a2a_overlay_style{z-index:2147483647}.a2a_floating_style,.a2a_overlay_style{animation:a2aFadeIn .2s ease-in;padding:4px}.a2a_vertical_style:not(.a2a_flex_style) a{clear:left;display:block;overflow:hidden;padding:4px}.a2a_floating_style.a2a_default_style{bottom:0}.a2a_floating_style.a2a_default_style a,.a2a_overlay_style.a2a_default_style a{padding:4px}.a2a_count{background-color:#fff;border:1px solid #ccc;box-sizing:border-box;color:#2a2a2a;display:block;float:left;font:12px Arial,Helvetica,sans-serif;height:16px;margin-left:4px;position:relative;text-align:center;width:50px}.a2a_count:after,.a2a_count:before{border:solid transparent;border-width:4px 4px 4px 0;content:"";height:0;left:0;line-height:0;margin:-4px 0 0 -4px;position:absolute;top:50%;width:0}.a2a_count:before{border-right-color:#ccc}.a2a_count:after{border-right-color:#fff;margin-left:-3px}.a2a_count span{animation:a2aFadeIn .14s ease-in}.a2a_vertical_style .a2a_counter img{display:block}.a2a_vertical_style .a2a_count{float:none;margin-left:0;margin-top:6px}.a2a_vertical_style .a2a_count:after,.a2a_vertical_style .a2a_count:before{border:solid transparent;border-width:0 4px 4px 4px;content:"";height:0;left:50%;line-height:0;margin:-4px 0 0 -4px;position:absolute;top:0;width:0}.a2a_vertical_style .a2a_count:before{border-bottom-color:#ccc}.a2a_vertical_style .a2a_count:after{border-bottom-color:#fff;margin-top:-3px}.a2a_color_buttons .a2a_count,.a2a_color_buttons .a2a_count:after,.a2a_color_buttons .a2a_count:before,.a2a_color_buttons.a2a_vertical_style .a2a_count:after,.a2a_color_buttons.a2a_vertical_style .a2a_count:before{background-color:transparent;border:none;color:#fff;float:none;width:auto}.a2a_color_buttons.a2a_vertical_style .a2a_count{margin-top:0}.a2a_flex_style{display:flex;align-items:flex-start;gap:0}.a2a_default_style.a2a_flex_style{left:0;right:0;width:100%}.a2a_vertical_style.a2a_flex_style{flex-direction:column;top:0;bottom:0}.a2a_flex_style a{display:flex;justify-content:center;flex:1;padding:4px}.a2a_flex_style.a2a_vertical_style a{flex-direction:column}.a2a_floating_style.a2a_color_buttons,.a2a_floating_style.a2a_flex_style{border-radius:0;padding:0}.a2a_floating_style.a2a_default_style.a2a_flex_style{bottom:0}.a2a_kit.a2a_flex_style .a2a_counter img,.a2a_kit.a2a_flex_style .a2a_dd,.a2a_kit.a2a_flex_style .a2a_svg{float:none}.a2a_nowrap{white-space:nowrap}.a2a_note{margin:0 auto;padding:9px;font-size:12px;text-align:center}.a2a_note .a2a_note_note{margin:0;color:#2A2A2A}.a2a_wide a{display:block;margin-top:3px;border-top:1px solid #EEE;text-align:center}.a2a_label{position:absolute!important;clip-path:polygon(0px 0px,0px 0px,0px 0px);-webkit-clip-path:polygon(0px 0px,0px 0px,0px 0px);overflow:hidden;height:1px;width:1px}.a2a_kit,.a2a_menu,.a2a_modal,.a2a_overlay{-ms-touch-action:manipulation;touch-action:manipulation;outline:0}.a2a_dd{-webkit-user-drag:none}.a2a_dd img{border:0}.a2a_button_facebook_like iframe{max-width:none}</style><link rel="stylesheet" href="https://quilt-cdn.janrain.com/HEAD/providers.css" type="text/css"><meta http-equiv="P3P" content="CP=&quot;NOI DSP ADM OUR IND OTC&quot;"><link id="altmetric-embed-css" rel="stylesheet" type="text/css" href="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed-59614f5c46b49b21eeef3bb28c4fb38d1e7069e8d014752fcb66e84942556802.css"></head>
    

    



    
        
        
        
            <body class="pb-ui website-mms-site loaded">
            






    
    
        





    
    
        
        
    
    
    







<input type="hidden" id="isRoMode" name="isRoMode" value="false">

        <div id="pb-page-content" data-ng-non-bindable="">
                
            <div data-pb-dropzone="main" data-pb-dropzone-name="Main">
                
                    
                        



        
        <header data-sticky="false" class="ng-header js_stickyAd"><a href="#mainContent" class="ng-skipToMainContent">Skip to main content</a><div class="ng-header_topAd"><div class="ng-header_topAd-content d-flex justify-content-center align-items-center">



        
        <div id="DTM_Position_Topbanner" class="ad">
 <!--emptycomment-->
</div>
</div></div><div class="ng-header_journal-navbar"><div class="ng-header_journal-navbar-content"><div class="container-fluid"><div class="row"><div class="ng-header_journal-navbar_left col-lg-8 col-sm-12 pr-lg-0 d-flex align-items-center"><div data-location="nejm_group_product_nav" class="ng-header_journalNavMenu">



        
        <nav data-location="nejm_group_product_nav" role="navigation" class="ng-journalNavMenu">
<ul class="ng-journalNavMenu_list">
<li class="ng-journalNavMenu_list-item"><a href="/" class="ng-journalNavMenu_mainLink active" aria-current="page" aria-label="The New England Journal of Medicine selected item"><span class="ng-journalNavMenu_mainLink-text d-lg-block d-none">The New England Journal of Medicine</span><span class="ng-journalNavMenu_mainLink-text d-lg-none d-block">NEJM</span></a></li>
<li class="ng-journalNavMenu_list-item"><a href="https://evidence.nejm.org/" class="ng-journalNavMenu_mainLink"><span class="ng-journalNavMenu_mainLink-text"><span class="ng-journalNavMenu_mainLink-text-firstWord">NEJM</span> Evidence</span></a></li>
<li class="ng-journalNavMenu_list-item"><a href="https://ai.nejm.org/" class="ng-journalNavMenu_mainLink"><span class="ng-journalNavMenu_mainLink-text"><span class="ng-journalNavMenu_mainLink-text-firstWord">NEJM</span> AI</span></a></li>
<li class="ng-journalNavMenu_list-item"><a href="https://catalyst.nejm.org/" class="ng-journalNavMenu_mainLink"><span class="ng-journalNavMenu_mainLink-text"><span class="ng-journalNavMenu_mainLink-text-firstWord">NEJM</span> Catalyst</span></a></li>
<li class="ng-journalNavMenu_list-item"><a href="https://www.jwatch.org/" class="ng-journalNavMenu_mainLink"><span class="ng-journalNavMenu_mainLink-text"><span class="ng-journalNavMenu_mainLink-text-firstWord">NEJM</span> Journal Watch</span></a></li>
</ul>
</nav>

</div></div><div class="ng-header_journal-navbar_right col-lg-4 pl-lg-0 d-none d-xl-flex align-items-center justify-content-end"><div class="ng-header_loginBar d-xl-flex align-items-lg-center">



        
        <div data-location="authstring_nav" class="ng-header_loginBar-menu"><span class="ng-simple-menu_mainLink-icon signIn newIcon-2"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#user2"></use></svg></span></span><span class="ng-header_loginBar-signIn"><a href="/sign-in?uri=/doi/full/10.1056/NEJMoa2035002" class="ng-header_loginBar-signIn-link">Sign In</a></span><span class="ng-header_loginBar-separator">|</span><span class="ng-header_loginBar-createAcc"><a href="/action/storeProxy?action=register&amp;promo=ONFLNRC1" class="ng-header_loginBar-createAcc-link ro-mode_disabled">Create Account</a></span></div><div data-location="authstring_nav" class="ng-header_loginBar-subscribe pl-xl-16"><a href="/action/storeProxy?action=subscribe&amp;promo=ONF4NRS1" class="ng-header_loginBar-subscribe-btn ng-btn_primary ro-mode_disabled">Subscribe</a></div>
</div></div></div></div></div></div><div class="ng-header_instBanner d-none d-lg-block"></div><div class="ng-header_logoBar"><div class="container-fluid"><div class="row"><div data-location="logo" class="ng-header_logoBar_left col-lg-4 col-6 d-flex align-items-center justify-content-start"><a href="/" title="The New England Journal of Medicine homepage" class="ng-header_logo-link"><img src="/specs/products/mms-nextgen/mms/releasedAssets/images/other-images/nejm-logo-166667e91992a5212bc723b03e45d39f.svg" alt="The New England Journal of Medicine homepage" width="366" height="58" class="ng-header_logo-image"></a></div><div class="ng-header_logoBar_right ng-header_navBar col-lg-8 col-sm-12 p-lg-0 align-items-center justify-content-end"><div class="ng-header_navBar-content"><div class="container-fluid"><div class="row"><div class="ng-header_instBanner-md col-12 d-block d-lg-none"></div><div class="ng-header_loginBar-md col-12 d-block d-xl-none">



        
        <div data-location="authstring_nav" class="ng-header_loginBar-menu"><span class="ng-simple-menu_mainLink-icon signIn newIcon-2"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#user2"></use></svg></span></span><span class="ng-header_loginBar-signIn"><a href="/sign-in?uri=/doi/full/10.1056/NEJMoa2035002" class="ng-header_loginBar-signIn-link">Sign In</a></span><span class="ng-header_loginBar-separator">|</span><span class="ng-header_loginBar-createAcc"><a href="/action/storeProxy?action=register&amp;promo=ONFLNRC1" class="ng-header_loginBar-createAcc-link ro-mode_disabled">Create Account</a></span></div><div data-location="authstring_nav" class="ng-header_loginBar-subscribe pl-xl-16"><a href="/action/storeProxy?action=subscribe&amp;promo=ONF4NRS1" class="ng-header_loginBar-subscribe-btn ng-btn_primary ro-mode_disabled">Subscribe</a></div>
</div><div class="ng-header_navBar_left col-lg-8 col-sm-12 d-flex align-items-center"><div class="ng-header_stickyLogo mr-32"><a href="/" title="The New England Journal of Medicine homepage" class="ng-header_stickyLogo-link"><img src="/specs/products/mms-nextgen/mms/releasedAssets/images/other-images/nejm-small-logo-070df7a3f4d8cfa2e71c3c45bb4b172f.svg" alt="The New England Journal of Medicine homepage" class="ng-header_stickyLogo-image"></a></div><div class="ng-header_mainMenu">









    
    
        <div data-widget-def="menuWidget" data-widget-id="97fb3983-db63-4b0b-97dd-d9bb7929fce1" data-location="main_nav">
        



        
        <nav class="ng-menu"><ul class="ng-menu_list ng-simple-menu"><li class="ng-menu_list-item ng-simple-menu_item hasChildren"><a href="/toc/nejm/current" class="ng-simple-menu_mainLink"><span class="ng-simple-menu_mainLink-text">current issue</span><span class="ng-simple-menu_mainLink-arrowIcon"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#arrows-down"></use></svg></span></span></a><div class="ng-simple-menu_dropblock"><div class="ng-simple-menu_dropblock-cont"><div class="ng-simple-menu_list"><ul class="ng-simple-menu_list-items"><li class="ng-simple-menu_list-item"><a href="/toc/nejm/current" class="ng-simple-menu_list-link">VIEW CURRENT ISSUE</a></li><li class="ng-simple-menu_list-item"><a href="/toc/nejm/recently-published" class="ng-simple-menu_list-link">BROWSE RECENTLY PUBLISHED</a></li><li class="ng-simple-menu_list-item"><a href="/loi/nejm" class="ng-simple-menu_list-link">BROWSE ALL ISSUES</a></li></ul></div></div></div></li><li class="ng-menu_list-item ng-simple-menu_item hasChildren"><a href="/medical-specialties" class="ng-simple-menu_mainLink"><span class="ng-simple-menu_mainLink-text">SPECIALTIES</span><span class="ng-simple-menu_mainLink-arrowIcon"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#arrows-down"></use></svg></span></span></a><div class="ng-simple-menu_dropblock"><div class="ng-simple-menu_dropblock-cont"><div class="ng-simple-menu_list"><ul class="ng-simple-menu_list-items"><li class="ng-simple-menu_list-item"><a href="/browse/specialty/cardiology" class="ng-simple-menu_list-link">Cardiology</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/clinical-medicine" class="ng-simple-menu_list-link">Clinical Medicine</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/endocrinology" class="ng-simple-menu_list-link">Endocrinology</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/gastroenterology" class="ng-simple-menu_list-link">Gastroenterology</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/hematology-oncology" class="ng-simple-menu_list-link">Hematology/Oncology</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/infectious-disease" class="ng-simple-menu_list-link">Infectious Disease</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/nephrology" class="ng-simple-menu_list-link">Nephrology</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/neurology-neurosurgery" class="ng-simple-menu_list-link">Neurology/Neurosurgery</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/obstetrics-gynecology" class="ng-simple-menu_list-link">Obstetrics/Gynecology</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/pediatrics" class="ng-simple-menu_list-link">Pediatrics</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/pulmonary-critical-care" class="ng-simple-menu_list-link">Pulmonary/Critical Care</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/surgery" class="ng-simple-menu_list-link">Surgery</a></li><li class="ng-simple-menu_list-item"><a href="/medical-specialties" class="ng-simple-menu_list-link">View All Specialties</a></li></ul></div></div></div></li><li class="ng-menu_list-item ng-simple-menu_item hasChildren"><a href="/topics" class="ng-simple-menu_mainLink"><span class="ng-simple-menu_mainLink-text">TOPICS</span><span class="ng-simple-menu_mainLink-arrowIcon"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#arrows-down"></use></svg></span></span></a><div class="ng-simple-menu_dropblock"><div class="ng-simple-menu_dropblock-cont"><div class="ng-simple-menu_list"><ul class="ng-simple-menu_list-items"><li class="ng-simple-menu_list-item"><a href="/ai-in-medicine" class="ng-simple-menu_list-link">AI in Medicine</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/climate-change" class="ng-simple-menu_list-link">Climate Change</a></li><li class="ng-simple-menu_list-item"><a href="/coronavirus" class="ng-simple-menu_list-link">Coronavirus</a></li><li class="ng-simple-menu_list-item"><a href="/equity" class="ng-simple-menu_list-link">Efforts toward Equity</a></li><li class="ng-simple-menu_list-item"><a href="/firearm-injury-prevention" class="ng-simple-menu_list-link">Firearm Injury Prevention</a></li><li class="ng-simple-menu_list-item"><a href="/nam" class="ng-simple-menu_list-link">From the National Academy of Medicine</a></li><li class="ng-simple-menu_list-item"><a href="/fundamentals-of-medical-ethics" class="ng-simple-menu_list-link">Fundamentals of Medical Ethics</a></li><li class="ng-simple-menu_list-item"><a href="/gray-matters" class="ng-simple-menu_list-link">Gray Matters</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/health-policy" class="ng-simple-menu_list-link">Health Policy</a></li><li class="ng-simple-menu_list-item"><a href="/medicine-and-society" class="ng-simple-menu_list-link">Medicine and Society</a></li><li class="ng-simple-menu_list-item"><a href="/nutrition-in-medicine" class="ng-simple-menu_list-link">Nutrition in Medicine</a></li><li class="ng-simple-menu_list-item"><a href="/outbreaks" class="ng-simple-menu_list-link">Outbreaks Center</a></li><li class="ng-simple-menu_list-item"><a href="/race-and-medicine" class="ng-simple-menu_list-link">Race and Medicine</a></li><li class="ng-simple-menu_list-item"><a href="/recognizing-historical-injustices" class="ng-simple-menu_list-link">Recognizing Historical Injustices and the Journal</a></li><li class="ng-simple-menu_list-item"><a href="/tobacco-use-reduction" class="ng-simple-menu_list-link">Tobacco Use Reduction</a></li><li class="ng-simple-menu_list-item"><a href="/topics" class="ng-simple-menu_list-link">View All Topics</a></li></ul></div></div></div></li><li class="ng-menu_list-item ng-simple-menu_item hasChildren"><a href="/multimedia" class="ng-simple-menu_mainLink"><span class="ng-simple-menu_mainLink-text">MULTIMEDIA</span><span class="ng-simple-menu_mainLink-arrowIcon"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#arrows-down"></use></svg></span></span></a><div class="ng-simple-menu_dropblock"><div class="ng-simple-menu_dropblock-cont"><div class="ng-simple-menu_list"><ul class="ng-simple-menu_list-items"><li class="ng-simple-menu_list-item"><a href="/rss-feed" class="ng-simple-menu_list-link">Podcasts</a></li><li class="ng-simple-menu_list-item"><a href="/double-take" class="ng-simple-menu_list-link">Double Takes</a></li><li class="ng-simple-menu_list-item"><a href="https://illustrated-glossary.nejm.org/" class="ng-simple-menu_list-link">Illustrated Glossary</a></li><li class="ng-simple-menu_list-item"><a href="/image-challenge" class="ng-simple-menu_list-link">Image Challenge</a></li><li class="ng-simple-menu_list-item"><a href="/browse/nejm-media-type/images-in-clinical-medicine" class="ng-simple-menu_list-link">Images in Clinical Medicine</a></li><li class="ng-simple-menu_list-item"><a href="/browse/nejm-media-type/interactive-medical-case" class="ng-simple-menu_list-link">Interactive Medical Cases</a></li><li class="ng-simple-menu_list-item"><a href="/plain-language-research-summaries" class="ng-simple-menu_list-link">Plain Language/Research Summaries</a></li><li class="ng-simple-menu_list-item"><a href="/multimedia/quick-take-video" class="ng-simple-menu_list-link">Quick Takes</a></li><li class="ng-simple-menu_list-item"><a href="/browse/nejm-media-type/videos-in-clinical-medicine" class="ng-simple-menu_list-link">Videos in Clinical Medicine</a></li><li class="ng-simple-menu_list-item"><a href="/multimedia" class="ng-simple-menu_list-link">View All Multimedia</a></li></ul></div></div></div></li><li class="ng-menu_list-item ng-simple-menu_item hasChildren"><a href="/learning" class="ng-simple-menu_mainLink"><span class="ng-simple-menu_mainLink-text">LEARNING/CME</span><span class="ng-simple-menu_mainLink-arrowIcon"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#arrows-down"></use></svg></span></span></a><div class="ng-simple-menu_dropblock"><div class="ng-simple-menu_dropblock-cont"><div class="ng-simple-menu_list"><ul class="ng-simple-menu_list-items"><li class="ng-simple-menu_list-item"><a href="/continuing-medical-education" class="ng-simple-menu_list-link">Weekly CME</a></li><li class="ng-simple-menu_list-item"><a href="/cme-ce/obesity" class="ng-simple-menu_list-link">Obesity CME/CE</a></li><li class="ng-simple-menu_list-item"><a href="/learning" class="ng-simple-menu_list-link">VIEW ALL LEARNING/CME</a></li></ul></div></div></div></li><li class="ng-menu_list-item ng-simple-menu_item"><a href="/author-center/home" class="ng-simple-menu_mainLink"><span class="ng-simple-menu_mainLink-text">AUTHOR CENTER</span></a></li></ul></nav>

        </div>
    

</div><button aria-label="Search" class="ng-header_searchBtn searchBtnNav d-block ml-24"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#search"></use></svg></span></button></div><div class="ng-header_loginBar ng-header_loginBar-sticky col-4">



        
        <div data-location="authstring_nav" class="ng-header_loginBar-menu"><span class="ng-simple-menu_mainLink-icon signIn newIcon-2"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#user2"></use></svg></span></span><span class="ng-header_loginBar-signIn"><a href="/sign-in?uri=/doi/full/10.1056/NEJMoa2035002" class="ng-header_loginBar-signIn-link">Sign In</a></span><span class="ng-header_loginBar-separator">|</span><span class="ng-header_loginBar-createAcc"><a href="/action/storeProxy?action=register&amp;promo=ONFLNRC1" class="ng-header_loginBar-createAcc-link ro-mode_disabled">Create Account</a></span></div><div data-location="authstring_nav" class="ng-header_loginBar-subscribe pl-xl-16"><a href="/action/storeProxy?action=subscribe&amp;promo=ONF4NRS1" class="ng-header_loginBar-subscribe-btn ng-btn_primary ro-mode_disabled">Subscribe</a></div>
</div></div></div></div></div><div class="ng-header_logoBar_right-lg col-lg-8 col-6 d-flex align-items-center justify-content-end d-xl-none"><button aria-label="Search" class="ng-header_searchBtn d-flex justify-content-end"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#search"></use></svg></span></button><div class="ng-header_openCloseBtns d-flex align-items-center justify-content-end"><button aria-label="Open" class="ng-header_openBtn"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#burger"></use></svg></span></button><button aria-label="Close" class="ng-header_closeBtn"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#close"></use></svg></span></button></div></div><div class="ng-header_quickSearch col-12"><div class="ng-header_quickSearch-content">



        
        <div class="ng-quick-search js-ng-quick-search"><form action="/search" method="get" class="ng-quick-search_form js-form"><div class="ng-quick-search_inputArea js-inputArea"><input type="search" name="q" placeholder="Enter keyword, author, title or citation" autocomplete="off" value="" required="required" class="ng-quick-search_allField ng-large-text-input js-allField js-allField-def-tmpl ui-autocomplete-input"><button type="submit" aria-label="Search Button" class="ng-quick-search_iconBtn d-xl-none d-block js-submitBtn"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#search"></use></svg></span></button><ul id="ui-id-1" tabindex="0" class="ui-menu ui-widget ui-widget-content ui-autocomplete ui-front" style="display: none;"></ul></div><div class="ng-quick-search_btnsArea d-none d-xl-flex align-items-center justify-content-end"><a href="/search/advanced" class="ng-quick-search_advSearchLink ng-btn_link js-advancedSearchLink">Advanced Search</a><button type="submit" class="ng-quick-search_textBtn ng-btn_secondary ng-btn_iconRight js-submitBtn"><span class="ng-btn_text">SEARCH</span><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#arrows-right"></use></svg></span></button></div></form></div>
</div></div></div></div></div></header><div class="ng-header_overlay"></div><div class="ng-header_after">









    
    
        <div data-widget-def="literatumAd" data-widget-id="4931ddbd-d46e-4597-b4fd-92549e9847ca" id="ad-global-banner-FULLx64-1">
        



        
        



    

    

    
        
    



        </div>
    

</div>

                    
                        



        
        <div>









    
    
        <main data-widget-def="axelPublicationContent" data-widget-id="fcdb5261-d6a2-4a9c-81d5-3a3e2304e9c1" id="mainContent">
        



        
        <div class="article-tools__savePopup"><div class="ng-save"><input type="hidden" value="/action/getSavedTags" class="getKeywordsServiceUrl"><input type="hidden" value="/action/mmsSaveItemsService?itemType=article" class="saveServiceUrl"><input type="hidden" value="article" class="saveType"><input type="hidden" value="10.1056/NEJMoa2035002" class="inputDoi"><input type="hidden" value="D.M. Weinreich and Others" class="inputAuthor"><input type="hidden" value="N Engl J Med 2021;384:238-251" class="inputCitation"><input type="hidden" value="12-17-2020" class="inputEPubDate"><input type="hidden" value="January 2021" class="inputCoverDate"><input type="hidden" value="Original Article" class="inputContentType"><input type="hidden" value="REGN-COV2, a Neutralizing Antibody Cocktail, in Outpatients with Covid-19" class="inputArticleTitle"><input type="hidden" value="/browse/nejm-article-type/original-article" class="inputContentTypeUrl"><button type="button" id="saveArticleShowPopupBtn" aria-hidden="true" tabindex="-1" class="ng-save-btn ng-btn_secondary isLoggedOut">Save</button></div></div><div class="article-tools__articleAlertPopup"><div id="articleAlertModal" tabindex="-1" role="dialog" aria-labelledby="exampleModalCenterTitle" aria-hidden="true" class="ng-modal modal"><div role="document" class="ng-modal_dialog modal-dialog modal-dialog-centered"><div class="ng-modal_content modal-content"><div class="ng-modal_header modal-header"><h5 id="articleAlertModalTitle" class="ng-modal_title modal-title">Create an E-mail Alert for This Article</h5><button type="button" data-dismiss="modal" aria-label="Close" class="ng-modal_close close"><span aria-hidden="true"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#close"></use></svg></span></span></button></div><div class="ng-modal_body modal-body"></div></div></div></div></div><div class="ng-do-media_popup"><div id="doPopup" tabindex="-1" role="dialog" aria-labelledby="exampleModalCenterTitle" aria-hidden="true" class="ng-modal modal"><div role="document" class="ng-modal_dialog modal-dialog modal-dialog-centered"><div class="ng-modal_content modal-content"><div class="ng-modal_header modal-header"><button type="button" data-dismiss="modal" aria-label="Close" class="ng-modal_close close"><span aria-hidden="true"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#close"></use></svg></span></span></button></div><div class="ng-modal_body modal-body"></div></div></div></div></div><link id="build-style-article" rel="stylesheet" type="text/css" href="/products/mms-nextgen/mms/releasedAssets/css/build-article-5b89b331018866a4a965.css"><article xmlns="http://www.w3.org/1999/xhtml" data-design="pill" data-has="right-rail" data-type="research-article" vocab="http://schema.org/" typeof="ScholarlyArticle" lang="en" dir="ltr"><header data-extent="frontmatter" data-location="header_article"><div class="core-container"><div data-article-access="free" data-article-access-type="free" class="meta-panel"><div class="meta-panel__left-content"><div class="meta-panel__type"><a href="/browse/nejm-article-type/original-article">Original Article</a></div></div><div class="meta-panel__right-content"><div class="meta-panel__share">









    
    
        <div data-widget-def="UX3share" data-widget-id="eee5f139-16f2-48f8-97ea-1b114367da16" data-location="share_tools_article">
        



        
        <!-- Go to https://www.addtoany.com/buttons/customize/ to customize your tools --><script type="text/javascript" defer="defer" src="https://static.addtoany.com/menu/page.js" nonce="94d6670fb4c0f1da-SJC"></script><div class="share"><div class="share__block share__inline-links"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="d-flex list-unstyled a2a a2a_kit a2a_default_style mb-0 a2a_kit_size_32" style="line-height: 32px;"><li class="a2a_listitem_custom"><a role="link" title="Facebook" data-interactiontype="social" class="share__link a2a_button_facebook" target="_blank" rel="nofollow noopener" href="/#facebook"><span class="icon-component " style="height: 24px; width: 24px"><svg aria-hidden="true" style="height: 24px; width: 24px"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#social-facebook"></use></svg></span></a></li><li class="a2a_listitem_custom"><a role="link" title="X (formerly Twitter)" data-interactiontype="social" class="share__link a2a_button_twitter" target="_blank" rel="nofollow noopener" href="/#twitter"><span class="icon-component " style="height: 24px; width: 24px"><svg aria-hidden="true" style="height: 24px; width: 24px"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#social-twitter"></use></svg></span></a></li><li class="a2a_listitem_custom"><a role="link" title="Linked In" data-interactiontype="social" class="share__link a2a_button_linkedin" target="_blank" rel="nofollow noopener" href="/#linkedin"><span class="icon-component " style="height: 24px; width: 24px"><svg aria-hidden="true" style="height: 24px; width: 24px"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#social-linkedin"></use></svg></span></a></li><li class="a2a_listitem_custom"><a role="link" title="Email" data-interactiontype="content_email_click" class="share__link a2a_button_email" target="_blank" rel="nofollow noopener" href="/#email"><span class="icon-component " style="height: 24px; width: 24px"><svg aria-hidden="true" style="height: 24px; width: 24px"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#social-email"></use></svg></span></a></li><li class="a2a_listitem_custom"><a role="link" title="Bluesky" data-interactiontype="social" class="share__link a2a_button_bluesky" target="_blank" rel="nofollow noopener" href="/#bluesky"><span class="icon-component " style="height: 24px; width: 24px"><svg aria-hidden="true" style="height: 24px; width: 24px"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#social-bluesky"></use></svg></span></a></li></ul></div></div>

        </div>
    

</div></div></div><h1 property="name">REGN-COV2, a Neutralizing Antibody Cocktail, in Outpatients with Covid-19</h1><div class="core-relations my-3"></div><div class="contributors"><span class="authors"><span class="heading">Authors</span>: <span role="list"><span property="author" typeof="Person" role="listitem"><span property="givenName">David M.</span> <span property="familyName">Weinreich</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person" role="listitem"><span property="givenName">Sumathi</span> <span property="familyName">Sivapalasingam</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person" role="listitem"><span property="givenName">Thomas</span> <span property="familyName">Norton</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person" role="listitem"><span property="givenName">Shazia</span> <span property="familyName">Ali</span>, <span property="honorificSuffix">Pharm.D.</span></span>, <span property="author" typeof="Person" role="listitem"><span property="givenName">Haitao</span> <span property="familyName">Gao</span>, <span property="honorificSuffix">Ph.D.</span></span>, <span property="author" typeof="Person" role="listitem"><span property="givenName">Rafia</span> <span property="familyName">Bhore</span>, <span property="honorificSuffix">Ph.D.</span></span>, <span property="author" typeof="Person" role="listitem"><span property="givenName">Bret J.</span> <span property="familyName">Musser</span>, <span property="honorificSuffix">Ph.D.</span></span><span data-displayed-on="all">, <span data-action="reveal" tabindex="0" role="listitem">+26</span> </span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Yuhwen</span> <span property="familyName">Soo</span>, <span property="honorificSuffix">Ph.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Diana</span> <span property="familyName">Rofail</span>, <span property="honorificSuffix">Ph.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Joseph</span> <span property="familyName">Im</span>, <span property="honorificSuffix">B.S.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Christina</span> <span property="familyName">Perry</span>, <span property="honorificSuffix">M.B.A.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Cynthia</span> <span property="familyName">Pan</span>, <span property="honorificSuffix">B.Pharm.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Romana</span> <span property="familyName">Hosain</span>, <span property="honorificSuffix">M.D., M.P.H.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Adnan</span> <span property="familyName">Mahmood</span>, <span property="honorificSuffix">M.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">John D.</span> <span property="familyName">Davis</span>, <span property="honorificSuffix">Ph.D.</span> <a class="orcid-id" href="https://orcid.org/0000-0001-6282-1670" property="identifier" aria-label="ORCID identifier" target="_blank">https://orcid.org/0000-0001-6282-1670</a></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Kenneth C.</span> <span property="familyName">Turner</span>, <span property="honorificSuffix">Ph.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Andrea T.</span> <span property="familyName">Hooper</span>, <span property="honorificSuffix">Ph.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Jennifer D.</span> <span property="familyName">Hamilton</span>, <span property="honorificSuffix">Ph.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Alina</span> <span property="familyName">Baum</span>, <span property="honorificSuffix">Ph.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Christos A.</span> <span property="familyName">Kyratsous</span>, <span property="honorificSuffix">Ph.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Yunji</span> <span property="familyName">Kim</span>, <span property="honorificSuffix">Pharm.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Amanda</span> <span property="familyName">Cook</span>, <span property="honorificSuffix">B.S., Dip.Reg.Aff.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Wendy</span> <span property="familyName">Kampman</span>, <span property="honorificSuffix">M.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Anita</span> <span property="familyName">Kohli</span>, <span property="honorificSuffix">M.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Yessica</span> <span property="familyName">Sachdeva</span>, <span property="honorificSuffix">M.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Ximena</span> <span property="familyName">Graber</span>, <span property="honorificSuffix">M.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Bari</span> <span property="familyName">Kowal</span>, <span property="honorificSuffix">M.S.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Thomas</span> <span property="familyName">DiCioccio</span>, <span property="honorificSuffix">Ph.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Neil</span> <span property="familyName">Stahl</span>, <span property="honorificSuffix">Ph.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Leah</span> <span property="familyName">Lipsich</span>, <span property="honorificSuffix">Ph.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Ned</span> <span property="familyName">Braunstein</span>, <span property="honorificSuffix">M.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Gary</span> <span property="familyName">Herman</span>, <span property="honorificSuffix">M.D.</span></span></span><span data-hidden-on="all">, and <span property="author" typeof="Person" role="listitem"><span property="givenName">George D.</span> <span property="familyName">Yancopoulos</span>, <span property="honorificSuffix">M.D., Ph.D.</span></span></span>, for <span property="author" typeof="Person" role="listitem">the Trial Investigators<sup><a href="#fn1" role="doc-noteref">*</a></sup></span><span data-displayed-on="none" data-on-display="all" aria-hidden="true"> <span data-action="hide" tabindex="0" role="listitem">-26</span></span></span></span><a href="#tab-contributors" class="to-authors-affiliations" data-id="article-authors-viewall">Author Info &amp; Affiliations</a></div><div class="core-self-citation"><div class="core-date-published">Published <span property="datePublished">December 17, 2020</span></div><div property="isPartOf" typeof="Periodical"><span property="name">N Engl J Med</span> 2021<span property="isPartOf" typeof="PublicationVolume">;<span property="volumeNumber">384</span></span>:<span property="pageStart">238</span>-<span property="pageEnd">251</span></div><div class="doi">DOI: 10.1056/NEJMoa2035002</div><div class="core-enumeration"><a href="/toc/nejm/384/3"><span property="isPartOf" typeof="PublicationVolume">VOL. <span property="volumeNumber">384</span></span> <span property="isPartOf" typeof="PublicationIssue">NO. <span property="issueNumber">3</span></span></a></div><div><a href="#tab-information">Copyright © 2020</a></div></div><div class="info-panel"><div class="info-panel__left-content"><div class="info-panel__metrics info-panel__item"></div></div><div data-location="tools_article" class="info-panel__right-content"><div class="info-panel__article_tools info-panel__item">



        
        <div data-permission="/servlet/linkout?type=rightslink&amp;url=publisherName%3Dmassmed%26author%3DDavid%2BM.%2BWeinreich%252C%2BSumathi%2BSivapalasingam%252C%2BThomas%2BNorton%252C%2Bet%2Bal%26publication%3Dnejm%26orderBeanReset%3Dtrue%26volumeNum%3D384%26issueNum%3D3%26contentID%3D10.1056%252FNEJMoa2035002%26title%3DREGN-COV2%252C%2Ba%2BNeutralizing%2BAntibody%2BCocktail%252C%2Bin%2BOutpatients%2Bwith%2BCovid-19%26publicationDate%3D01%252F21%252F2021" class="article-tools"><button id="articleToolsAlertBtn" data-url="/action/addCitationAlert?doi=10.1056%2FNEJMoa2035002" data-toggle="" data-target="#articleAlertModal" aria-label="Sign in or create account to add an article alert" data-interactiontype="article_alert" class="article-tools__citation btn btn--slim isLoggedOut"><span title="" data-toggle="tooltip" class="d-inline-block" data-original-title="Sign in or create account to add an article alert"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#alerts"></use></svg></span></span></button><button id="articleToolsSaveBtn" data-toggle="modal" data-target="#saveArticle" aria-label="Sign in or create account to save this article" data-interactiontype="article_tools_save_click" class="article-tools__favorite btn btn--slim isLoggedOut"><span title="" data-toggle="tooltip" class="d-inline-block" data-original-title="Sign in or create account to save this article"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#bookmarkFilled"></use></svg></span></span></button><a href="/servlet/linkout?type=rightslink&amp;url=publisherName%3Dmassmed%26author%3DDavid%2BM.%2BWeinreich%252C%2BSumathi%2BSivapalasingam%252C%2BThomas%2BNorton%252C%2Bet%2Bal%26publication%3Dnejm%26orderBeanReset%3Dtrue%26volumeNum%3D384%26issueNum%3D3%26contentID%3D10.1056%252FNEJMoa2035002%26title%3DREGN-COV2%252C%2Ba%2BNeutralizing%2BAntibody%2BCocktail%252C%2Bin%2BOutpatients%2Bwith%2BCovid-19%26publicationDate%3D01%252F21%252F2021" target="_blank" title="" data-toggle="tooltip" aria-label="Permissions" data-interactiontype="article_tools_permissions_click" class="article-tools__permissions btn btn--slim" data-original-title="Permissions"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#permissions"></use></svg></span></a><a href="/about-nejm/reprints" title="" data-toggle="tooltip" aria-label="Reprints" data-interactiontype="article_tools_reprints_click" class="article-tools__reprints btn btn--slim" data-original-title="Reprints"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#reprints"></use></svg></span></a><a href="/cms/asset/4f1f760e-fdc9-4e12-9a98-0f5926580e36/nejmoa2035002.pptx" target="_blank" title="" data-toggle="tooltip" aria-label="Download Slides" data-interactiontype="article_tools_slide_set_download" data-multimedia-type="Article Slideset" data-multimedia-filename="nejmoa2035002.pptx" class="article-tools__downloadSlides btn btn--slim" data-original-title="Download Slides"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#download"></use></svg></span></a><div class="article-tools__permissionsPopup"><div id="permissionsModal" tabindex="-1" role="dialog" aria-labelledby="exampleModalCenterTitle" aria-hidden="true" class="ng-modal modal"><div role="document" class="ng-modal_dialog modal-dialog modal-dialog-centered"><div class="ng-modal_content modal-content"><div class="ng-modal_header modal-header"><h5 id="permissionsModalTitle" class="ng-modal_title modal-title">Permissions</h5><button type="button" data-dismiss="modal" aria-label="Close" class="ng-modal_close close"><span aria-hidden="true"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#close"></use></svg></span></span></button></div><div class="ng-modal_body modal-body">For permission requests, please contact NEJM Reprints at <a href="mailto:reprints@nejm.org">reprints@nejm.org</a></div></div></div></div></div></div>
</div><div class="info-panel__citations info-panel__item"><a href="#tab-citations" class="btn btn--slim" aria-label="View Citations" data-toggle="tooltip" data-original-title="View Citations" data-interactiontype="article_tools_citation_download" data-multimedia-type="Citation"><i aria-hidden="true" class="icon-format_quote"></i></a></div><div class="info-panel__formats info-panel__item"><a href="https://www.nejm.org/doi/pdf/10.1056/NEJMoa2035002" class="btn btn--pdf btn--slim" aria-label="View PDF" data-toggle="tooltip" data-original-title="View PDF" data-behavior="trackDownloadEvent" data-doi="10.1056/NEJMoa2035002" data-interactiontype="article_tools_download_pdf" data-multimedia-type="Article PDF" data-multimedia-filename="nejmoa2035002.pdf"><i aria-hidden="true" class="icon-PDF"></i></a></div></div></div></div></header><div data-core-nav="header" data-extent="frontmatter"><div class="core-nav-wrapper core-container" aria-label="Article navigation"><div class="core-sections-menu"><button data-id="article-toolbar-showhide" aria-controls="article_sections_menu" aria-expanded="false" aria-label="Toggle section navigation menu" style="margin-top: 0px;"><i class="icon-list" aria-hidden="true"></i><span>Contents</span></button><nav id="article_sections_menu" aria-label="Contents" data-core-nav="article" style="margin-top: 0px;"><ul><li><a href="#summary-abstract" aria-current="true">Abstract</a></li><li><a href="#sec-1" aria-current="false">Methods</a></li><li><a href="#sec-2" aria-current="false">Results</a></li><li><a href="#sec-3" aria-current="false">Discussion</a></li><li class="bordered"><a href="#backnotes" aria-current="false">Notes</a></li><li><a href="#supplementary-materials" aria-current="false">Supplementary Material</a></li><li><a href="#bibliography" aria-current="false">References</a></li></ul></nav></div><nav id="article_collateral_menu"><ul data-core-nav="collateral" class="collateral-pill" style="margin-top: 0px;"><li><a href="#core-collateral-info" data-id="article-nav-menubar-info" title="" tabindex="0" data-toggle="tooltip" data-placement="left" data-offset="4px, 16px" data-original-title="Information &amp; Authors"><i aria-hidden="true" class="icon-info"></i><span class="sr-only">Information &amp; Authors</span></a></li><li><a href="#core-collateral-metrics" data-id="article-nav-menubar-metrics" title="" tabindex="0" data-toggle="tooltip" data-placement="left" data-offset="4px, 16px" data-original-title="Metrics &amp; Citations"><i aria-hidden="true" class="icon-timeline"></i><span class="sr-only">Metrics &amp; Citations</span></a></li><li><a href="#core-collateral-fulltext-options" data-id="article-nav-menubar-metrics" title="" tabindex="0" data-toggle="tooltip" data-placement="left" data-offset="4px, 16px" data-original-title="View Options"><i aria-hidden="true" class="icon-eye"></i><span class="sr-only">View Options</span></a></li><li><a href="#core-collateral-references" data-id="article-nav-menubar-references" title="" tabindex="0" data-toggle="tooltip" data-placement="left" data-offset="4px, 16px" data-original-title="References"><i aria-hidden="true" class="icon-references"></i><span class="sr-only">References</span></a></li><li><a href="#core-collateral-media" data-id="article-nav-menubar-media" title="" tabindex="0" data-toggle="tooltip" data-placement="left" data-offset="4px, 16px" data-original-title="Media"><i aria-hidden="true" class="icon-photo"></i><span class="sr-only">Media</span></a></li><li><a href="#core-collateral-tables" data-id="article-nav-menubar-tables" title="" tabindex="0" data-toggle="tooltip" data-placement="left" data-offset="4px, 16px" data-original-title="Tables"><i aria-hidden="true" class="icon-tables"></i><span class="sr-only">Tables</span></a></li><li><a href="#core-collateral-share" data-id="article-nav-menubar-share" title="" tabindex="0" data-toggle="tooltip" data-placement="left" data-offset="4px, 16px" data-original-title="Share"><i aria-hidden="true" class="icon-share"></i><span class="sr-only">Share</span></a></li></ul></nav></div></div><div data-core-wrapper="content"><div id="abstracts" data-extent="frontmatter" data-location="articleTab_article"><div class="core-container"><section id="summary-abstract" property="abstract" typeof="Text" role="doc-abstract"><h2 property="name">Abstract</h2><section id="abs-sec-1"><h3>Background</h3><div role="paragraph">Recent data suggest that complications and death from coronavirus disease 2019 (Covid-19) may be related to high viral loads.</div></section><section id="abs-sec-2"><h3>Methods</h3><div role="paragraph">In this ongoing, double-blind, phase 1–3 trial involving nonhospitalized patients with Covid-19, we investigated two fully human, neutralizing monoclonal antibodies against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein, used in a combined cocktail (REGN-COV2) to reduce the risk of the emergence of treatment-resistant mutant virus. Patients were randomly assigned (1:1:1) to receive placebo, 2.4 g of REGN-COV2, or 8.0 g of REGN-COV2 and were prospectively characterized at baseline for endogenous immune response against SARS-CoV-2 (serum antibody–positive or serum antibody–negative). Key end points included the time-weighted average change in viral load from baseline (day 1) through day 7 and the percentage of patients with at least one Covid-19–related medically attended visit through day 29. Safety was assessed in all patients.</div></section><section id="abs-sec-3"><h3>Results</h3><div role="paragraph">Data from 275 patients are reported. The least-squares mean difference (combined REGN-COV2 dose groups vs. placebo group) in the time-weighted average change in viral load from day 1 through day 7 was −0.56 log<sub>10</sub> copies per milliliter (95% confidence interval [CI], −1.02 to −0.11) among patients who were serum antibody–negative at baseline and −0.41 log<sub>10</sub> copies per milliliter (95% CI, −0.71 to −0.10) in the overall trial population. In the overall trial population, 6% of the patients in the placebo group and 3% of the patients in the combined REGN-COV2 dose groups reported at least one medically attended visit; among patients who were serum antibody–negative at baseline, the corresponding percentages were 15% and 6% (difference, −9 percentage points; 95% CI, −29 to 11). The percentages of patients with hypersensitivity reactions, infusion-related reactions, and other adverse events were similar in the combined REGN-COV2 dose groups and the placebo group.</div></section><section id="abs-sec-4"><h3>Conclusions</h3><div role="paragraph">In this interim analysis, the REGN-COV2 antibody cocktail reduced viral load, with a greater effect in patients whose immune response had not yet been initiated or who had a high viral load at baseline. Safety outcomes were similar in the combined REGN-COV2 dose groups and the placebo group. (Funded by Regeneron Pharmaceuticals and the Biomedical and Advanced Research and Development Authority of the Department of Health and Human Services; ClinicalTrials.gov number, <a href="http://clinicaltrials.gov/show/NCT04425629" target="_blank">NCT04425629</a>.)</div></section></section></div></div><section id="bodymatter" data-extent="bodymatter" property="articleBody" typeof="Text" data-location="articleTab_article"><div class="core-container"><div role="paragraph">Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), a novel coronavirus first identified in December 2019,<sup><a href="#core-r1" role="doc-biblioref" data-xml-rid="r1" id="body-ref-r1" href-manipulated="true" aria-label="Reference 1">1</a></sup> is the causative agent of coronavirus disease 2019 (Covid-19). After becoming infected, most persons have few or no symptoms despite having high viral loads,<sup><a href="#core-r2" role="doc-biblioref" data-xml-rid="r2 r3 r4 r5" id="body-ref-r5" href-manipulated="true">2-5</a></sup> and their condition can be managed on an outpatient basis. In a smaller number of persons, hypoxemia develops, leading to hospitalization and receipt of supplemental oxygen.<sup><a href="#core-r6" role="doc-biblioref" data-xml-rid="r6 r7 r8" id="body-ref-r8" href-manipulated="true">6-8</a></sup> An early hypothesis regarding the pathogenesis of Covid-19 hypoxemia pointed to an immune system hyperresponse to viral infection<sup><a href="#core-r9" role="doc-biblioref" data-xml-rid="r9" id="body-ref-r9" href-manipulated="true" aria-label="Reference 9">9</a></sup>; this led to studies of various immunomodulating agents, with mixed results.<sup><a href="#core-r10" role="doc-biblioref" data-xml-rid="r10 r11 r12 r13" id="body-ref-r13" href-manipulated="true">10-13</a></sup> More recent data have shown high viral titers in hospitalized patients,<sup><a href="#core-r14" role="doc-biblioref" data-xml-rid="r14" id="body-ref-r14-1" href-manipulated="true" aria-label="Reference 14">14</a></sup> suggesting that the virus is in part responsible for ongoing hypoxemia.</div><div role="paragraph">In an ongoing trial, we are investigating REGN-COV2, an antibody cocktail containing two SARS-CoV-2–neutralizing antibodies, in nonhospitalized patients with Covid-19. Our central hypothesis is that complications and death from Covid-19 emanate from the SARS-CoV-2 viral burden and that reducing this burden should lead to clinical benefit. REGN-COV2 is a cocktail made up of two noncompeting, neutralizing human IgG1 antibodies that target the receptor-binding domain of the SARS-CoV-2 spike protein, thereby preventing viral entry into human cells through the angiotensin-converting enzyme 2 (ACE2) receptor.<sup><a href="#core-r15" role="doc-biblioref" data-xml-rid="r15 r16" id="body-ref-r16" href-manipulated="true">15,16</a></sup> We prospectively pursued a “cocktail” approach because of previous experience with the emergence of treatment-resistant mutant virus when a single antibody, suptavumab, was used to target respiratory syncytial virus.<sup><a href="#core-r17" role="doc-biblioref" data-xml-rid="r17" id="body-ref-r17" href-manipulated="true" aria-label="Reference 17">17</a></sup> Preclinical studies confirmed that the REGN-COV2 cocktail protects against the rapid emergence of such mutants seen with either single antibody.<sup><a href="#core-r15" role="doc-biblioref" data-xml-rid="r15" id="body-ref-r15-2" href-manipulated="true" aria-label="Reference 15">15</a></sup> In vivo studies in nonhuman primates have shown profound antiviral activity of REGN-COV2 in reducing viral load when given in a prophylactic context and in improving viral clearance when given in a therapeutic context.<sup><a href="#core-r18" role="doc-biblioref" data-xml-rid="r18" id="body-ref-r18" href-manipulated="true" aria-label="Reference 18">18</a></sup></div><div role="paragraph">We further hypothesized that in an outpatient context, patients would present at various stages of development of their own native humoral immune response and that exogenously provided antibodies would have the most benefit in patients whose immune response had not yet been initiated. Consequently, all patients were screened for the presence of preexisting antibodies against SARS-CoV-2 and were classified as either serum antibody–positive or serum antibody–negative at trial entry.</div><div role="paragraph">Here, we describe results of an initial analysis involving 275 symptomatic patients from our ongoing phase 1–3 trial involving outpatients with confirmed SARS-CoV-2 infection.</div><section id="sec-1" data-type="methods"><h2>Methods</h2><section id="sec-1-1"><h3>Trial Design</h3><div role="paragraph">We are conducting an ongoing operationally seamless (continual enrollment), multicenter, randomized, double-blind, placebo-controlled, phase 1–3 clinical trial involving symptomatic, nonhospitalized patients with Covid-19. The interim analysis we describe here involved the first 275 patients enrolled during the phase 1–2 portion of the trial and was conducted to assess the safety and efficacy of REGN-COV2, to gain an understanding of the natural history of Covid-19 in outpatients, and to refine the end points for subsequent analyses. The trial continues to recruit beyond the first 275 patients for whom data are described in this report; the results for the key primary and secondary prespecified end points are planned to be reported at trial completion. The data cutoff for this interim analysis was September 4, 2020.</div><div role="paragraph">In the phase 1–2 portion of the trial reported here, all patients were randomly assigned (1:1:1) to receive placebo, REGN-COV2 at a dose of 2.4 g (low dose), or REGN-COV2 at a dose of 8.0 g (high dose) (Fig. S1 in the <a href="#ap2">Supplementary Appendix</a>, available with the full text of this article at NEJM.org). Each of the two antibodies that make up REGN-COV2 — casirivimab (REGN10933) and imdevimab (REGN10987) — is given in equal doses in the cocktail.</div><div role="paragraph">Details of the randomization stratification are provided in the <a href="#ap2">Supplementary Appendix</a>. The phase 1 portion of the trial included additional pharmacokinetic analyses but was otherwise identical to the phase 2 portion. The population of patients in the current analysis was pooled from both phases.</div></section><section id="sec-1-2"><h3>Patients</h3><div role="paragraph">To be eligible for participation, patients had to be 18 years of age or older and nonhospitalized. All patients had to have a confirmed SARS-CoV-2 infection, with a SARS-CoV-2–positive test result received no more than 72 hours before randomization and symptom onset no more than 7 days before randomization. The full list of inclusion and exclusion criteria are provided in the <a href="#ap2">Supplementary Appendix</a>. The <a href="#ap1">protocol</a> is available at NEJM.org.</div><div role="paragraph">An assay for anti–SARS-CoV-2 antibodies was performed in all patients. Because these results were not available at randomization, patients underwent randomization regardless of their baseline serologic status, and the analyses were prespecified to first evaluate efficacy in the subgroup of patients who were serum antibody–negative — that is, those patients who tested negative for all three of the following antibodies: IgA anti-S1 domain of spike protein, IgG anti-S1 domain of spike protein, and IgG anti-nucleocapsid protein. Patients who were positive for any one of these antibodies were designated as serum antibody–positive. A small number of patients could not be evaluated or had borderline results (unknown serum antibody status); analyses involving these patients were conducted but are not reported here.</div></section><section id="sec-1-3"><h3>Intervention and Assessments</h3><div role="paragraph">At baseline (day 1), REGN-COV2 (at the high dose or low dose) or saline placebo was administered intravenously in a 250-ml normal saline solution over a period of 1 hour. The schedule of assessments is described in the protocol, along with a summary of protocol amendments. Quantitative virologic analysis, SARS-CoV-2 serum antibody testing, and measurement of the two components of REGN-COV2 in serum are described in the <a href="#ap2">Supplementary Appendix</a>.</div></section><section id="sec-1-4"><h3>End Points</h3><div role="paragraph">Multiple prespecified end points were designated for the phase 1–2 portion of the trial (see the <a href="#ap2">Supplementary Appendix</a> and the statistical analysis plan, which is available with the protocol). However, because of the lack of a priori information that would allow us to correctly select end points, and because certain employees of Regeneron Pharmaceuticals (who had no role in the conduct of the trial) had access to unblinded early data from the trial as described in the protocol, no formal hypothesis testing was performed.</div><div role="paragraph">The prespecified key virologic end point in the statistical analysis plan was defined as the time-weighted average change in the viral load (in log<sub>10</sub> copies per milliliter) from baseline (day 1) through day 7, as measured by quantitative reverse-transcriptase–polymerase-chain-reaction (RT-PCR) testing of nasopharyngeal swab samples obtained from serum antibody–negative patients. The change in viral load from baseline to various days during the trial was an additional prespecified virologic end point, and the change in absolute viral load (measured in copies per milliliter) was a post hoc virologic end point.</div><div role="paragraph">The prespecified key clinical end point was the percentage of patients with at least one Covid-19–related medically attended visit through day 29 in both the serum antibody–negative subgroup and the overall trial population. Medically attended visits could include telemedicine visits, in-person physician visits, urgent care or emergency department visits, and hospitalization.</div><div role="paragraph">For assessments of safety, we collected data on adverse events that occurred or worsened during the observation period (grade 3 and 4; phase 1 only), serious adverse events that occurred or worsened during the observation period (phases 1 and 2), and the following adverse events of special interest (phases 1 and 2): grade 2 or higher hypersensitivity or infusion-related reactions. Pharmacokinetic variables included the concentrations of casirivimab and imdevimab in serum over time.</div></section><section id="sec-1-5"><h3>Trial Oversight</h3><div role="paragraph">Regeneron designed the trial; gathered the data, together with the trial investigators; and analyzed the data. Regeneron and the authors vouch for the accuracy and completeness of the data, and Regeneron vouches for the fidelity of the trial to the protocol. The authors provided critical feedback and final approval of the manuscript for submission. No one who is not an author contributed to writing the manuscript. All the investigators had confidentiality agreements with Regeneron.</div><div role="paragraph">The investigators, site personnel, and Regeneron employees who were involved in collecting and analyzing data were unaware of the treatment-group assignments. An independent data and safety monitoring committee periodically monitored unblinded data to make recommendations about trial modification and termination. The independent committee and, separately, Regeneron physicians who were aware of the treatment-group assignments and were not involved in the conduct of the trial performed interim data reviews for adapting the trial design.</div><div role="paragraph">The trial was conducted in accordance with the principles of the Declaration of Helsinki, International Council for Harmonisation Good Clinical Practice guidelines, and applicable regulatory requirements. The local institutional review board or ethics committee at each study center oversaw trial conduct and documentation. One center was found to have violations of Good Clinical Practice guidelines (not related to the collection of data on efficacy or safety end points) and was withdrawn from the trial after analyses had been completed. All the patients provided written informed consent before participating in the trial.</div></section><section id="sec-1-6"><h3>Statistical Analysis</h3><div role="paragraph">The statistical analysis plan for the presented analysis was finalized before database lock and unblinding. The full analysis set included the first 275 patients with Covid-19 symptoms who underwent randomization in the combined phase 1–2 portions of the trial. A sample of 275 patients (72 in phase 1 and 203 in phase 2) was considered sufficient for the assessment of virologic efficacy, clinical trends, and safety for the purpose of informing subsequent analyses. Because patients could enroll if they had tested positive for SARS-CoV-2 no more than 72 hours before randomization, patients who tested negative by qualitative RT-PCR at baseline (lower limit of detection, 714 copies per milliliter [2.85 log<sub>10</sub> copies per milliliter]) were excluded from analyses of virologic end points in a modified full analysis set. Because of the a priori hypothesis that patients whose immune system was already clearing the virus were unlikely to benefit from additional antibody therapy, analyses were prespecified in the statistical analysis plan to focus on the serum antibody–negative subgroup. All patients who received REGN-COV2 or placebo were included in the safety population.</div><div role="paragraph">The time-weighted average change from baseline (day 1) through day 7 was calculated for each patient as the area under the concentration–time curve, with the use of the linear trapezoidal rule for change from baseline divided by the time interval of the observation period. This end point was analyzed with an analysis-of-covariance model with treatment group, risk factor, and baseline serum antibody status as fixed effects and baseline viral load and treatment group–by–baseline viral load as covariates. Confidence intervals in this report were not adjusted for multiplicity. Statistical analyses were performed with SAS software, version 9.4 or higher (SAS Institute). Additional statistical and pharmacokinetic analysis methods are described in the <a href="#ap2">Supplementary Appendix</a>.</div></section></section><section id="sec-2" data-type="results"><h2>Results</h2><section id="sec-2-1"><h3>Baseline Characteristics</h3><div role="paragraph">Of the 275 patients who underwent randomization between June 16, 2020, and August 13, 2020, a total of 269 received REGN-COV2 or placebo. Among the 275 patients, 90 were assigned to receive high-dose REGN-COV2, 92 to receive low-dose REGN-COV2, and 93 to receive placebo (<a href="#f1">Figure 1</a>).</div><div class="figure-wrap" data-presentation="diminished-in-flow"><header><div class="label">Figure 1</div><nav><a href="#f1" title="Open in viewer" class="open-in-viewer" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa2035002_f1.jpg"><i aria-hidden="true" class="icon-expand"></i></a></nav></header><figure id="f1" class="graphic"><a aria-label="Open figure in viewer" class="open-in-viewer" data-index="0" href="#f1" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa2035002_f1.jpg"><img src="/cms/10.1056/NEJMoa2035002/asset/4eef3f7d-a00a-46f4-9759-44174e57e4cc/assets/images/large/nejmoa2035002_f1.jpg" height="2120" width="2640" aria-labelledby="f1" loading="lazy"></a><figcaption><div class="caption">Screening, Randomization, and Treatment.</div><div class="notes"><div role="doc-footnote">One patient underwent randomization in error, and Regeneron requested that the patient withdraw from the trial. Four patients in the low-dose REGN-COV2 group withdrew consent: one patient could not participate in the follow-up period, one patient could not have blood drawn and an intravenous line placed, and two patients withdrew consent with no additional information available. Three patients in the high-dose REGN-COV2 group withdrew consent: one patient could not participate in the follow-up period, one patient could not have blood drawn and an intravenous line placed, and one withdrew consent with no additional information available.</div></div></figcaption></figure></div><div role="paragraph">The median age of the patients in the trial was 44.0 years, 49% were male, 13% identified as Black or African American, and 56% identified as Hispanic or Latino (<a href="#t1">Table 1</a>). The median number of days of reported Covid-19–related symptoms before randomization was 3.0.</div><div class="figure-wrap" data-presentation="diminished-in-flow"><header><div class="label">Table 1</div><nav><a href="#t1" title="Open in viewer" class="open-in-viewer" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2035002_t1.jpg"><i aria-hidden="true" class="icon-expand"></i></a></nav></header><figure id="t1" class="table"><div class="graphic-wrap" data-presentation="suppressed-in-viewer"><a aria-label="Open figure in viewer" class="open-in-viewer" data-index="0" href="#t1" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2035002_t1.jpg"><img src="/cms/10.1056/NEJMoa2035002/asset/1e13be33-2ef4-4927-ae76-954a73920f38/assets/images/large/nejmoa2035002_t1.jpg" height="2833" width="2615" loading="lazy"></a></div><div class="table-wrap catalyst-standard" data-presentation="suppressed-in-flow"><table data-shading="custom"><thead><tr class="head1" data-type="row head1"><th class="txlx-borders" data-xml-align="left">Characteristic</th><th class="txxx-borders" colspan="3"><span>REGN-COV2</span></th><th class="txxx-borders">Placebo<br>(N=93)</th><th class="txxr-borders">Total<br>(N=275)</th></tr><tr class="head2" data-type="row head2"><td class="xxlx-borders">&nbsp;</td><th class="xxxx-borders">2.4 g<br>(N=92)</th><th class="xxxx-borders">8.0 g<br>(N=90)</th><th class="xxxx-borders">Combined<br>(N=182)</th><td class="xxxx-borders">&nbsp;</td><th class="xxxr-borders">&nbsp;</th></tr></thead><tbody><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging03 shading" data-xml-align="left">Median age (IQR) — yr<a href="#t1fn2" role="doc-noteref">†</a></td><td class="xxxx-borders shading">43.0 (33.5–51.0)</td><td class="xxxx-borders shading">44.0 (36.0–53.0)</td><td class="xxxx-borders shading">43.0 (35.0–52.0)</td><td class="xxxx-borders shading">45.0 (34.0–54.0)</td><td class="xxxr-borders shading">44.0 (35.0–52.0)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging03" data-xml-align="left">Male sex — no. (%)</td><td class="xxxx-borders">46 (50)</td><td class="xxxx-borders">38 (42)</td><td class="xxxx-borders">84 (46)</td><td class="xxxx-borders">50 (54)</td><td class="xxxr-borders">134 (49)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging03 shading" data-xml-align="left">Hispanic or Latino ethnic group — no. (%)<a href="#t1fn3" role="doc-noteref">‡</a></td><td class="xxxx-borders shading">52 (57)</td><td class="xxxx-borders shading">55 (61)</td><td class="xxxx-borders shading">107 (59)</td><td class="xxxx-borders shading">46 (49)</td><td class="xxxr-borders shading">153 (56)</td></tr><tr data-type="row"><td class="xxlx-borders hanging03">Race — no. (%)<a href="#t1fn3" role="doc-noteref">‡</a></td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13 shading" data-xml-align="left">White</td><td class="xxxx-borders shading">74 (80)</td><td class="xxxx-borders shading">78 (87)</td><td class="xxxx-borders shading">152 (84)</td><td class="xxxx-borders shading">72 (77)</td><td class="xxxr-borders shading">224 (81)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13" data-xml-align="left">Black or African American</td><td class="xxxx-borders">15 (16)</td><td class="xxxx-borders">6 (7)</td><td class="xxxx-borders">21 (12)</td><td class="xxxx-borders">14 (15)</td><td class="xxxr-borders">35 (13)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13 shading" data-xml-align="left">Asian</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">1 (1)</td><td class="xxxx-borders shading">1 (1)</td><td class="xxxx-borders shading">2 (2)</td><td class="xxxr-borders shading">3 (1)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13" data-xml-align="left">American Indian or Alaska Native</td><td class="xxxx-borders">0</td><td class="xxxx-borders">0</td><td class="xxxx-borders">0</td><td class="xxxx-borders">2 (2)</td><td class="xxxr-borders">2 (1)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13 shading" data-xml-align="left">Unknown</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">1 (1)</td><td class="xxxx-borders shading">1 (1)</td><td class="xxxx-borders shading">2 (2)</td><td class="xxxr-borders shading">3 (1)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13" data-xml-align="left">Not reported</td><td class="xxxx-borders">3 (3)</td><td class="xxxx-borders">4 (4)</td><td class="xxxx-borders">7 (4)</td><td class="xxxx-borders">1 (1)</td><td class="xxxr-borders">8 (3)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging03 shading" data-xml-align="left">Median weight (IQR) — kg<a href="#t1fn2" role="doc-noteref">†</a></td><td class="xxxx-borders shading">85.65 (72.20–97.10)</td><td class="xxxx-borders shading">86.25 (72.60–98.30)</td><td class="xxxx-borders shading">86.10 (72.60–97.30)</td><td class="xxxx-borders shading">83.90 (72.90–97.70)</td><td class="xxxr-borders shading">86.00 (72.60–97.50)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging03" data-xml-align="left">Body-mass index<a href="#t1fn4" role="doc-noteref">§</a></td><td class="xxxx-borders">30.39±6.578</td><td class="xxxx-borders">30.63±7.216</td><td class="xxxx-borders">30.51±6.874</td><td class="xxxx-borders">29.73±7.149</td><td class="xxxr-borders">30.25±6.961</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging03 shading" data-xml-align="left">Obesity — no. (%)<a href="#t1fn5" role="doc-noteref">¶</a></td><td class="xxxx-borders shading">39 (42)</td><td class="xxxx-borders shading">42 (47)</td><td class="xxxx-borders shading">81 (45)</td><td class="xxxx-borders shading">34 (37)</td><td class="xxxr-borders shading">115 (42)</td></tr><tr data-type="row"><td class="xxlx-borders hanging03">Baseline viral load in nasopharyngeal swab</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-type="row"><td class="xxlx-borders hanging13 shading">Raw values</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging23" data-xml-align="left">No. of patients</td><td class="xxxx-borders">84</td><td class="xxxx-borders">83</td><td class="xxxx-borders">167</td><td class="xxxx-borders">91</td><td class="xxxr-borders">258</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging23 shading" data-xml-align="left">Mean viral load — copies/ml</td><td class="xxxx-borders shading">16,080,000±27,810,000</td><td class="xxxx-borders shading">19,170,000±29,120,000</td><td class="xxxx-borders shading">17,620,000±28,420,000</td><td class="xxxx-borders shading">12,950,000±25,620,000</td><td class="xxxr-borders shading">15,970,000±27,510,000</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging23" data-xml-align="left">Median viral load (range) — copies/ml</td><td class="xxxx-borders">260,000 (1–71,000,000)</td><td class="xxxx-borders">195,000 (1–71,000,000)</td><td class="xxxx-borders">200,000 (1–71,000,000)</td><td class="xxxx-borders">50,500 (1–71,000,000)</td><td class="xxxr-borders">156,000 (1–71,000,000)</td></tr><tr data-type="row"><td class="xxlx-borders hanging13 shading">Log<sub>10</sub> scale</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging23" data-xml-align="left">No. of patients</td><td class="xxxx-borders">84</td><td class="xxxx-borders">83</td><td class="xxxx-borders">167</td><td class="xxxx-borders">91</td><td class="xxxr-borders">258</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging23 shading" data-xml-align="left">Mean viral load — log<sub>10</sub> copies/ml</td><td class="xxxx-borders shading">5.04±2.495</td><td class="xxxx-borders shading">5.00±2.527</td><td class="xxxx-borders shading">5.02±2.503</td><td class="xxxx-borders shading">4.67±2.366</td><td class="xxxr-borders shading">4.90±2.457</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging23" data-xml-align="left">Median viral load (range) — log<sub>10</sub> copies/ml</td><td class="xxxx-borders">5.41 (0.0–7.9)</td><td class="xxxx-borders">5.29 (0.0–7.9)</td><td class="xxxx-borders">5.30 (0.0–7.9)</td><td class="xxxx-borders">4.70 (0.0–7.9)</td><td class="xxxr-borders">5.19 (0.0–7.9)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging03 shading" data-xml-align="left">Positive baseline qualitative RT-PCR — no. (%)<a href="#t1fn6" role="doc-noteref">‖</a></td><td class="xxxx-borders shading">73 (79)</td><td class="xxxx-borders shading">74 (82)</td><td class="xxxx-borders shading">147 (81)</td><td class="xxxx-borders shading">81 (87)</td><td class="xxxr-borders shading">228 (83)</td></tr><tr data-type="row"><td class="xxlx-borders hanging03">Baseline serum C-reactive protein level</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13 shading" data-xml-align="left">No. of patients</td><td class="xxxx-borders shading">87</td><td class="xxxx-borders shading">86</td><td class="xxxx-borders shading">173</td><td class="xxxx-borders shading">92</td><td class="xxxr-borders shading">265</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13" data-xml-align="left">Mean level — mg/liter</td><td class="xxxx-borders">11.1±28.1</td><td class="xxxx-borders">12.2±20.0</td><td class="xxxx-borders">11.7±24.4</td><td class="xxxx-borders">21.5±43.5</td><td class="xxxr-borders">15.1±32.6</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13 shading" data-xml-align="left">Median level (range) — mg/liter</td><td class="xxxx-borders shading">3.0 (0.2–239.7)</td><td class="xxxx-borders shading">4.8 (0.1–138.7)</td><td class="xxxx-borders shading">3.7 (0.1–239.7)</td><td class="xxxx-borders shading">4.8 (0.1–232.0)</td><td class="xxxr-borders shading">4.1 (0.1–239.7)</td></tr><tr data-type="row"><td class="xxlx-borders hanging03">Baseline serum antibody status — no. (%)</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13 shading" data-xml-align="left">Negative</td><td class="xxxx-borders shading">41 (45)</td><td class="xxxx-borders shading">39 (43)</td><td class="xxxx-borders shading">80 (44)</td><td class="xxxx-borders shading">33 (35)</td><td class="xxxr-borders shading">113 (41)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13" data-xml-align="left">Positive</td><td class="xxxx-borders">37 (40)</td><td class="xxxx-borders">39 (43)</td><td class="xxxx-borders">76 (42)</td><td class="xxxx-borders">47 (51)</td><td class="xxxr-borders">123 (45)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13 shading" data-xml-align="left">Unknown<a href="#t1fn7" role="doc-noteref">**</a></td><td class="xxxx-borders shading">14 (15)</td><td class="xxxx-borders shading">12 (13)</td><td class="xxxx-borders shading">26 (14)</td><td class="xxxx-borders shading">13 (14)</td><td class="xxxr-borders shading">39 (14)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging03" data-xml-align="left">Median time from symptom onset to randomization (range) — days</td><td class="xxxx-borders">3.5 (0–7)</td><td class="xxxx-borders">3.0 (0–8)</td><td class="xxxx-borders">3.0 (0–8)</td><td class="xxxx-borders">3.0 (0–8)</td><td class="xxxr-borders">3.0 (0–8)</td></tr><tr data-xml-align="center" data-type="row"><td class="xblx-borders hanging03 shading" data-xml-align="left">At least one risk factor for hospitalization — no. (%)<a href="#t1fn8" role="doc-noteref">††</a></td><td class="xbxx-borders shading">57 (62)</td><td class="xbxx-borders shading">61 (68)</td><td class="xbxx-borders shading">118 (65)</td><td class="xbxx-borders shading">58 (62)</td><td class="xbxr-borders shading">176 (64)</td></tr></tbody></table></div><figcaption><div class="caption">Demographic and Baseline Medical Characteristics.<a href="#t1fn1" role="doc-noteref">*</a></div><div class="notes"><div role="doc-footnote" data-has="label"><div class="label">*</div><div id="t1fn1" role="paragraph">Plus–minus values are means ±SD. Percentages may not total 100 because of rounding. RT-PCR denotes reverse-transcriptase polymerase chain reaction.</div></div><div role="doc-footnote" data-has="label"><div class="label">†</div><div id="t1fn2" role="paragraph">The interquartile range (IQR) is defined as quartile 1 to quartile 3.</div></div><div role="doc-footnote" data-has="label"><div class="label">‡</div><div id="t1fn3" role="paragraph">Race and ethnic group were reported by the patients.</div></div><div role="doc-footnote" data-has="label"><div class="label">§</div><div id="t1fn4" role="paragraph">The body-mass index is the weight in kilograms divided by the square of the height in meters.</div></div><div role="doc-footnote" data-has="label"><div class="label">¶</div><div id="t1fn5" role="paragraph">Obesity is defined as a body-mass index of greater than 30.</div></div><div role="doc-footnote" data-has="label"><div class="label">‖</div><div id="t1fn6" role="paragraph">A positive result was defined as a viral load greater than or equal to the lower limit of detection (714 copies per milliliter [2.85 log<sub>10</sub> copies per milliliter]).</div></div><div role="doc-footnote" data-has="label"><div class="label">**</div><div id="t1fn7" role="paragraph">An unknown serum antibody status indicates that the status could not be evaluated or that the results were borderline.</div></div><div role="doc-footnote" data-has="label"><div class="label">††</div><div id="t1fn8" role="paragraph">Risk factors for hospitalization include an age of more than 50 years, obesity, cardiovascular disease (including hypertension), chronic lung disease (including asthma), chronic metabolic disease (including diabetes), chronic kidney disease (including receipt of dialysis), chronic liver disease, and immunocompromise (immunosuppression or receipt of immunosuppressants).</div></div></div></figcaption></figure></div><div role="paragraph">At randomization, 30 of 275 patients (11%) tested negative for SARS-CoV-2 by qualitative RT-PCR and 17 of 275 (6%) tested positive for SARS-CoV-2 but did not have baseline viral load data; therefore, 228 of the 275 patients (83%) who underwent randomization made up the modified full analysis set (i.e., those patients who were confirmed SARS-CoV-2–positive by RT-PCR at baseline). At baseline, 123 patients (45%) were serum antibody–positive, 113 (41%) were serum antibody–negative, and 39 (14%) had unknown antibody status. Baseline characteristics according to serum antibody status are shown in Table S1.</div></section><section id="sec-2-2"><h3>Natural History</h3><div role="paragraph">Any treatment effect of REGN-COV2 can be properly interpreted only in the context of an understanding of the endogenous immune response and its effect on viral load and disease course. Therefore, in addition to the prespecified trial end points, a major focus of the trial is to examine the natural history of Covid-19.</div><div role="paragraph">The median and mean baseline viral loads were 7.18 log<sub>10</sub> copies per milliliter and 6.60 log<sub>10</sub> copies per milliliter, respectively, among serum antibody–negative patients and were 3.49 log<sub>10</sub> copies per milliliter and 3.30 log<sub>10</sub> copies per milliliter, respectively, among serum antibody–positive patients (Fig. S2). The raw median baseline viral load among serum antibody–negative patients was also higher than that among serum antibody–positive patients (1.5×10<sup>7</sup> copies per milliliter vs. 3.1×10<sup>3</sup> copies per milliliter). In a retrospective analysis, the presence and titer of neutralizing antibodies were also associated with viral load: serum antibody–positive patients who lacked neutralizing activity had a viral load range similar to that among serum antibody–negative patients (see the Supplementary Study Results section in the <a href="#ap2">Supplementary Appendix</a>). Of the 6 patients in the placebo group who had a medically attended visit for worsening Covid-19 symptoms, only 1 was from the serum antibody–positive subgroup (1 of 47 [2%]), as compared with 5 from the serum antibody–negative subgroup (5 of 33 [15%]) (<a href="#t2">Table 2</a>). By these measures, patients in the serum antibody–positive subgroup had substantially lower viral loads and a lower likelihood of having a medically attended visit than patients in the serum antibody–negative subgroup.</div><div class="figure-wrap" data-presentation="diminished-in-flow"><header><div class="label">Table 2</div><nav><a href="#t2" title="Open in viewer" class="open-in-viewer" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2035002_t2.jpg"><i aria-hidden="true" class="icon-expand"></i></a></nav></header><figure id="t2" class="table"><div class="graphic-wrap" data-presentation="suppressed-in-viewer"><a aria-label="Open figure in viewer" class="open-in-viewer" data-index="0" href="#t2" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2035002_t2.jpg"><img src="/cms/10.1056/NEJMoa2035002/asset/94e47e11-9f70-43f6-bd7d-7a955e75f701/assets/images/large/nejmoa2035002_t2.jpg" height="3323" width="2615" loading="lazy"></a></div><div class="table-wrap catalyst-standard" data-presentation="suppressed-in-flow"><table data-shading="custom"><thead><tr class="head1" data-type="row head1"><th class="txlx-borders" data-xml-align="left">End Point</th><th class="txxx-borders" colspan="3"><span>REGN-COV2</span></th><th class="txxr-borders">Placebo</th></tr><tr class="head2" data-type="row head2"><td class="xxlx-borders">&nbsp;</td><th class="xxxx-borders">2.4 g</th><th class="xxxx-borders">8.0 g</th><th class="xxxx-borders">Combined</th><th class="xxxr-borders">&nbsp;</th></tr></thead><tbody><tr data-type="row"><td class="xxlx-borders hanging04 shading"><b>Time-weighted average change in viral load from day 1 through day 7</b><a href="#t2fn2" role="doc-noteref">†</a></td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-type="row"><td class="xxlx-borders hanging04">Modified full analysis set<a href="#t2fn3" role="doc-noteref">‡</a></td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders" data-xml-align="center">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging14" data-xml-align="left">No. of patients</td><td class="xxxx-borders">70</td><td class="xxxx-borders">73</td><td class="xxxx-borders">143</td><td class="xxxr-borders">78</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging14" data-xml-align="left">Least-squares mean change — log<sub>10</sub> copies/ml</td><td class="xxxx-borders">−1.60±0.14</td><td class="xxxx-borders">−1.90 ±0.14</td><td class="xxxx-borders">−1.74±0.11</td><td class="xxxr-borders">−1.34±0.13</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging24" data-xml-align="left">95% CI</td><td class="xxxx-borders">−1.87 to −1.32</td><td class="xxxx-borders">−2.18 to −1.62</td><td class="xxxx-borders">−1.95 to −1.53</td><td class="xxxr-borders">−1.60 to −1.08</td></tr><tr data-type="row"><td class="xxlx-borders hanging14">Difference vs. placebo at day 7 — log<sub>10</sub> copies/ml</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging24" data-xml-align="left">Least-squares mean</td><td class="xxxx-borders">−0.25±0.18</td><td class="xxxx-borders">−0.56±0.18</td><td class="xxxx-borders">−0.41±0.15</td><td class="xxxr-borders" data-xml-align="left">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging24" data-xml-align="left">95% CI</td><td class="xxxx-borders">−0.60 to 0.10</td><td class="xxxx-borders">−0.91 to −0.21</td><td class="xxxx-borders">−0.71 to −0.10</td><td class="xxxr-borders" data-xml-align="left">&nbsp;</td></tr><tr data-type="row"><td class="xxlx-borders hanging04 shading">Baseline serum antibody status: negative</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading" data-xml-align="center">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging14 shading" data-xml-align="left">No. of patients</td><td class="xxxx-borders shading">34</td><td class="xxxx-borders shading">35</td><td class="xxxx-borders shading">69</td><td class="xxxr-borders shading">28</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging14 shading" data-xml-align="left">Least-squares mean change — log<sub>10</sub> copies/ml</td><td class="xxxx-borders shading">−1.89±0.18</td><td class="xxxx-borders shading">−1.96±0.18</td><td class="xxxx-borders shading">−1.94±0.13</td><td class="xxxr-borders shading">−1.37±0.20</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging24 shading" data-xml-align="left">95% CI</td><td class="xxxx-borders shading">−2.24 to −1.53</td><td class="xxxx-borders shading">−2.33 to −1.60</td><td class="xxxx-borders shading">−2.20 to −1.67</td><td class="xxxr-borders shading">−1.76 to −0.98</td></tr><tr data-type="row"><td class="xxlx-borders hanging14 shading">Difference vs. placebo at day 7 — log<sub>10</sub> copies/ml</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging24 shading" data-xml-align="left">Least-squares mean</td><td class="xxxx-borders shading">−0.52±0.26</td><td class="xxxx-borders shading">−0.60±0.26</td><td class="xxxx-borders shading">−0.56±0.23</td><td class="xxxr-borders shading" data-xml-align="left">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging24 shading" data-xml-align="left">95% CI</td><td class="xxxx-borders shading">−1.04 to 0.00</td><td class="xxxx-borders shading">−1.12 to −0.08</td><td class="xxxx-borders shading">−1.02 to −0.11</td><td class="xxxr-borders shading" data-xml-align="left">&nbsp;</td></tr><tr data-type="row"><td class="xxlx-borders hanging04">Baseline serum antibody status: positive</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders" data-xml-align="center">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging14" data-xml-align="left">No. of patients</td><td class="xxxx-borders">27</td><td class="xxxx-borders">29</td><td class="xxxx-borders">56</td><td class="xxxr-borders">37</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging14" data-xml-align="left">Least-squares mean change — log<sub>10</sub> copies/ml</td><td class="xxxx-borders">−1.24±0.19</td><td class="xxxx-borders">−1.63±0.20</td><td class="xxxx-borders">−1.45±0.13</td><td class="xxxr-borders">−1.24±0.16</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging24" data-xml-align="left">95% CI</td><td class="xxxx-borders">−1.61 to −0.86</td><td class="xxxx-borders">−2.03 to −1.24</td><td class="xxxx-borders">−1.71 to −1.18</td><td class="xxxr-borders">−1.55 to −0.93</td></tr><tr data-type="row"><td class="xxlx-borders hanging14">Difference vs. placebo at day 7, log<sub>10</sub> copies/ml</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging24" data-xml-align="left">Least-squares mean</td><td class="xxxx-borders">0.00±0.24</td><td class="xxxx-borders">−0.39±0.25</td><td class="xxxx-borders">−0.21±0.20</td><td class="xxxr-borders" data-xml-align="left">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging24" data-xml-align="left">95% CI</td><td class="xxxx-borders">−0.48 to 0.49</td><td class="xxxx-borders">−0.89 to 0.11</td><td class="xxxx-borders">−0.62 to 0.20</td><td class="xxxr-borders" data-xml-align="left">&nbsp;</td></tr><tr data-type="row"><td class="xxlx-borders hanging04 shading">Baseline serum antibody status: unknown<a href="#t2fn4" role="doc-noteref">§</a></td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading" data-xml-align="center">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging14 shading" data-xml-align="left">No. of patients</td><td class="xxxx-borders shading">9</td><td class="xxxx-borders shading">9</td><td class="xxxx-borders shading">18</td><td class="xxxr-borders shading">13</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging14 shading" data-xml-align="left">Least-squares mean change — log<sub>10</sub> copies/ml</td><td class="xxxx-borders shading">−0.95±0.56</td><td class="xxxx-borders shading">−1.98±0.60</td><td class="xxxx-borders shading">−1.43±0.44</td><td class="xxxr-borders shading">−1.49±0.63</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging24 shading" data-xml-align="left">95% CI</td><td class="xxxx-borders shading">−2.12 to 0.22</td><td class="xxxx-borders shading">−3.22 to −0.73</td><td class="xxxx-borders shading">−2.34 to −0.51</td><td class="xxxr-borders shading">−2.79 to − 0.19</td></tr><tr data-type="row"><td class="xxlx-borders hanging14 shading">Difference vs. placebo at day 7 — log<sub>10</sub> copies/ml</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging24 shading" data-xml-align="left">Least-squares mean</td><td class="xxxx-borders shading">0.54±0.84</td><td class="xxxx-borders shading">−0.49±0.86</td><td class="xxxx-borders shading">0.06±0.76</td><td class="xxxr-borders shading" data-xml-align="left">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging24 shading" data-xml-align="left">95% CI</td><td class="xxxx-borders shading">−1.20 to 2.28</td><td class="xxxx-borders shading">−2.27 to 1.30</td><td class="xxxx-borders shading">−1.51 to 1.63</td><td class="xxxr-borders shading" data-xml-align="left">&nbsp;</td></tr><tr data-type="row"><td class="xxlx-borders hanging04"><b>At least one Covid-19–related, medically attended visit within 29 days</b><a href="#t2fn5" role="doc-noteref">¶</a></td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-type="row"><td class="xxlx-borders hanging04 shading">Full analysis set</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading" data-xml-align="center">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging14 shading" data-xml-align="left">No. of patients</td><td class="xxxx-borders shading">92</td><td class="xxxx-borders shading">90</td><td class="xxxx-borders shading">182</td><td class="xxxr-borders shading">93</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging14 shading" data-xml-align="left">Patients with ≥1 visit within 29 days — no. (%)</td><td class="xxxx-borders shading">3 (3)</td><td class="xxxx-borders shading">3 (3)</td><td class="xxxx-borders shading">6 (3)</td><td class="xxxr-borders shading">6 (6)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging24 shading" data-xml-align="left">Difference vs. placebo — percentage points</td><td class="xxxx-borders shading">−3</td><td class="xxxx-borders shading">−3</td><td class="xxxx-borders shading">−3</td><td class="xxxr-borders shading" data-xml-align="left">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging34 shading" data-xml-align="left">95% CI</td><td class="xxxx-borders shading">−18 to 11</td><td class="xxxx-borders shading">−18 to 11</td><td class="xxxx-borders shading">−16 to 9</td><td class="xxxr-borders shading" data-xml-align="left">&nbsp;</td></tr><tr data-type="row"><td class="xxlx-borders hanging04">Baseline serum antibody status: negative</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders" data-xml-align="center">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging14" data-xml-align="left">No. of patients</td><td class="xxxx-borders">41</td><td class="xxxx-borders">39</td><td class="xxxx-borders">80</td><td class="xxxr-borders">33</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging14" data-xml-align="left">Patients with ≥1 visit within 29 days — no. (%)</td><td class="xxxx-borders">2 (5)</td><td class="xxxx-borders">3 (8)</td><td class="xxxx-borders">5 (6)</td><td class="xxxr-borders">5 (15)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging24" data-xml-align="left">Difference vs. placebo — percentage points</td><td class="xxxx-borders">−10</td><td class="xxxx-borders">−8</td><td class="xxxx-borders">−9</td><td class="xxxr-borders" data-xml-align="left">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging34" data-xml-align="left">95% CI</td><td class="xxxx-borders">−32 to 13</td><td class="xxxx-borders">−30 to 16</td><td class="xxxx-borders">−29 to 11</td><td class="xxxr-borders" data-xml-align="left">&nbsp;</td></tr><tr data-type="row"><td class="xxlx-borders hanging04 shading">Baseline serum antibody status: positive</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading" data-xml-align="center">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging14 shading" data-xml-align="left">No. of patients</td><td class="xxxx-borders shading">37</td><td class="xxxx-borders shading">39</td><td class="xxxx-borders shading">76</td><td class="xxxr-borders shading">47</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging14 shading" data-xml-align="left">Patients with ≥1 visit within 29 days — no. (%)</td><td class="xxxx-borders shading">1 (3)</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">1 (1)</td><td class="xxxr-borders shading">1 (2)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging24 shading" data-xml-align="left">Difference vs. placebo — percentage points</td><td class="xxxx-borders shading">1</td><td class="xxxx-borders shading">−2</td><td class="xxxx-borders shading">−1</td><td class="xxxr-borders shading" data-xml-align="left">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging34 shading" data-xml-align="left">95% CI</td><td class="xxxx-borders shading">−21 to 22</td><td class="xxxx-borders shading">−23 to 19</td><td class="xxxx-borders shading">−19 to 17</td><td class="xxxr-borders shading" data-xml-align="left">&nbsp;</td></tr><tr data-type="row"><td class="xxlx-borders hanging04">Baseline serum antibody status: unknown<a href="#t2fn4" role="doc-noteref">§</a></td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders" data-xml-align="center">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging14" data-xml-align="left">No. of patients</td><td class="xxxx-borders">14</td><td class="xxxx-borders">12</td><td class="xxxx-borders">26</td><td class="xxxr-borders">13</td></tr><tr data-xml-align="center" data-type="row"><td class="xblx-borders hanging14" data-xml-align="left">Patients with ≥1 visit within 29 days — no. (%)</td><td class="xbxx-borders">0</td><td class="xbxx-borders">0</td><td class="xbxx-borders">0</td><td class="xbxr-borders">0</td></tr></tbody></table></div><figcaption><div class="caption">Key Virologic and Clinical End Points.<a href="#t2fn1" role="doc-noteref">*</a></div><div class="notes"><div role="doc-footnote" data-has="label"><div class="label">*</div><div id="t2fn1" role="paragraph">Plus–minus values are least-squares means ±SE. Covid-19 denotes coronavirus disease 2019.</div></div><div role="doc-footnote" data-has="label"><div class="label">†</div><div id="t2fn2" role="paragraph">The time-weighted average change in viral load was based on an analysis-of-covariance model with treatment group, risk factor, and baseline serum antibody status as fixed effects and baseline viral load and treatment group–by–baseline viral load as covariates. Confidence intervals were not adjusted for multiplicity.</div></div><div role="doc-footnote" data-has="label"><div class="label">‡</div><div id="t2fn3" role="paragraph">The modified full analysis set excluded patients who tested negative for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) by qualitative reverse-transcriptase polymerase chain reaction at baseline.</div></div><div role="doc-footnote" data-has="label"><div class="label">§</div><div id="t2fn4" role="paragraph">An unknown serum antibody status indicates that the status could not be evaluated or that the results were borderline.</div></div><div role="doc-footnote" data-has="label"><div class="label">¶</div><div id="t2fn5" role="paragraph">Confidence intervals for the difference (REGN-COV2 minus placebo) were based on the exact method and were not adjusted for multiplicity.</div></div></div></figcaption></figure></div></section><section id="sec-2-3"><h3>Virologic Efficacy</h3><div role="paragraph">The prespecified key virologic end point was the time-weighted average change from baseline in viral load through day 7 (log<sub>10</sub> scale) in patients in the modified full analysis set who were serum antibody–negative at baseline. In this group, the least-squares mean difference from placebo was −0.52 log<sub>10</sub> copies per milliliter (95% confidence interval [CI], −1.04 to 0.00) in the low-dose REGN-COV2 group, −0.60 log<sub>10</sub> copies per milliliter (95% CI, −1.12 to −0.08) in the high-dose REGN-COV2 group, and −0.56 log<sub>10</sub> copies per milliliter (95% CI, −1.02 to −0.11) in the combined REGN-COV2 group (<a href="#t2">Table 2</a>). In the overall trial population, the least-squares mean differences from placebo were −0.25 log<sub>10</sub> copies per milliliter (95% CI, −0.60 to 0.10), −0.56 log<sub>10</sub> copies per milliliter (95% CI, −0.91 to −0.21), and −0.41 log<sub>10</sub> copies per milliliter (95% CI, −0.71 to −0.10), respectively.</div><div role="paragraph">Additional, post hoc virologic end points included viral load over time and virologic outcomes according to baseline viral load (&gt;10<sup>4</sup>, &gt;10<sup>5</sup>, &gt;10<sup>6</sup>, or &gt;10<sup>7</sup> copies per milliliter) and according to baseline serum antibody status (<a href="#f2">Figure 2</a>, Figs. S3 through S5, and Table S2). Similar treatment benefits were observed in the covariate-adjusted (prespecified) and unadjusted (post hoc) analyses (Fig. S4). Patients with the highest viral loads had the largest treatment benefit. In an analysis on a log<sub>10</sub> scale involving patients whose baseline viral load was higher than 10<sup>7</sup> copies per milliliter, the mean reduction in viral load at day 7 was approximately 2-log greater among patients who received REGN-COV2 than among patients who received placebo (<a href="#f2">Figure 2</a>). Most of the reduction in viral load was evident by trial day 3 (2 days after infusion).</div><div class="figure-wrap" data-presentation="diminished-in-flow"><header><div class="label">Figure 2</div><nav><a href="#f2" title="Open in viewer" class="open-in-viewer" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa2035002_f2.jpg"><i aria-hidden="true" class="icon-expand"></i></a></nav></header><figure id="f2" class="graphic"><a aria-label="Open figure in viewer" class="open-in-viewer" data-index="0" href="#f2" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa2035002_f2.jpg"><img src="/cms/10.1056/NEJMoa2035002/asset/6dfe3683-c06a-498e-b72e-63041484af8e/assets/images/large/nejmoa2035002_f2.jpg" height="2016" width="2640" aria-labelledby="f2" loading="lazy"></a><figcaption><div class="caption">SARS-CoV-2 Viral Load over Time.</div><div class="notes"><div role="doc-footnote">Shown is the change in mean viral load (in log<sub>10</sub> copies per milliliter) from baseline at each visit through day 7 in the overall population (modified full analysis set, which excluded patients who tested negative for severe acute respiratory syndrome coronavirus 2 [SARS-CoV-2] by qualitative reverse-transcriptase polymerase chain reaction at baseline) and in groups defined according to baseline antibody status and baseline viral load. 𝙸 bars in Panel C indicate the standard error. The least-squares mean difference between the groups in the time-weighted average change in viral load (TWA LS mean) from baseline through day 7, expressed as log<sub>10</sub> copies per milliliter, was based on analysis-of-covariance models with treatment group, risk factor, and baseline antibody status as fixed effects and baseline viral load and treatment group–by–baseline viral load as covariates. The lower limit of detection (dashed line) is 714 copies per milliliter (2.85 log<sub>10</sub> copies per milliliter).</div></div></figcaption></figure></div></section><section id="sec-2-4"><h3>Clinical Efficacy</h3><div role="paragraph">The key prespecified clinical end point was the percentage of patients with one or more medically attended visits. In the full analysis set, 6 of 93 patients (6%) in the placebo group and 6 of 182 patients (3%) in the combined REGN-COV2 group had a medically attended visit, a relative difference of approximately 49% (absolute difference vs. placebo, −3 percentage points; 95% CI, −16 to 9). In the serum antibody–negative subgroup, 5 of 33 patients (15%) in the placebo group and 5 of 80 patients (6%) in the combined REGN-COV2 group had a medically attended visit, a relative difference of approximately 59% (absolute difference vs. placebo, −9 percentage points; 95% CI, −29 to 11) (<a href="#t2">Table 2</a>). Results from a subsequent descriptive analysis involving a larger data set<sup><a href="#core-r19" role="doc-biblioref" data-xml-rid="r19" id="body-ref-r19" href-manipulated="true" aria-label="Reference 19">19</a></sup> indicated that time to alleviation of symptoms was not strongly associated with treatment (or with baseline viral load or baseline serum antibody status) (unpublished data).</div></section><section id="sec-2-5"><h3>Safety</h3><div role="paragraph">In this interim analysis, both REGN-COV2 doses (2.4 g and 8.0 g) were associated with few and mainly low-grade toxic effects (<a href="#t3">Table 3</a> and Table S3). Among the 269 patients in the safety population, the incidence of serious adverse events and adverse events of special interest that occurred or worsened during the observation period, which included grade 2 or higher infusion-related reactions and hypersensitivity reactions, were balanced between the combined REGN-COV2 dose groups and the placebo group. An adverse event of special interest was reported in 2 of 93 patients (2%) in the placebo group and in 2 of 176 patients (1%) in the combined REGN-COV2 dose groups.</div><div class="figure-wrap" data-presentation="diminished-in-flow"><header><div class="label">Table 3</div><nav><a href="#t3" title="Open in viewer" class="open-in-viewer" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2035002_t3.jpg"><i aria-hidden="true" class="icon-expand"></i></a></nav></header><figure id="t3" class="table"><div class="graphic-wrap" data-presentation="suppressed-in-viewer"><a aria-label="Open figure in viewer" class="open-in-viewer" data-index="0" href="#t3" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2035002_t3.jpg"><img src="/cms/10.1056/NEJMoa2035002/asset/2fe99bb1-da2e-469d-9589-8b11f161d50f/assets/images/large/nejmoa2035002_t3.jpg" height="1171" width="1999" loading="lazy"></a></div><div class="table-wrap catalyst-standard" data-presentation="suppressed-in-flow"><table data-shading="custom"><thead><tr class="head1" data-type="row head1"><th class="txlx-borders" data-xml-align="left">Event</th><th class="txxx-borders" colspan="3"><span>REGN-COV2</span></th><th class="txxr-borders">Placebo<br>(N=93)</th></tr><tr class="head2" data-type="row head2"><td class="xxlx-borders">&nbsp;</td><th class="xxxx-borders">2.4 g<br>(N=88)</th><th class="xxxx-borders">8.0 g<br>(N=88)</th><th class="xxxx-borders">Combined<br>(N=176)</th><th class="xxxr-borders">&nbsp;</th></tr><tr class="head3" data-type="row head3"><td class="xxlx-borders">&nbsp;</td><th class="xxxr-borders" colspan="4"><span>number of patients (percent)</span></th></tr></thead><tbody><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02 shading" data-xml-align="left">Any serious adverse event</td><td class="xxxx-borders shading">1 (1)</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">1 (1)</td><td class="xxxr-borders shading">2 (2)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02" data-xml-align="left">Any adverse event of special interest<a href="#t3fn1" role="doc-noteref">*</a></td><td class="xxxx-borders">0</td><td class="xxxx-borders">2 (2)</td><td class="xxxx-borders">2 (1)</td><td class="xxxr-borders">2 (2)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02 shading" data-xml-align="left">Any serious adverse event of special interest<a href="#t3fn1" role="doc-noteref">*</a></td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">0</td><td class="xxxr-borders shading">0</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02" data-xml-align="left">Grade ≥2 infusion-related reaction within 4 days</td><td class="xxxx-borders">0</td><td class="xxxx-borders">2 (2)</td><td class="xxxx-borders">2 (1)</td><td class="xxxr-borders">1 (1)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02 shading" data-xml-align="left">Grade ≥2 hypersensitivity reaction within 29 days</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">1 (1)</td><td class="xxxx-borders shading">1 (1)</td><td class="xxxr-borders shading">2 (2)</td></tr><tr data-type="row"><td class="xxlx-borders hanging02">Adverse events that occurred or worsened during the observation period<a href="#t3fn2" role="doc-noteref">†</a></td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders" data-xml-align="center">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Grade 3 or 4 event</td><td class="xxxx-borders shading">1 (1)</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">1 (1)</td><td class="xxxr-borders shading">1 (1)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Event that led to death</td><td class="xxxx-borders">0</td><td class="xxxx-borders">0</td><td class="xxxx-borders">0</td><td class="xxxr-borders">0</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Event that led to withdrawal from the trial</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">0</td><td class="xxxr-borders shading">0</td></tr><tr data-xml-align="center" data-type="row"><td class="xblx-borders hanging12" data-xml-align="left">Event that led to infusion interruption<a href="#t3fn1" role="doc-noteref">*</a></td><td class="xbxx-borders">0</td><td class="xbxx-borders">1 (1)</td><td class="xbxx-borders">1 (1)</td><td class="xbxr-borders">1 (1)</td></tr></tbody></table></div><figcaption><div class="caption">Serious Adverse Events and Adverse Events of Special Interest in the Safety Population.</div><div class="notes"><div role="doc-footnote" data-has="label"><div class="label">*</div><div id="t3fn1" role="paragraph">Events were grade 2 or higher hypersensitivity reactions or infusion-related reactions.</div></div><div role="doc-footnote" data-has="label"><div class="label">†</div><div id="t3fn2" role="paragraph">Events listed here were not present at baseline or were an exacerbation of a preexisting condition that occurred during the observation period, which is defined as the time from administration of REGN-COV2 or placebo to the last study visit.</div></div></div></figcaption></figure></div></section><section id="sec-2-6"><h3>Pharmacokinetics</h3><div role="paragraph">The mean and individual concentration–time profiles for the components of REGN-COV2 — casirivimab and imdevimab — increased in a dose-proportional manner and were consistent with linear pharmacokinetics for single intravenous doses (Figs. S6 and S7). The mean (±SD) day 29 concentrations of casirivimab and imdevimab in serum were 68.0±45.2 mg per liter and 64.9±53.9 mg per liter, respectively, for the low (1.2 g) doses and 219±69.0 and 181±64.9 mg per liter, respectively, for the high (4.0 g) doses (Table S4); the mean estimated half-life ranged from 25 to 37 days for both antibodies (Table S5).</div></section></section><section id="sec-3" data-type="discussion"><h2>Discussion</h2><div role="paragraph">To test the hypothesis that exogenously provided antibodies would have the most benefit in patients whose own immune response had not yet been initiated, our trial first characterized the natural history of Covid-19 and showed that, in the outpatient context, preexisting antibodies against SARS-CoV-2 were associated with lower viral loads at baseline and a potential lower likelihood of future medically attended visits. One possible reason for this observation is that patients whose endogenous immune responses were active (serum antibody–positive) were already efficiently clearing the virus, as compared with patients whose immune response had not yet been initiated (serum antibody–negative). These findings are consistent with those in other studies that have shown an association between native antibodies against SARS-CoV-2 and viral loads.<sup><a href="#core-r14" role="doc-biblioref" data-xml-rid="r14 r20" id="body-ref-r20" href-manipulated="true">14,20</a></sup> Overall, our findings are consistent with the hypothesis that most infected persons successfully recover because of their endogenous immune response.<sup><a href="#core-r21" role="doc-biblioref" data-xml-rid="r21" id="body-ref-r21" href-manipulated="true" aria-label="Reference 21">21</a></sup> This understanding of the natural history of Covid-19 supported our prospective hypothesis that an exogenously provided antibody cocktail would have the most benefit in patients whose own immune response had not yet been initiated, since such patients would have higher baseline viral loads and a higher likelihood of seeking additional medical treatment.</div><div role="paragraph">Our data indicate that REGN-COV2 enhanced clearance of virus, particularly in patients in whom an endogenous immune response had not yet been initiated (i.e., serum antibody–negative) or who had a high viral load at baseline. A possible difference in the percentage of patients with medically attended visits was observed between the combined REGN-COV2 dose groups and the placebo group (difference, −3 percentage points; 95% CI, −16 to 9), and this effect was also driven almost entirely by patients who were serum antibody–negative at baseline (difference, −9 percentage points; 95% CI, −29 to 11).</div><div role="paragraph">As hypothesized, in patients whose immune response was active at trial entry, the potential to improve this response with an exogenous antibody cocktail was minimal. Administration of such a cocktail did not increase the viral load and therefore did not appear to impede ongoing antiviral activity. In this regard, it may be useful to evaluate the potential for REGN-COV2 to affect long-term immunity to SARS-CoV-2, regardless of patients’ serum antibody status.</div><div role="paragraph">Higher viral loads have been correlated with an increased risk of death among hospitalized patients.<sup><a href="#core-r22" role="doc-biblioref" data-xml-rid="r22" id="body-ref-r22" href-manipulated="true" aria-label="Reference 22">22</a></sup> High-titer convalescent-phase plasma may lower the SARS-CoV-2 viral load and thereby reduce the risk of death from Covid-19.<sup><a href="#core-r23" role="doc-biblioref" data-xml-rid="r23 r24" id="body-ref-r24" href-manipulated="true">23,24</a></sup> Likewise, in our trial, clearance of the virus was correlated with better clinical outcomes. The neutralizing titers achieved with REGN-COV2 were more than 1000 times the titers achievable with convalescent-phase plasma, and REGN-COV2 had a profound and rapid effect on viral load, with most reduction occurring within 48 hours. This was striking even in the patients with the highest quantifiable viral loads, greater than 10<sup>7</sup> copies per milliliter; these patients were presumably at the highest risk for additional complications and death. Our results also suggest a testable hypothesis that a shorter time to elimination of viral load would reduce the time of potential infectivity. This hypothesis is being studied in a separate REGN-COV2 trial (ClinicalTrials.gov number, <a href="http://clinicaltrials.gov/show/NCT04452318" target="_blank">NCT04452318</a>).</div><div role="paragraph">The time from the first Covid-19 symptom to randomization was similar in serum antibody–positive patients and serum antibody–negative patients. This observation suggests that symptom onset is not a good predictor of when an immune response is initiated in an individual patient. Similarly, other measures of symptomatology were not strongly correlated with endogenous or exogenously provided antibodies (unpublished data).</div><div role="paragraph">The safety of REGN-COV2 was as expected for a fully human antibody against an exogenous target. A low incidence of serious adverse events that occurred or worsened during the observation period and of infusion-related or hypersensitivity reactions was observed.</div><div role="paragraph">The pharmacokinetics of each antibody were linear and dose-proportional. Although antidrug-antibody results are not available, no patient had a concentration–time profile in serum that was consistent with altered elimination due to the development of antidrug antibodies. For more than 95% of patients, concentrations of the drug in serum at day 29 were well above the predicted neutralization target concentration based on in vitro and preclinical data. This long half-life of REGN-COV2 suggests that treatment could result in long-term passive immunity for several months. The pharmacokinetic data were similar at each dose of REGN-COV2.</div><div role="paragraph">An important limitation of this interim portion of our trial is that, although the analyses according to antibody status were prespecified, no formal hypothesis testing was performed to control type I error; in addition, the analyses according to baseline viral load were post hoc. These results should therefore be rigorously tested in the next analysis in this ongoing trial.</div><div role="paragraph">Similar findings showing a reduction in viral load and potential improvement in clinical outcomes were independently reported with a single neutralizing antibody against SARS-CoV-2.<sup><a href="#core-r25" role="doc-biblioref" data-xml-rid="r25" id="body-ref-r25" href-manipulated="true" aria-label="Reference 25">25</a></sup> It was recently shown that an antibody cocktail approach provided a profound survival benefit for patients infected with Ebola virus.<sup><a href="#core-r26" role="doc-biblioref" data-xml-rid="r26" id="body-ref-r26" href-manipulated="true" aria-label="Reference 26">26</a></sup> Our analysis suggests that an antibody cocktail against SARS-CoV-2 can also be an effective antiviral therapy, enhancing viral clearance and thus leading to improved outcomes, particularly in patients whose own immune response to the virus is slow to initiate. Further studies, including the continuing phase 3 portion of this trial, are needed to confirm these effects.</div></section>



        
        
</div></section><section id="backmatter" data-extent="backmatter" data-location="articleTab_article"><div class="core-container"><section id="backnotes" data-location="notes_article"><h2>Notes</h2><div data-type="published/updated" role="paragraph">This article was published on December 17, 2020, and updated on December 18, 2020, at NEJM.org.</div><div data-type="data-sharing" role="paragraph">A <a href="#ap4">data sharing statement</a> provided by the authors is available with the full text of this article at NEJM.org.</div><div role="paragraph">Supported by Regeneron Pharmaceuticals and the Biomedical and Advanced Research and Development Authority of the Department of Health and Human Services (contract number <span class="named-content" data-type="funder">HHS</span>O100201700020C).</div><div role="paragraph"><a href="#ap3">Disclosure forms</a> provided by the authors are available with the full text of this article at NEJM.org.</div><div role="paragraph">We thank the patients; their families; the investigational site members involved in this trial (principal and subprincipal investigators, listed in the <a href="#ap2">Supplementary Appendix</a>); the Regeneron trial team (members listed in the <a href="#ap2">Supplementary Appendix</a>); the members of the independent data and safety monitoring committee; S. Balachandra Dass, Ph.D., Caryn Trbovic, Ph.D., and Brian Head, Ph.D., from Regeneron Pharmaceuticals for assistance with development of an earlier version of the manuscript; and Prime for formatting and copy editing suggestions for an earlier version of the manuscript.</div></section><section id="supplementary-materials" class="core-supplementary-materials"><h2>Supplementary Material</h2><div role="list"><div id="ap1" class="core-supplementary-material" role="listitem"><div class="core-description"><span class="core-label">Protocol</span> <span class="core-filename">(nejmoa2035002_protocol.pdf)</span></div><div class="core-link"><ul><li><a href="/doi/suppl/10.1056/NEJMoa2035002/suppl_file/nejmoa2035002_protocol.pdf" download="nejmoa2035002_protocol.pdf" data-interactiontype="multimedia_download" data-multimedia-type="Supplementary Material" data-behavior="trackDownloadEvent" data-multimedia-filename="nejmoa2035002_protocol.pdf" data-doi="10.1056/NEJMoa2035002">Download</a></li><li>2.31 MB</li></ul></div></div><div id="ap2" class="core-supplementary-material" role="listitem"><div class="core-description"><span class="core-label">Supplementary Appendix</span> <span class="core-filename">(nejmoa2035002_appendix.pdf)</span></div><div class="core-link"><ul><li><a href="/doi/suppl/10.1056/NEJMoa2035002/suppl_file/nejmoa2035002_appendix.pdf" download="nejmoa2035002_appendix.pdf" data-interactiontype="multimedia_download" data-multimedia-type="Supplementary Material" data-behavior="trackDownloadEvent" data-multimedia-filename="nejmoa2035002_appendix.pdf" data-doi="10.1056/NEJMoa2035002">Download</a></li><li>2.10 MB</li></ul></div></div><div id="ap3" class="core-supplementary-material" role="listitem"><div class="core-description"><span class="core-label">Disclosure Forms</span> <span class="core-filename">(nejmoa2035002_disclosures.pdf)</span></div><div class="core-link"><ul><li><a href="/doi/suppl/10.1056/NEJMoa2035002/suppl_file/nejmoa2035002_disclosures.pdf" download="nejmoa2035002_disclosures.pdf" data-interactiontype="multimedia_download" data-multimedia-type="Supplementary Material" data-behavior="trackDownloadEvent" data-multimedia-filename="nejmoa2035002_disclosures.pdf" data-doi="10.1056/NEJMoa2035002">Download</a></li><li>622.66 KB</li></ul></div></div><div id="ap4" class="core-supplementary-material" role="listitem"><div class="core-description"><span class="core-label">Data Sharing Statement</span> <span class="core-filename">(nejmoa2035002_data-sharing.pdf)</span></div><div class="core-link"><ul><li><a href="/doi/suppl/10.1056/NEJMoa2035002/suppl_file/nejmoa2035002_data-sharing.pdf" download="nejmoa2035002_data-sharing.pdf" data-interactiontype="multimedia_download" data-multimedia-type="Supplementary Material" data-behavior="trackDownloadEvent" data-multimedia-filename="nejmoa2035002_data-sharing.pdf" data-doi="10.1056/NEJMoa2035002">Download</a></li><li>69.02 KB</li></ul></div></div></div></section><section id="bibliography" class="core-reference-list" role="doc-bibliography" data-location="references_article"><h2>References</h2><div role="list" data-method="clamp" id="collapsible-text"><div role="listitem" data-has="label"><div class="label">1.</div><div id="r1" class="citations"><div class="citation"><div class="citation-content">Zhu N, Zhang D, Wang W, et al. A novel coronavirus from patients with pneumonia in China, 2019. <em>N Engl J Med</em> 2020;382:727-733.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r1"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="/servlet/linkout?suffix=e_1_3_5_2_2&amp;dbid=4&amp;doi=10.1056%2FNEJMoa2035002&amp;key=10.1056%2FNEJMoa2001017&amp;site=mms-site" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/31978945/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000517119800008" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=A+novel+coronavirus+from+patients+with+pneumonia+in+China%2C+2019.&amp;publication_year=2020&amp;journal=N+Engl+J+Med&amp;pages=727-733&amp;doi=10.1056%2FNEJMoa2001017&amp;pmid=31978945" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">2.</div><div id="r2" class="citations"><div class="citation"><div class="citation-content">Gudbjartsson DF, Helgason A, Jonsson H, et al. Spread of SARS-CoV-2 in the Icelandic population. <em>N Engl J Med</em> 2020;382:2302-2315.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r5"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="/servlet/linkout?suffix=e_1_3_5_3_2&amp;dbid=4&amp;doi=10.1056%2FNEJMoa2035002&amp;key=10.1056%2FNEJMoa2006100&amp;site=mms-site" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/32289214/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000541151500010" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Spread+of+SARS-CoV-2+in+the+Icelandic+population.&amp;publication_year=2020&amp;journal=N+Engl+J+Med&amp;pages=2302-2315&amp;doi=10.1056%2FNEJMoa2006100&amp;pmid=32289214" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">3.</div><div id="r3" class="citations"><div class="citation"><div class="citation-content">Lavezzo E, Franchin E, Ciavarella C, et al. Suppression of a SARS-CoV-2 outbreak in the Italian municipality of Vo’. <em>Nature</em> 2020;584:425-429.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r5"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1038/s41586-020-2488-1" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/32604404/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000556239500001" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Suppression+of+a+SARS-CoV-2+outbreak+in+the+Italian+municipality+of+Vo%E2%80%99.&amp;publication_year=2020&amp;journal=Nature&amp;pages=425-429&amp;doi=10.1038%2Fs41586-020-2488-1&amp;pmid=32604404" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">4.</div><div id="r4" class="citations"><div class="citation"><div class="citation-content">Lee S, Kim T, Lee E, et al. Clinical course and molecular viral shedding among asymptomatic and symptomatic patients with SARS-CoV-2 infection in a community treatment center in the Republic of Korea. <em>JAMA Intern Med</em> 2020;180:1447-1452.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r5"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1001/jamainternmed.2020.3862" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/32780793/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000604965700009" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Clinical+course+and+molecular+viral+shedding+among+asymptomatic+and+symptomatic+patients+with+SARS-CoV-2+infection+in+a+community+treatment+center+in+the+Republic+of+Korea.&amp;publication_year=2020&amp;journal=JAMA+Intern+Med&amp;pages=1447-1452&amp;doi=10.1001%2Fjamainternmed.2020.3862&amp;pmid=32780793" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">5.</div><div id="r5" class="citations"><div class="citation"><div class="citation-content">Oran DP, Topol EJ. Prevalence of asymptomatic SARS-CoV-2 infection: a narrative review. <em>Ann Intern Med</em> 2020;173:362-367.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r5"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.7326/M20-3012" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/32491919/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000567080900010" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Prevalence+of+asymptomatic+SARS-CoV-2+infection%3A+a+narrative+review.&amp;publication_year=2020&amp;journal=Ann+Intern+Med&amp;pages=362-367&amp;doi=10.7326%2FM20-3012&amp;pmid=32491919" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">6.</div><div id="r6" class="citations"><div class="citation"><div class="citation-content">Goyal P, Choi JJ, Pinheiro LC, et al. Clinical characteristics of Covid-19 in New York City. <em>N Engl J Med</em> 2020;382:2372-2374.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r8"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="/servlet/linkout?suffix=e_1_3_5_7_2&amp;dbid=4&amp;doi=10.1056%2FNEJMoa2035002&amp;key=10.1056%2FNEJMc2010419&amp;site=mms-site" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/32302078/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000541151500019" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Clinical+characteristics+of+Covid-19+in+New+York+City.&amp;publication_year=2020&amp;journal=N+Engl+J+Med&amp;pages=2372-2374&amp;doi=10.1056%2FNEJMc2010419&amp;pmid=32302078" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">7.</div><div id="r7" class="citations"><div class="citation"><div class="citation-content">Guan WJ, Ni ZY, Hu Y, et al. Clinical characteristics of coronavirus disease 2019 in China. <em>N Engl J Med</em> 2020;382:1708-1720.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r8"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="/servlet/linkout?suffix=e_1_3_5_8_2&amp;dbid=4&amp;doi=10.1056%2FNEJMoa2035002&amp;key=10.1056%2FNEJMoa2002032&amp;site=mms-site" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/32109013/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000531351300014" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Clinical+characteristics+of+coronavirus+disease+2019+in+China.&amp;publication_year=2020&amp;journal=N+Engl+J+Med&amp;pages=1708-1720&amp;doi=10.1056%2FNEJMoa2002032&amp;pmid=32109013" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">8.</div><div id="r8" class="citations"><div class="citation"><div class="citation-content">Richardson S, Hirsch JS, Narasimhan M, et al. Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York City area. <em>JAMA</em> 2020;323:2052-2059.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r8"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1001/jama.2020.6775" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/32320003/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000538023900036" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Presenting+characteristics%2C+comorbidities%2C+and+outcomes+among+5700+patients+hospitalized+with+COVID-19+in+the+New+York+City+area.&amp;publication_year=2020&amp;journal=JAMA&amp;pages=2052-2059&amp;doi=10.1001%2Fjama.2020.6775&amp;pmid=32320003" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">9.</div><div id="r9" class="citations"><div class="citation"><div class="citation-content">Blanco-Melo D, Nilsson-Payant BE, Liu WC, et al. Imbalanced host response to SARS-CoV-2 drives development of COVID-19. <em>Cell</em> 2020;181(5):1036-1045.e9.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r9"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/j.cell.2020.04.026" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/32416070/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000537399500011" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Imbalanced+host+response+to+SARS-CoV-2+drives+development+of+COVID-19.&amp;publication_year=2020&amp;journal=Cell&amp;pages=1036-1045.e9&amp;doi=10.1016%2Fj.cell.2020.04.026&amp;pmid=32416070" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">10.</div><div id="r10" class="citations"><div class="citation"><div class="citation-content">Regeneron and Sanofi provide update on Kevzara® (sarilumab) phase 3 U.S. trial in COVID-19 patients. Regeneron, July 2, 2020 (<a href="https://investor.regeneron.com/news-releases/news-release-details/regeneron-and-sanofi-provide-update-kevzarar-sarilumab-phase-3">https://investor.regeneron.com/news-releases/news-release-details/regeneron-and-sanofi-provide-update-kevzarar-sarilumab-phase-3</a>).</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r13"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Regeneron+and+Sanofi+provide+update+on+Kevzara%C2%AE+%28sarilumab%29+phase+3+U.S.+trial+in+COVID-19+patients&amp;publication_year=2020" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">11.</div><div id="r11" class="citations"><div class="citation"><div class="citation-content">Roche provides an update on the phase III COVACTA Trial of Actemra/RoActemra in hospitalized patients with severe COVID-19 associated pneumonia. Roche, July 29, 2020 (<a href="https://www.roche.com/media/releases/med-cor-2020-07-29.htm">https://www.roche.com/media/releases/med-cor-2020-07-29.htm</a>).</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r13"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Roche+provides+an+update+on+the+phase+III+COVACTA+Trial+of+Actemra%2FRoActemra+in+hospitalized+patients+with+severe+COVID-19+associated+pneumonia.&amp;publication_year=2020" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">12.</div><div id="r12" class="citations"><div class="citation"><div class="citation-content">Rosas I, Bräu N, Waters M, et al. Tocilizumab in hospitalized patients with COVID-19 pneumonia. August 27, 2020 (<a href="https://www.medrxiv.org/content/10.1101/2020.08.27.20183442v2">https://www.medrxiv.org/content/10.1101/2020.08.27.20183442v2</a>). preprint.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r13"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Tocilizumab+in+hospitalized+patients+with+COVID-19+pneumonia.&amp;publication_year=2020" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">13.</div><div id="r13" class="citations"><div class="citation"><div class="citation-content">RECOVERY Collaborative Group. Dexamethasone in hospitalized patients with Covid-19 — preliminary report. <em>N Engl J Med</em>.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r13"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="/servlet/linkout?suffix=e_1_3_5_14_2&amp;dbid=4&amp;doi=10.1056%2FNEJMoa2035002&amp;key=10.1056%2FNEJMoa2021436&amp;site=mms-site" target="_blank">Crossref</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000623807600009" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Dexamethasone+in+hospitalized+patients+with+Covid-19+%E2%80%94+preliminary+report.&amp;journal=N+Engl+J+Med&amp;doi=10.1056%2FNEJMoa2021436" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">14.</div><div id="r14" class="citations"><div class="citation"><div class="citation-content">Wölfel R, Corman VM, Guggemos W, et al. Virological assessment of hospitalized patients with COVID-2019. <em>Nature</em> 2020;581:465-469.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r14" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1038/s41586-020-2196-x" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/32235945/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000535223600001" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Virological+assessment+of+hospitalized+patients+with+COVID-2019.&amp;publication_year=2020&amp;journal=Nature&amp;pages=465-469&amp;doi=10.1038%2Fs41586-020-2196-x&amp;pmid=32235945" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r14" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r14-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] high viral titers in hospitalized patients, </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r20" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] against SARS-CoV-2 and viral loads. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">15.</div><div id="r15" class="citations"><div class="citation"><div class="citation-content">Baum A, Fulton BO, Wloga E, et al. Antibody cocktail to SARS-CoV-2 spike protein prevents rapid mutational escape seen with individual antibodies. <em>Science</em> 2020;369:1014-1018.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r15" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1126/science.abd0831" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/32540904/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000562436800055" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Antibody+cocktail+to+SARS-CoV-2+spike+protein+prevents+rapid+mutational+escape+seen+with+individual+antibodies&amp;publication_year=2020&amp;journal=Science&amp;pages=1014-1018&amp;doi=10.1126%2Fscience.abd0831&amp;pmid=32540904" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r15" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r16" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] enzyme 2 (ACE2) receptor. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r15-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] mutants seen with either single antibody. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">16.</div><div id="r16" class="citations"><div class="citation"><div class="citation-content">Hansen J, Baum A, Pascal KE, et al. Studies in humanized mice and convalescent humans yield a SARS-CoV-2 antibody cocktail. <em>Science</em> 2020;369:1010-1014.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r16"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1126/science.abd0827" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/32540901/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000562436800054" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Studies+in+humanized+mice+and+convalescent+humans+yield+a+SARS-CoV-2+antibody+cocktail&amp;publication_year=2020&amp;journal=Science&amp;pages=1010-1014&amp;doi=10.1126%2Fscience.abd0827&amp;pmid=32540901" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">17.</div><div id="r17" class="citations"><div class="citation"><div class="citation-content">Simões EAF, Forleo-Neto E, Geba GP, et al. Suptavumab for the prevention of medically attended respiratory syncytial virus infection in preterm infants. <em>Clin Infect Dis</em> 2020 September 8 (Epub ahead of print).</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r17"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1093/cid/ciaa951" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/32897368/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000735309500119" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Suptavumab+for+the+prevention+of+medically+attended+respiratory+syncytial+virus+infection+in+preterm+infants.&amp;publication_year=2020&amp;journal=Clin+Infect+Dis&amp;doi=10.1093%2Fcid%2Fciaa951&amp;pmid=32897368" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">18.</div><div id="r18" class="citations"><div class="citation"><div class="citation-content">Baum A, Ajithdoss D, Copin R, et al. REGN-COV2 antibodies prevent and treat SARS-CoV-2 infection in rhesus macaques and hamsters. <em>Science</em> 2020;370:1110-1115.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r18"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1126/science.abe2402" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/33037066/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000595345600056" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=REGN-COV2+antibodies+prevent+and+treat+SARS-CoV-2+infection+in+rhesus+macaques+and+hamsters.&amp;publication_year=2020&amp;journal=Science&amp;pages=1110-1115&amp;doi=10.1126%2Fscience.abe2402&amp;pmid=33037066" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">19.</div><div id="r19" class="citations"><div class="citation"><div class="citation-content">Regeneron’s COVID-19 outpatient trial prospectively demonstrates that REGN-COV2 antibody cocktail significantly reduced virus levels and need for further medical attention. Regeneron, October 28, 2020 (<a href="https://investor.regeneron.com/news-releases/news-release-details/regenerons-covid-19-outpatient-trial-prospectively-demonstrates">https://investor.regeneron.com/news-releases/news-release-details/regenerons-covid-19-outpatient-trial-prospectively-demonstrates</a>).</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r19"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Regeneron%E2%80%99s+COVID-19+outpatient+trial+prospectively+demonstrates+that+REGN-COV2+antibody+cocktail+significantly+reduced+virus+levels+and+need+for+further+medical+attention.&amp;publication_year=2020" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">20.</div><div id="r20" class="citations"><div class="citation"><div class="citation-content">Wellinghausen N, Plonné D, Voss M, Ivanova R, Frodl R, Deininger S. SARS-CoV-2-IgG response is different in COVID-19 outpatients and asymptomatic contact persons. <em>J Clin Virol</em> 2020;130:104542-104542.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r20"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/j.jcv.2020.104542" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/32707511/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000571737600012" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=SARS-CoV-2-IgG+response+is+different+in+COVID-19+outpatients+and+asymptomatic+contact+persons.&amp;publication_year=2020&amp;journal=J+Clin+Virol&amp;pages=104542-104542&amp;doi=10.1016%2Fj.jcv.2020.104542&amp;pmid=32707511" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">21.</div><div id="r21" class="citations"><div class="citation"><div class="citation-content">Tenforde MW, Kim SS, Lindsell CJ, et al. Symptom duration and risk factors for delayed return to usual health among outpatients with COVID-19 in a multistate health care systems network — United States, March–June 2020. <em>MMWR Morb Mortal Wkly Rep</em> 2020;69:993-998.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r21"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.15585/mmwr.mm6930e1" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/32730238/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000554866700003" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Symptom+duration+and+risk+factors+for+delayed+return+to+usual+health+among+outpatients+with+COVID-19+in+a+multistate+health+care+systems+network+%E2%80%94+United+States%2C+March%E2%80%93June+2020.&amp;publication_year=2020&amp;journal=MMWR+Morb+Mortal+Wkly+Rep&amp;pages=993-998&amp;doi=10.15585%2Fmmwr.mm6930e1&amp;pmid=32730238" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">22.</div><div id="r22" class="citations"><div class="citation"><div class="citation-content">Magleby R, Westblade LF, Trzebucki A, et al. Impact of SARS-CoV-2 viral load on risk of intubation and mortality among hospitalized patients with coronavirus disease 2019. <em>Clin Infect Dis</em> 2020 June 30 (Epub ahead of print).</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r22"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1093/cid/ciaa851" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/32603425/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000735309500093" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Impact+of+SARS-CoV-2+viral+load+on+risk+of+intubation+and+mortality+among+hospitalized+patients+with+coronavirus+disease+2019.&amp;publication_year=2020&amp;journal=Clin+Infect+Dis&amp;doi=10.1093%2Fcid%2Fciaa851&amp;pmid=32603425" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">23.</div><div id="r23" class="citations"><div class="citation"><div class="citation-content">Joyner MJ, Senefeld JW, Klassen SA, et al. Effect of convalescent plasma on mortality among hospitalized patients with COVID-19: initial three-month experience. August 12, 2020. preprint.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r24"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/32817978/" target="_blank">PubMed</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Effect+of+convalescent+plasma+on+mortality+among+hospitalized+patients+with+COVID-19%3A+initial+three-month+experience.&amp;publication_year=2020&amp;pmid=32817978" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">24.</div><div id="r24" class="citations"><div class="citation"><div class="citation-content">Li L, Zhang W, Hu Y, et al. Effect of convalescent plasma therapy on time to clinical improvement in patients with severe and life-threatening COVID-19: a randomized clinical trial. <em>JAMA</em> 2020;324:460-470.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r24"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1001/jama.2020.10044" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/32492084/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000561261900017" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Effect+of+convalescent+plasma+therapy+on+time+to+clinical+improvement+in+patients+with+severe+and+life-threatening+COVID-19%3A+a+randomized+clinical+trial.&amp;publication_year=2020&amp;journal=JAMA&amp;pages=460-470&amp;doi=10.1001%2Fjama.2020.10044&amp;pmid=32492084" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">25.</div><div id="r25" class="citations"><div class="citation"><div class="citation-content">Chen P, Nirula A, Heller B, et al. SARS-CoV-2 neutralizing antibody LY-CoV555 in outpatients with Covid-19. <em>N Engl J Med</em> 2021;384:229-237.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r25"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="/servlet/linkout?suffix=e_1_3_5_26_2&amp;dbid=4&amp;doi=10.1056%2FNEJMoa2035002&amp;key=10.1056%2FNEJMoa2029849&amp;site=mms-site" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/33113295/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000613533100008" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=SARS-CoV-2+neutralizing+antibody+LY-CoV555+in+outpatients+with+Covid-19.&amp;publication_year=2021&amp;journal=N+Engl+J+Med&amp;pages=229-237&amp;doi=10.1056%2FNEJMoa2029849&amp;pmid=33113295" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">26.</div><div id="r26" class="citations"><div class="citation"><div class="citation-content">Mulangu S, Dodd LE, Davey RT Jr, et al. A randomized, controlled trial of Ebola virus disease therapeutics. <em>N Engl J Med</em> 2019;381:2293-2303.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r26"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="/servlet/linkout?suffix=e_1_3_5_27_2&amp;dbid=4&amp;doi=10.1056%2FNEJMoa2035002&amp;key=10.1056%2FNEJMoa1910993&amp;site=mms-site" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/31774950/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000505221600004" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=A+randomized%2C+controlled+trial+of+Ebola+virus+disease+therapeutics.&amp;publication_year=2019&amp;journal=N+Engl+J+Med&amp;pages=2293-2303&amp;doi=10.1056%2FNEJMoa1910993&amp;pmid=31774950" target="_blank">Google Scholar</a></div></div></div></div></div></div><div class="citations-truncation"><button data-label-expand="Show all references" data-label-collapse="Show fewer" data-label-remaining="references remaining" class="btn btn--secondary" aria-expanded="false" aria-controls="collapsible-text"><span>Show all references</span></button></div></section></div></section></div><div class="core-collateral"><div id="core-collateral-info" role="tabpanel" data-core-tabs="core-collateral-info" tabindex="-1" aria-labelledby="pane-core-collateral-info"><header><h2 id="pane-core-collateral-info"><i class="icon-info" aria-hidden="true"></i>Information &amp; Authors</h2><button data-close="collateral" aria-label="Close"><i class="icon-close"></i></button></header><div role="tablist"><button aria-controls="tab-information" role="tab" id="tab-information-label" aria-selected="true" class="active">Information</button><button aria-controls="tab-contributors" role="tab" id="tab-contributors-label" tabindex="-1" aria-selected="false">Authors</button></div><section id="tab-information" aria-labelledby="tab-information-label" role="tabpanel" tabindex="0"><h3>Information</h3><section class="core-self-citation"><h4>Published In</h4><div class="core-journal-presentation"><div class="core-journal-description"><div property="isPartOf" typeof="Periodical"><span property="name">New England Journal of Medicine</span></div><div class="core-enumeration"><a href="/toc/nejm/384/3"><span property="isPartOf" typeof="PublicationVolume">Volume <span property="volumeNumber">384</span></span> • <span property="isPartOf" typeof="PublicationIssue">Number <span property="issueNumber">3</span></span> • <span property="datePublished">January 21, 2021</span></a></div><div class="core-pagination"><span class="heading">Pages</span>: <span class="content"><span property="pageStart">238</span>-<span property="pageEnd">251</span></span></div></div></div></section><section class="core-copyright"><h4>Copyright</h4><div role="paragraph">Copyright © 2020 Massachusetts Medical Society. All rights reserved.</div><div>For personal use only. Any commercial reuse of NEJM Group content requires <a href="mailto:permissions@nejm.org">permission</a>.</div></section><section class="core-history"><h4>History</h4><div><b class="core-label">Published online</b>: December 17, 2020</div><div><b class="core-label">Published in issue</b>: January 21, 2021</div></section><section data-location="recirc_topics_article" class="core-classifications"><h4>Topics</h4><div class="keywords"><ol><li><a href="/browse/topic/coronavirus" alt="View article keyword Coronavirus" data-interactiontype="article_recirculation_click">Coronavirus</a></li><li role="presentation" aria-hidden="true" class="list-line-break"></li><li><a href="/browse/topic/viral-infections" alt="View article keyword Viral Infections" data-interactiontype="article_recirculation_click">Viral Infections</a></li><li role="presentation" aria-hidden="true" class="list-line-break"></li></ol></div></section></section><section id="tab-contributors" aria-labelledby="tab-contributors-label" role="tabpanel" tabindex="-1"><h3>Authors</h3><section class="core-authors"><h4>Authors</h4><div role="paragraph"><span property="author" typeof="Person"><span property="givenName">David M.</span> <span property="familyName">Weinreich</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Sumathi</span> <span property="familyName">Sivapalasingam</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Thomas</span> <span property="familyName">Norton</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Shazia</span> <span property="familyName">Ali</span>, <span property="honorificSuffix">Pharm.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Haitao</span> <span property="familyName">Gao</span>, <span property="honorificSuffix">Ph.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Rafia</span> <span property="familyName">Bhore</span>, <span property="honorificSuffix">Ph.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Bret J.</span> <span property="familyName">Musser</span>, <span property="honorificSuffix">Ph.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Yuhwen</span> <span property="familyName">Soo</span>, <span property="honorificSuffix">Ph.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Diana</span> <span property="familyName">Rofail</span>, <span property="honorificSuffix">Ph.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Joseph</span> <span property="familyName">Im</span>, <span property="honorificSuffix">B.S.</span></span>, <span property="author" typeof="Person"><span property="givenName">Christina</span> <span property="familyName">Perry</span>, <span property="honorificSuffix">M.B.A.</span></span>, <span property="author" typeof="Person"><span property="givenName">Cynthia</span> <span property="familyName">Pan</span>, <span property="honorificSuffix">B.Pharm.</span></span>, <span property="author" typeof="Person"><span property="givenName">Romana</span> <span property="familyName">Hosain</span>, <span property="honorificSuffix">M.D., M.P.H.</span></span>, <span property="author" typeof="Person"><span property="givenName">Adnan</span> <span property="familyName">Mahmood</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">John D.</span> <span property="familyName">Davis</span>, <span property="honorificSuffix">Ph.D.</span> <a class="orcid-id" href="https://orcid.org/0000-0001-6282-1670" property="identifier" aria-label="ORCID identifier" target="_blank">https://orcid.org/0000-0001-6282-1670</a></span>, <span property="author" typeof="Person"><span property="givenName">Kenneth C.</span> <span property="familyName">Turner</span>, <span property="honorificSuffix">Ph.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Andrea T.</span> <span property="familyName">Hooper</span>, <span property="honorificSuffix">Ph.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Jennifer D.</span> <span property="familyName">Hamilton</span>, <span property="honorificSuffix">Ph.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Alina</span> <span property="familyName">Baum</span>, <span property="honorificSuffix">Ph.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Christos A.</span> <span property="familyName">Kyratsous</span>, <span property="honorificSuffix">Ph.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Yunji</span> <span property="familyName">Kim</span>, <span property="honorificSuffix">Pharm.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Amanda</span> <span property="familyName">Cook</span>, <span property="honorificSuffix">B.S., Dip.Reg.Aff.</span></span>, <span property="author" typeof="Person"><span property="givenName">Wendy</span> <span property="familyName">Kampman</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Anita</span> <span property="familyName">Kohli</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Yessica</span> <span property="familyName">Sachdeva</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Ximena</span> <span property="familyName">Graber</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Bari</span> <span property="familyName">Kowal</span>, <span property="honorificSuffix">M.S.</span></span>, <span property="author" typeof="Person"><span property="givenName">Thomas</span> <span property="familyName">DiCioccio</span>, <span property="honorificSuffix">Ph.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Neil</span> <span property="familyName">Stahl</span>, <span property="honorificSuffix">Ph.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Leah</span> <span property="familyName">Lipsich</span>, <span property="honorificSuffix">Ph.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Ned</span> <span property="familyName">Braunstein</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Gary</span> <span property="familyName">Herman</span>, <span property="honorificSuffix">M.D.</span></span>, and <span property="author" typeof="Person"><span property="givenName">George D.</span> <span property="familyName">Yancopoulos</span>, <span property="honorificSuffix">M.D., Ph.D.</span></span>, for <span property="author" typeof="Person">the Trial Investigators<sup><a href="#fn1" role="doc-noteref">*</a></sup></span></div></section><section class="core-affiliations"><h4>Affiliations</h4><div property="affiliation" typeof="Organization"><span property="name">From Regeneron Pharmaceuticals, Tarrytown, NY (D.M.W., S.S., T.N., S.A., H.G., R.B., B.J.M., Y. Soo, D.R., J.I., C. Perry, C. Pan, R.H., A.M., J.D.D., K.C.T., A.T.H., J.D.H., A.B., C.A.K., Y.K., A.C., W.K., B.K., T.D., N.S., L.L., N.B., G.H., G.D.Y.); Arizona Liver Health, Tucson (A.K.), and Arizona Liver Health, Chandler (Y. Sachdeva); and AGA Clinical Trials, Hialeah, FL (X.G.).</span></div></section><section class="core-authors-notes"><h4>Notes</h4><div role="doc-footnote">Address reprint requests to Dr. Weinreich at Regeneron Pharmaceuticals, 777 Old Saw Mill River Rd., Tarrytown, NY 10591-6707, or at <a href="mailto:david.weinreich@regeneron.com">david.weinreich@regeneron.com</a>.</div><div role="doc-footnote" data-has="label"><div class="label">*</div><div id="fn1" role="paragraph">A complete list of the trial investigators is provided in the <a href="#ap2">Supplementary Appendix</a>, available at NEJM.org.</div></div></section></section></div><div id="core-collateral-metrics" role="tabpanel" data-core-tabs="core-collateral-metrics" tabindex="-1" aria-labelledby="pane-core-collateral-metrics"><header><h2 id="pane-core-collateral-metrics"><i class="icon-timeline" aria-hidden="true"></i>Metrics &amp; Citations</h2><button data-close="collateral" aria-label="Close"><i class="icon-close"></i></button></header><div role="tablist"><button aria-controls="tab-metrics-inner" role="tab" id="tab-metrics-inner-label" aria-selected="true" class="active" data-interactiontype="article_tab" data-tabname="metricsWindow">Metrics</button><button aria-controls="tab-citations" role="tab" id="tab-citations-label" tabindex="-1" aria-selected="false" data-interactiontype="article_tab" data-tabname="metricsWindow">Citations<span class="citations-count">1270</span></button></div><section id="tab-metrics-inner" aria-labelledby="tab-metrics-inner-label" role="tabpanel" tabindex="0"><h3>Metrics</h3><section>









    
    
        <div data-widget-def="UX3HTMLWidget" data-widget-id="95ea9f58-ec0e-4db2-b2ab-280fc876af53" data-location="article_metrics_article">
        



        
            <h4 class="">
                Altmetrics
            </h4>
        
        <div data-badge-details="right" data-badge-type="large-donut" data-doi="10.1056/NEJMoa2035002" data-hide-no-mentions="true" data-link-target="_blank" class="altmetric-embed" data-uuid="7c09c612-88de-1667-8e32-355c105de502"><div style="overflow:hidden;">
    <div class="altmetric-normal-legend">
        <a target="_blank" href="https://www.altmetric.com/details.php?domain=www.nejm.org&amp;citation_id=96205841" style="display:inline-block;">
                <img alt="Article has an altmetric score of 1007" src="https://badges.altmetric.com/?size=320&amp;score=1007&amp;types=mabvcrtf" width="180" height="180" style="border:0; margin:0; max-width: none;">
        </a>
        <p class="altmetric-see-more-details" style="padding-top: 10px; text-align: center;"><a target="_blank" href="https://www.altmetric.com/details.php?domain=www.nejm.org&amp;citation_id=96205841">See more details</a></p>
    </div>
    <div id="_altmetric_popover_el_7c09c612-88de-1667-8e32-355c105de502" class="altmetric-embed right" style="margin:0; padding:0; display:inline-block; float:left; position:relative;">
        <div class="altmetric_container">
            <div class="altmetric-embed altmetric-popover-inner right">
                <div style="padding:0; margin: 0;" class="altmetric-embed altmetric-popover-content">
                        <div style="padding-left: 10px; line-height:18px; border-left: 16px solid #FF0000;">
      <a class="link-to-altmetric-details-tab" target="_blank" href="https://www.altmetric.com/details.php?domain=www.nejm.org&amp;citation_id=96205841&amp;tab=news">
          Picked up by <b>75</b> news outlets
      </a>
    </div>
    <div style="padding-left: 10px; line-height:18px; border-left: 16px solid #ffd140;">
      <a class="link-to-altmetric-details-tab" target="_blank" href="https://www.altmetric.com/details.php?domain=www.nejm.org&amp;citation_id=96205841&amp;tab=blogs">
          Blogged by <b>11</b>
      </a>
    </div>
    <div style="padding-left: 10px; line-height:18px; border-left: 16px solid #9f79f2;">
      <a class="link-to-altmetric-details-tab" target="_blank" href="https://www.altmetric.com/details.php?domain=www.nejm.org&amp;citation_id=96205841&amp;tab=policy-documents">
          Referenced in <b>3</b> policy sources
      </a>
    </div>
    <div style="padding-left: 10px; line-height:18px; border-left: 16px solid #74CFED;">
      <a class="link-to-altmetric-details-tab" target="_blank" href="https://www.altmetric.com/details.php?domain=www.nejm.org&amp;citation_id=96205841&amp;tab=twitter">
          Posted by <b>510</b> X users
      </a>
    </div>
    <div style="padding-left: 10px; line-height:18px; border-left: 16px solid #f27700;">
      <a class="link-to-altmetric-details-tab" target="_blank" href="https://www.altmetric.com/details.php?domain=www.nejm.org&amp;citation_id=96205841&amp;tab=patents">
          Referenced in <b>18</b> patents
      </a>
    </div>
    <div style="padding-left: 10px; line-height:18px; border-left: 16px solid #2445bd;">
      <a class="link-to-altmetric-details-tab" target="_blank" href="https://www.altmetric.com/details.php?domain=www.nejm.org&amp;citation_id=96205841&amp;tab=facebook">
          On <b>8</b> Facebook pages
      </a>
    </div>
    <div style="padding-left: 10px; line-height:18px; border-left: 16px solid #958899;">
      <a class="link-to-altmetric-details-tab" target="_blank" href="https://www.altmetric.com/details.php?domain=www.nejm.org&amp;citation_id=96205841&amp;tab=wikipedia">
          Referenced in <b>1</b> Wikipedia pages
      </a>
    </div>
    <div style="padding-left: 10px; line-height:18px; border-left: 16px solid #D5E8F0;">
      <a class="link-to-altmetric-details-tab" target="_blank" href="https://www.altmetric.com/details.php?domain=www.nejm.org&amp;citation_id=96205841&amp;tab=reddit">
          Reddited by <b>3</b>
      </a>
    </div>
    <div style="padding-left: 10px; line-height:18px; border-left: 16px solid #94DB5E;">
      <a class="link-to-altmetric-details-tab" target="_blank" href="https://www.altmetric.com/details.php?domain=www.nejm.org&amp;citation_id=96205841&amp;tab=video">
          On <b>3</b> videos
      </a>
    </div>
    <div style="padding-left: 10px; line-height:18px; border-left: 16px solid #A1E3E4;">
      <a class="link-to-altmetric-details-tab" target="_blank" href="https://www.altmetric.com/details.php?domain=www.nejm.org&amp;citation_id=96205841&amp;tab=guidelines">
          Referenced in <b>4</b> clinical guideline sources
      </a>
    </div>
    <div style="padding-left: 10px; line-height:18px; border-left: 16px solid #70B1FF;">
      <a class="link-to-altmetric-details-tab" target="_blank" href="https://www.altmetric.com/details.php?domain=www.nejm.org&amp;citation_id=96205841&amp;tab=bluesky">
          Referenced by <b>1</b> Bluesky users
      </a>
    </div>

    <div class="altmetric-embed readers" style="margin-top: 10px;">
          <div class="altmetric-embed tip_mendeley" style="padding-left: 10px; line-height:18px; border-left: 16px solid #A60000;">
              <b>1095</b> readers on Mendeley
          </div>
    </div>

                </div>
            </div>
        </div>
    </div>
</div></div>
<script async="" type="text/javascript" src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" nonce="94d6670fb4c0f1da-SJC"></script>

        </div>
    

</section></section><section id="tab-citations" aria-labelledby="tab-citations-label" role="tabpanel" tabindex="-1"><h3>Citations</h3><section>



        
            <h4 class="">
                Export citation
            </h4>
        
        <div class="citation-download cd-sec">
<p class="citation-download_msg">Select the format you want to export the citation of this publication.</p>
<form action="/action/downloadCitation" name="frmCitmgr" method="post" target="_self" class="citation-download_form"><input type="hidden" name="doi" value="10.1056/NEJMoa2035002"> <input type="hidden" name="downloadFileName" value="csp_384_"> <input type="hidden" name="include" value="abs">
<div class="dropdown dropdown-selectable dropdown-selectable--form-control"><input type="hidden" name="format" value=""> <label class="form-label">Format*</label> <button id="slct_format" type="button" data-toggle="dropdown" aria-haspopup="true" aria-expanded="false" class="btn dropdown-toggle d-flex align-items-center justify-content-between">Please Select </button>
<div aria-labelledby="slct_format" role="listbox" class="dropdown-menu"><a href="#" data-value="ris" class="dropdown-item">RIS (ProCite, Reference Manager)</a><a href="#" data-value="endnote" class="dropdown-item">EndNote</a><a href="#" data-value="bibtex" class="dropdown-item">BibTex</a><a href="#" data-value="medlars" class="dropdown-item">Medlars</a><a href="#" data-value="refworks" class="dropdown-item">RefWorks</a></div>
<div class="invalid-feedback">Please select an item in the list</div>
</div>
<div class="citation-download_checkbox"><label class="checkbox--primary"><input type="checkbox" name="direct" value="true"><span class="checkbox--primary-icons"><span class="checkbox--primary-unchecked"><span class="icon-component "><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#toggles-checboxUnchecked"></use></svg></span></span><span class="checkbox--primary-checked"><span class="icon-component "><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#toggles-checboxChecked"></use></svg></span></span></span><span class="checkbox--primary-label"><span class="checkbox--primary-label-text">Direct Import</span></span></label></div>
<div class="citation-download_btn"><button type="submit" name="submit" value="Download" class="ng-btn_default ng-btn_iconLeft" data-interactiontype="article_tools_citation_download" data-multimedia-type="Citation"><span class="icon-component "><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#citations"></use></svg></span><span class="ng-btn_text">Export citation</span></button></div>
</form></div>
</section><section>









    
    
        <div data-widget-def="UX3CitedByWidget" data-widget-id="efb4df9a-8e1a-47f9-bfb7-271959277a9f" data-location="citedby_article">
        



        
            <h4 class="">
                Cited by
            </h4>
        
        <section id="cited-by" class="cited-by"><div class="cited-by__wrapper"><div id="cited-by__content" class="cited-by__content"><ol data-source="/pb/widgets/citedBy?page=1&amp;widgetId=efb4df9a-8e1a-47f9-bfb7-271959277a9f&amp;pbContext=%3BrequestedJournal%3Ajournal%3Anejm%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Barticle%3Aarticle%3Adoi%5C%3A10.1056%2FNEJMoa2035002%3Bissue%3Aissue%3Adoi%5C%3A10.1056%2Fnejm_2021.384.issue-3%3Bwgroup%3Astring%3AMMS+NextGen+Website+Group%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text%3Bwebsite%3Awebsite%3Amms-site%3Bjournal%3Ajournal%3Anejms" data-lazyload="false" data-total="1270" class="cited-by__list list-unstyled"><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">I. Kh. Borukaeva, </li><li class="list-inline-item cited-by__entry__author">Z. Kh. Abazova, </li><li class="list-inline-item cited-by__entry__author">Z. A. Kambachokova, </li><li class="list-inline-item cited-by__entry__author">A. A. Kambachokova, </li><li class="list-inline-item cited-by__entry__author">A. A. Kardanov, </li><li class="list-inline-item cited-by__entry__author">M. S. Djabrailova, </li><li class="list-inline-item cited-by__entry__author">Z. I. Сhanieva, </li><li class="list-inline-item cited-by__entry__author">Kh. Kh. Akhmatov, </li><li class="list-inline-item cited-by__entry__author">M. A. Abdurakhmanov, </li><li class="list-inline-item cited-by__entry__author">Sh. M. Baskariev, </li><li class="list-inline-item cited-by__entry__author">E. B. Mezhikhova, </li><li class="list-inline-item cited-by__entry__author">D. A. Shogenova, </li></ul><span class="cited-by__entry__title">Current Perspective on the Treatment of the Novel Coronavirus Infection COVID-19, </span><span class="cited-by__entry__series-title">Antibiot Khimioter = Antibiotics and Chemotherapy, </span><span class="cited-by__entry__volume"><strong>70</strong>, </span><span class="cited-by__entry__issue">1-2, </span><span class="cited-by__entry__page-range">(88-99), </span><span class="cited-by__entry__pub-date">(2025).</span><a href="https://doi.org/10.37489/0235-2990-2025-70-1-2-88-99" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.37489/0235-2990-2025-70-1-2-88-99</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.37489/0235-2990-2025-70-1-2-88-99" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">Jinsoo Kim, </li><li class="list-inline-item cited-by__entry__author">Suyeon Kim, </li><li class="list-inline-item cited-by__entry__author">Dongbum Kim, </li><li class="list-inline-item cited-by__entry__author">Minyoung Kim, </li><li class="list-inline-item cited-by__entry__author">Kyeongbin Baek, </li><li class="list-inline-item cited-by__entry__author">Bo Min Kang, </li><li class="list-inline-item cited-by__entry__author">Seungchan An, </li><li class="list-inline-item cited-by__entry__author">In Guk Park, </li><li class="list-inline-item cited-by__entry__author">Songrae Kim, </li><li class="list-inline-item cited-by__entry__author">Sangkyu Park, </li><li class="list-inline-item cited-by__entry__author">Jun Gyo Suh, </li><li class="list-inline-item cited-by__entry__author">Minsoo Noh, </li><li class="list-inline-item cited-by__entry__author">Younghee Lee, </li><li class="list-inline-item cited-by__entry__author">Hyung-Joo Kwon, </li></ul><span class="cited-by__entry__title">Therapeutic Intervention of an Intranasally Administered Monoclonal Antibody Targeting the SARS-CoV-2 Omicron Spike Protein Against SARS-CoV-2 Omicron Infection in Mice, </span><span class="cited-by__entry__series-title">Viral Immunology, </span><span class="cited-by__entry__pub-date">(2025).</span><a href="https://doi.org/10.1089/vim.2024.0095" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.1089/vim.2024.0095</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.1089/vim.2024.0095" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">Peng Zhu, </li><li class="list-inline-item cited-by__entry__author">Yan Chen, </li><li class="list-inline-item cited-by__entry__author">Xia Xu, </li><li class="list-inline-item cited-by__entry__author">Deyong Tan, </li><li class="list-inline-item cited-by__entry__author">Ledong Xiao, </li><li class="list-inline-item cited-by__entry__author">Chengling Liao, </li><li class="list-inline-item cited-by__entry__author">Huan Xia, </li><li class="list-inline-item cited-by__entry__author">Ting Zhang, </li><li class="list-inline-item cited-by__entry__author">Jing Zou, </li><li class="list-inline-item cited-by__entry__author">Xuan Chen, </li><li class="list-inline-item cited-by__entry__author">Man Li, </li><li class="list-inline-item cited-by__entry__author">Yang Yang, </li><li class="list-inline-item cited-by__entry__author">Jian Zhou, </li><li class="list-inline-item cited-by__entry__author">Jia Liu, </li><li class="list-inline-item cited-by__entry__author">Wei Zhang, </li><li class="list-inline-item cited-by__entry__author">Honghao Zhou, </li><li class="list-inline-item cited-by__entry__author">Qing Li, </li></ul><span class="cited-by__entry__title">Antibody response after SARS-CoV-2 infection or vaccination in China: A cross-sectional study, </span><span class="cited-by__entry__series-title">Vaccine: X, </span><span class="cited-by__entry__volume"><strong>24</strong>, </span><span class="cited-by__entry__page-range">(100644), </span><span class="cited-by__entry__pub-date">(2025).</span><a href="https://doi.org/10.1016/j.jvacx.2025.100644" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.1016/j.jvacx.2025.100644</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.1016/j.jvacx.2025.100644" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">Majd Alsoubani, </li><li class="list-inline-item cited-by__entry__author">Jennifer Chow, </li></ul><span class="cited-by__entry__title">Navigating Coronavirus Disease 2019 in Immunocompromised Populations, </span><span class="cited-by__entry__series-title">Infectious Disease Clinics of North America, </span><span class="cited-by__entry__volume"><strong>39</strong>, </span><span class="cited-by__entry__issue">2, </span><span class="cited-by__entry__page-range">(309-329), </span><span class="cited-by__entry__pub-date">(2025).</span><a href="https://doi.org/10.1016/j.idc.2025.02.005" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.1016/j.idc.2025.02.005</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.1016/j.idc.2025.02.005" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">Amy Hirsch Shumaker, </li><li class="list-inline-item cited-by__entry__author">Adarsh Bhimraj, </li></ul><span class="cited-by__entry__title">Pharmacologic Treatment and Management of Coronavirus Disease 2019, </span><span class="cited-by__entry__series-title">Infectious Disease Clinics of North America, </span><span class="cited-by__entry__volume"><strong>39</strong>, </span><span class="cited-by__entry__issue">2, </span><span class="cited-by__entry__page-range">(275-291), </span><span class="cited-by__entry__pub-date">(2025).</span><a href="https://doi.org/10.1016/j.idc.2025.02.004" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.1016/j.idc.2025.02.004</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.1016/j.idc.2025.02.004" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">Seiya Oba, </li><li class="list-inline-item cited-by__entry__author">Tadashi Hosoya, </li><li class="list-inline-item cited-by__entry__author">Daisuke Kawata, </li><li class="list-inline-item cited-by__entry__author">Yoji Komiya, </li><li class="list-inline-item cited-by__entry__author">Hideyuki Iwai, </li><li class="list-inline-item cited-by__entry__author">Ryuji Koike, </li><li class="list-inline-item cited-by__entry__author">Sho Miyamoto, </li><li class="list-inline-item cited-by__entry__author">Takayuki Kanno, </li><li class="list-inline-item cited-by__entry__author">Akira Ainai, </li><li class="list-inline-item cited-by__entry__author">Tadaki Suzuki, </li><li class="list-inline-item cited-by__entry__author">Hideki Hasegawa, </li><li class="list-inline-item cited-by__entry__author">Shinsuke Yasuda, </li></ul><span class="cited-by__entry__title">Iguratimod, a promising therapeutic agent for COVID-19 that attenuates excessive inflammation in mouse models, </span><span class="cited-by__entry__series-title">European Journal of Pharmacology, </span><span class="cited-by__entry__volume"><strong>996</strong>, </span><span class="cited-by__entry__page-range">(177537), </span><span class="cited-by__entry__pub-date">(2025).</span><a href="https://doi.org/10.1016/j.ejphar.2025.177537" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.1016/j.ejphar.2025.177537</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.1016/j.ejphar.2025.177537" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">Ahmad Mourad, </li><li class="list-inline-item cited-by__entry__author">Gregory A. Grandits, </li><li class="list-inline-item cited-by__entry__author">Lianne K. Siegel, </li><li class="list-inline-item cited-by__entry__author">Nicole Engen, </li><li class="list-inline-item cited-by__entry__author">Christina Barkauskas, </li><li class="list-inline-item cited-by__entry__author">Nnakelu Eriobu, </li><li class="list-inline-item cited-by__entry__author">Mamta K. Jain, </li><li class="list-inline-item cited-by__entry__author">Tomas O. Jensen, </li><li class="list-inline-item cited-by__entry__author">Adit Ginde, </li><li class="list-inline-item cited-by__entry__author">Elizabeth Higgs, </li><li class="list-inline-item cited-by__entry__author">Daniel B. Knox, </li><li class="list-inline-item cited-by__entry__author">Jonathan Kitonsa, </li><li class="list-inline-item cited-by__entry__author">Kami Kim, </li><li class="list-inline-item cited-by__entry__author">Jakob J. Malin, </li><li class="list-inline-item cited-by__entry__author">Vasiliki Rapti, </li><li class="list-inline-item cited-by__entry__author">D. Ashley Price, </li><li class="list-inline-item cited-by__entry__author">Alfredo J. Mena Lora, </li><li class="list-inline-item cited-by__entry__author">Gail Mathews, </li><li class="list-inline-item cited-by__entry__author">Eleftherios Mylonakis, </li><li class="list-inline-item cited-by__entry__author">Thomas A. Murray, </li><li class="list-inline-item cited-by__entry__author">Uriel Sandkovsky, </li><li class="list-inline-item cited-by__entry__author">Roger Paredes, </li><li class="list-inline-item cited-by__entry__author">Srikanth Ramachandruni, </li><li class="list-inline-item cited-by__entry__author">Cavan Reilly, </li><li class="list-inline-item cited-by__entry__author">David Vock, </li><li class="list-inline-item cited-by__entry__author">John C. Williamson, </li><li class="list-inline-item cited-by__entry__author">Barnaby Edward Young, </li><li class="list-inline-item cited-by__entry__author">Wesley H. Self, </li><li class="list-inline-item cited-by__entry__author">Jens Lundgren, </li><li class="list-inline-item cited-by__entry__author">Thomas L. Holland, </li></ul><span class="cited-by__entry__title">Long-term outcomes of passive immunotherapy for COVID-19: a pooled analysis of a large multinational platform randomized clinical trial, </span><span class="cited-by__entry__series-title">Clinical Microbiology and Infection, </span><span class="cited-by__entry__volume"><strong>31</strong>, </span><span class="cited-by__entry__issue">6, </span><span class="cited-by__entry__page-range">(1053-1060), </span><span class="cited-by__entry__pub-date">(2025).</span><a href="https://doi.org/10.1016/j.cmi.2025.02.002" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.1016/j.cmi.2025.02.002</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.1016/j.cmi.2025.02.002" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">Carly R. Cabel, </li><li class="list-inline-item cited-by__entry__author">Briana A. Guzman, </li><li class="list-inline-item cited-by__entry__author">Elaheh Alizadeh, </li><li class="list-inline-item cited-by__entry__author">Shuaizhi Li, </li><li class="list-inline-item cited-by__entry__author">Cameron Holberg, </li><li class="list-inline-item cited-by__entry__author">Chonlarat Wichaidit, </li><li class="list-inline-item cited-by__entry__author">Darren A. Cusanovich, </li><li class="list-inline-item cited-by__entry__author">Andrew L. Paek, </li><li class="list-inline-item cited-by__entry__author">Gregory R. J. Thatcher, </li><li class="list-inline-item cited-by__entry__author">Koenraad Van Doorslaer, </li><li class="list-inline-item cited-by__entry__author">Rachel S. Nargi, </li><li class="list-inline-item cited-by__entry__author">Rachel E. Sutton, </li><li class="list-inline-item cited-by__entry__author">Naveenchandra Suryadevara, </li><li class="list-inline-item cited-by__entry__author">James E. Crowe, </li><li class="list-inline-item cited-by__entry__author">Robert H. Carnahan, </li><li class="list-inline-item cited-by__entry__author">Samuel K. Campos, </li><li class="list-inline-item cited-by__entry__author">Curtis A. Thorne, </li></ul><span class="cited-by__entry__title">Cell-based high-content approach for SARS-CoV-2 neutralization identifies unique monoclonal antibodies and PI3K pathway inhibitors, </span><span class="cited-by__entry__series-title">Frontiers in Cell and Developmental Biology, </span><span class="cited-by__entry__volume"><strong>13</strong>, </span><span class="cited-by__entry__pub-date">(2025).</span><a href="https://doi.org/10.3389/fcell.2025.1538934" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.3389/fcell.2025.1538934</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.3389/fcell.2025.1538934" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">Holly C. Simmons, </li><li class="list-inline-item cited-by__entry__author">Joel Finney, </li><li class="list-inline-item cited-by__entry__author">Ryutaro Kotaki, </li><li class="list-inline-item cited-by__entry__author">Yu Adachi, </li><li class="list-inline-item cited-by__entry__author">Annie Park Moseman, </li><li class="list-inline-item cited-by__entry__author">Akiko Watanabe, </li><li class="list-inline-item cited-by__entry__author">Shengli Song, </li><li class="list-inline-item cited-by__entry__author">Lindsey R. Robinson-McCarthy, </li><li class="list-inline-item cited-by__entry__author">Valerie Le Sage, </li><li class="list-inline-item cited-by__entry__author">Masayuki Kuraoka, </li><li class="list-inline-item cited-by__entry__author">E. Ashley Moseman, </li><li class="list-inline-item cited-by__entry__author">Garnett Kelsoe, </li><li class="list-inline-item cited-by__entry__author">Yoshimasa Takahashi, </li><li class="list-inline-item cited-by__entry__author">Kevin R. McCarthy, </li></ul><span class="cited-by__entry__title">A protective and broadly binding antibody class engages the influenza virus hemagglutinin head at its stem interface, </span><span class="cited-by__entry__series-title">mBio, </span><span class="cited-by__entry__pub-date">(2025).</span><a href="https://doi.org/10.1128/mbio.00892-25" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.1128/mbio.00892-25</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.1128/mbio.00892-25" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">Jing Sun, </li><li class="list-inline-item cited-by__entry__author">Deheng Sun, </li><li class="list-inline-item cited-by__entry__author">Qi Yang, </li><li class="list-inline-item cited-by__entry__author">Dong Wang, </li><li class="list-inline-item cited-by__entry__author">Jingjing Peng, </li><li class="list-inline-item cited-by__entry__author">Hu Guo, </li><li class="list-inline-item cited-by__entry__author">Xiaoyu Ding, </li><li class="list-inline-item cited-by__entry__author">Zhao Chen, </li><li class="list-inline-item cited-by__entry__author">Bin Yuan, </li><li class="list-inline-item cited-by__entry__author">Yan A. Ivanenkov, </li><li class="list-inline-item cited-by__entry__author">Jinwei Yuan, </li><li class="list-inline-item cited-by__entry__author">Bogdan A. Zagribelnyy, </li><li class="list-inline-item cited-by__entry__author">Yiyun He, </li><li class="list-inline-item cited-by__entry__author">Jingyi Su, </li><li class="list-inline-item cited-by__entry__author">Ling Wang, </li><li class="list-inline-item cited-by__entry__author">Jielin Tang, </li><li class="list-inline-item cited-by__entry__author">Zhun Li, </li><li class="list-inline-item cited-by__entry__author">Rong Li, </li><li class="list-inline-item cited-by__entry__author">Taotao Li, </li><li class="list-inline-item cited-by__entry__author">Xiaoyu Hu, </li><li class="list-inline-item cited-by__entry__author">Xing Liang, </li><li class="list-inline-item cited-by__entry__author">Airu Zhu, </li><li class="list-inline-item cited-by__entry__author">Peilan Wei, </li><li class="list-inline-item cited-by__entry__author">Yaya Fan, </li><li class="list-inline-item cited-by__entry__author">Sang Liu, </li><li class="list-inline-item cited-by__entry__author">Jie Zheng, </li><li class="list-inline-item cited-by__entry__author">Xin Guan, </li><li class="list-inline-item cited-by__entry__author">Alex Aliper, </li><li class="list-inline-item cited-by__entry__author">Minglei Yang, </li><li class="list-inline-item cited-by__entry__author">Dmitry S. Bezrukov, </li><li class="list-inline-item cited-by__entry__author">Zhanhong Xie, </li><li class="list-inline-item cited-by__entry__author">Victor A. Terentiev, </li><li class="list-inline-item cited-by__entry__author">Guilin Peng, </li><li class="list-inline-item cited-by__entry__author">Daniil A. Polykovskiy, </li><li class="list-inline-item cited-by__entry__author">Alexander S. Malyshev, </li><li class="list-inline-item cited-by__entry__author">Maxim N. Malkov, </li><li class="list-inline-item cited-by__entry__author">Qingsong Zhu, </li><li class="list-inline-item cited-by__entry__author">Alán Aspuru-Guzik, </li><li class="list-inline-item cited-by__entry__author">Xiao Ding, </li><li class="list-inline-item cited-by__entry__author">Xin Cai, </li><li class="list-inline-item cited-by__entry__author">Man Zhang, </li><li class="list-inline-item cited-by__entry__author">Jingxian Zhao, </li><li class="list-inline-item cited-by__entry__author">Nanshan Zhong, </li><li class="list-inline-item cited-by__entry__author">Feng Ren, </li><li class="list-inline-item cited-by__entry__author">Xinwen Chen, </li><li class="list-inline-item cited-by__entry__author">Alex Zhavoronkov, </li><li class="list-inline-item cited-by__entry__author">Jincun Zhao, </li></ul><span class="cited-by__entry__title">A novel, covalent broad-spectrum inhibitor targeting human coronavirus Mpro, </span><span class="cited-by__entry__series-title">Nature Communications, </span><span class="cited-by__entry__volume"><strong>16</strong>, </span><span class="cited-by__entry__issue">1, </span><span class="cited-by__entry__pub-date">(2025).</span><a href="https://doi.org/10.1038/s41467-025-59870-4" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.1038/s41467-025-59870-4</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.1038/s41467-025-59870-4" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry--see-more"><a href="javascript:void(0)" data-source="/pb/widgets/citedBy?page=1&amp;widgetId=efb4df9a-8e1a-47f9-bfb7-271959277a9f&amp;pbContext=%3BrequestedJournal%3Ajournal%3Anejm%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Barticle%3Aarticle%3Adoi%5C%3A10.1056%2FNEJMoa2035002%3Bissue%3Aissue%3Adoi%5C%3A10.1056%2Fnejm_2021.384.issue-3%3Bwgroup%3Astring%3AMMS+NextGen+Website+Group%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text%3Bwebsite%3Awebsite%3Amms-site%3Bjournal%3Ajournal%3Anejms" class="cited-by__see-more">See more</a></li></ol></div><div class="cited-by__spinner justify-content-center align-items-center d-none"><div role="status" class="spinner-border text-gray"><span class="sr-only">Loading...</span></div></div></div></section>

        </div>
    

</section></section></div><div id="core-collateral-fulltext-options" role="tabpanel" data-core-tabs="core-collateral-fulltext-options" tabindex="-1" aria-labelledby="pane-core-collateral-fulltext-options"><header><h2 id="pane-core-collateral-fulltext-options"><i class="icon-eye" aria-hidden="true"></i>View Options</h2><button data-close="collateral" aria-label="Close"><i class="icon-close"></i></button></header><div class="section--wrapper"><h3>View options</h3><section class="format--pdf"><h4> <abbr title="Portable Document Format">PDF</abbr></h4><a href="https://www.nejm.org/doi/pdf/10.1056/NEJMoa2035002" class="btn btn--pdf" aria-label="View PDF" data-behavior="trackDownloadEvent" data-doi="10.1056/NEJMoa2035002" data-interactiontype="article_tools_download_pdf" data-multimedia-type="Article PDF" data-multimedia-filename="nejmoa2035002.pdf"><i aria-hidden="true" class="icon-pdf"></i><span>View PDF</span></a></section></div><!-- Its needed to duplicate this for PB check Collateral.js as well--></div><div id="core-collateral-media" role="tabpanel" data-core-tabs="core-collateral-media" tabindex="-1" aria-labelledby="pane-core-collateral-media"><header><h2 id="pane-core-collateral-media"><i class="icon-photo" aria-hidden="true"></i>Media</h2><button data-close="collateral" aria-label="Close"><i class="icon-close"></i></button></header><div role="tablist"><button aria-controls="tab-figures" role="tab" id="tab-figures-label" aria-selected="true" class="active">Figures</button><button aria-controls="tab-other" role="tab" id="tab-other-label" tabindex="-1" aria-selected="false" class="inactive" aria-disabled="true">Other</button></div><section id="tab-figures" aria-labelledby="tab-figures-label" role="tabpanel" tabindex="0"><h3>Figures</h3><div class="text-right"><a class="btn btn--inverse  open-in-viewer" href="#figures"><span>Open all in viewer</span><i class="icon-open_in_new" aria-hidden="true"></i></a></div><div id="core-f1"><figure class="graphic"><a class="open-in-viewer" href="#f1" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa2035002_f1.jpg"><img src="/cms/10.1056/NEJMoa2035002/asset/4eef3f7d-a00a-46f4-9759-44174e57e4cc/assets/images/large/nejmoa2035002_f1.jpg" height="2120" width="2640" aria-labelledby="f1" loading="lazy"></a><figcaption><div class="caption">Screening, Randomization, and Treatment.</div><div class="notes"><div role="doc-footnote">One patient underwent randomization in error, and Regeneron requested that the patient withdraw from the trial. Four patients in the low-dose REGN-COV2 group withdrew consent: one patient could not participate in the follow-up period, one patient could not have blood drawn and an intravenous line placed, and two patients withdrew consent with no additional information available. Three patients in the high-dose REGN-COV2 group withdrew consent: one patient could not participate in the follow-up period, one patient could not have blood drawn and an intravenous line placed, and one withdrew consent with no additional information available.</div></div></figcaption></figure><div class="external-links"><a class="pill__to-original" href="#f1"><i class="icon-return" aria-hidden="true"></i><span>Go to Figure</span></a><a class="open-in-viewer" href="#f1" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa2035002_f1.jpg"><span>Open in Viewer</span><i class="icon-expand" aria-hidden="true"></i></a></div></div><div id="core-f2"><figure class="graphic"><a class="open-in-viewer" href="#f2" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa2035002_f2.jpg"><img src="/cms/10.1056/NEJMoa2035002/asset/6dfe3683-c06a-498e-b72e-63041484af8e/assets/images/large/nejmoa2035002_f2.jpg" height="2016" width="2640" aria-labelledby="f2" loading="lazy"></a><figcaption><div class="caption">SARS-CoV-2 Viral Load over Time.</div><div class="notes"><div role="doc-footnote">Shown is the change in mean viral load (in log<sub>10</sub> copies per milliliter) from baseline at each visit through day 7 in the overall population (modified full analysis set, which excluded patients who tested negative for severe acute respiratory syndrome coronavirus 2 [SARS-CoV-2] by qualitative reverse-transcriptase polymerase chain reaction at baseline) and in groups defined according to baseline antibody status and baseline viral load. 𝙸 bars in Panel C indicate the standard error. The least-squares mean difference between the groups in the time-weighted average change in viral load (TWA LS mean) from baseline through day 7, expressed as log<sub>10</sub> copies per milliliter, was based on analysis-of-covariance models with treatment group, risk factor, and baseline antibody status as fixed effects and baseline viral load and treatment group–by–baseline viral load as covariates. The lower limit of detection (dashed line) is 714 copies per milliliter (2.85 log<sub>10</sub> copies per milliliter).</div></div></figcaption></figure><div class="external-links"><a class="pill__to-original" href="#f2"><i class="icon-return" aria-hidden="true"></i><span>Go to Figure</span></a><a class="open-in-viewer" href="#f2" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa2035002_f2.jpg"><span>Open in Viewer</span><i class="icon-expand" aria-hidden="true"></i></a></div></div></section><section id="tab-other" aria-labelledby="tab-other-label" role="tabpanel" tabindex="-1"><h3>Other</h3></section></div><div id="core-collateral-tables" role="tabpanel" data-core-tabs="core-collateral-tables" tabindex="-1" aria-labelledby="pane-core-collateral-tables"><header><h2 id="pane-core-collateral-tables"><i class="icon-tables" aria-hidden="true"></i>Tables</h2><button data-close="collateral" aria-label="Close"><i class="icon-close"></i></button></header><!-- There is no content. --><div class="section--wrapper"><div class="text-right"><a class="btn btn--inverse  open-in-viewer" href="#tables"><span>Open all in viewer</span><i class="icon-open_in_new" aria-hidden="true"></i></a></div><div id="core-t1"><figure class="table"><a class="open-in-viewer" href="#t1" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2035002_t1.jpg"><div class="graphic-wrap" data-presentation="suppressed-in-viewer"><img src="/cms/10.1056/NEJMoa2035002/asset/1e13be33-2ef4-4927-ae76-954a73920f38/assets/images/large/nejmoa2035002_t1.jpg" height="2833" width="2615" loading="lazy"></div><div class="table-wrap catalyst-standard" data-presentation="suppressed-in-flow"><table data-shading="custom"><thead><tr class="head1" data-type="row head1"><th class="txlx-borders" data-xml-align="left">Characteristic</th><th class="txxx-borders" colspan="3"><span>REGN-COV2</span></th><th class="txxx-borders">Placebo<br>(N=93)</th><th class="txxr-borders">Total<br>(N=275)</th></tr><tr class="head2" data-type="row head2"><td class="xxlx-borders">&nbsp;</td><th class="xxxx-borders">2.4 g<br>(N=92)</th><th class="xxxx-borders">8.0 g<br>(N=90)</th><th class="xxxx-borders">Combined<br>(N=182)</th><td class="xxxx-borders">&nbsp;</td><th class="xxxr-borders">&nbsp;</th></tr></thead><tbody><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging03 shading" data-xml-align="left">Median age (IQR) — yr<a href="#core-t1fn2" role="doc-noteref">†</a></td><td class="xxxx-borders shading">43.0 (33.5–51.0)</td><td class="xxxx-borders shading">44.0 (36.0–53.0)</td><td class="xxxx-borders shading">43.0 (35.0–52.0)</td><td class="xxxx-borders shading">45.0 (34.0–54.0)</td><td class="xxxr-borders shading">44.0 (35.0–52.0)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging03" data-xml-align="left">Male sex — no. (%)</td><td class="xxxx-borders">46 (50)</td><td class="xxxx-borders">38 (42)</td><td class="xxxx-borders">84 (46)</td><td class="xxxx-borders">50 (54)</td><td class="xxxr-borders">134 (49)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging03 shading" data-xml-align="left">Hispanic or Latino ethnic group — no. (%)<a href="#core-t1fn3" role="doc-noteref">‡</a></td><td class="xxxx-borders shading">52 (57)</td><td class="xxxx-borders shading">55 (61)</td><td class="xxxx-borders shading">107 (59)</td><td class="xxxx-borders shading">46 (49)</td><td class="xxxr-borders shading">153 (56)</td></tr><tr data-type="row"><td class="xxlx-borders hanging03">Race — no. (%)<a href="#core-t1fn3" role="doc-noteref">‡</a></td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13 shading" data-xml-align="left">White</td><td class="xxxx-borders shading">74 (80)</td><td class="xxxx-borders shading">78 (87)</td><td class="xxxx-borders shading">152 (84)</td><td class="xxxx-borders shading">72 (77)</td><td class="xxxr-borders shading">224 (81)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13" data-xml-align="left">Black or African American</td><td class="xxxx-borders">15 (16)</td><td class="xxxx-borders">6 (7)</td><td class="xxxx-borders">21 (12)</td><td class="xxxx-borders">14 (15)</td><td class="xxxr-borders">35 (13)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13 shading" data-xml-align="left">Asian</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">1 (1)</td><td class="xxxx-borders shading">1 (1)</td><td class="xxxx-borders shading">2 (2)</td><td class="xxxr-borders shading">3 (1)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13" data-xml-align="left">American Indian or Alaska Native</td><td class="xxxx-borders">0</td><td class="xxxx-borders">0</td><td class="xxxx-borders">0</td><td class="xxxx-borders">2 (2)</td><td class="xxxr-borders">2 (1)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13 shading" data-xml-align="left">Unknown</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">1 (1)</td><td class="xxxx-borders shading">1 (1)</td><td class="xxxx-borders shading">2 (2)</td><td class="xxxr-borders shading">3 (1)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13" data-xml-align="left">Not reported</td><td class="xxxx-borders">3 (3)</td><td class="xxxx-borders">4 (4)</td><td class="xxxx-borders">7 (4)</td><td class="xxxx-borders">1 (1)</td><td class="xxxr-borders">8 (3)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging03 shading" data-xml-align="left">Median weight (IQR) — kg<a href="#core-t1fn2" role="doc-noteref">†</a></td><td class="xxxx-borders shading">85.65 (72.20–97.10)</td><td class="xxxx-borders shading">86.25 (72.60–98.30)</td><td class="xxxx-borders shading">86.10 (72.60–97.30)</td><td class="xxxx-borders shading">83.90 (72.90–97.70)</td><td class="xxxr-borders shading">86.00 (72.60–97.50)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging03" data-xml-align="left">Body-mass index<a href="#core-t1fn4" role="doc-noteref">§</a></td><td class="xxxx-borders">30.39±6.578</td><td class="xxxx-borders">30.63±7.216</td><td class="xxxx-borders">30.51±6.874</td><td class="xxxx-borders">29.73±7.149</td><td class="xxxr-borders">30.25±6.961</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging03 shading" data-xml-align="left">Obesity — no. (%)<a href="#core-t1fn5" role="doc-noteref">¶</a></td><td class="xxxx-borders shading">39 (42)</td><td class="xxxx-borders shading">42 (47)</td><td class="xxxx-borders shading">81 (45)</td><td class="xxxx-borders shading">34 (37)</td><td class="xxxr-borders shading">115 (42)</td></tr><tr data-type="row"><td class="xxlx-borders hanging03">Baseline viral load in nasopharyngeal swab</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-type="row"><td class="xxlx-borders hanging13 shading">Raw values</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging23" data-xml-align="left">No. of patients</td><td class="xxxx-borders">84</td><td class="xxxx-borders">83</td><td class="xxxx-borders">167</td><td class="xxxx-borders">91</td><td class="xxxr-borders">258</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging23 shading" data-xml-align="left">Mean viral load — copies/ml</td><td class="xxxx-borders shading">16,080,000±27,810,000</td><td class="xxxx-borders shading">19,170,000±29,120,000</td><td class="xxxx-borders shading">17,620,000±28,420,000</td><td class="xxxx-borders shading">12,950,000±25,620,000</td><td class="xxxr-borders shading">15,970,000±27,510,000</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging23" data-xml-align="left">Median viral load (range) — copies/ml</td><td class="xxxx-borders">260,000 (1–71,000,000)</td><td class="xxxx-borders">195,000 (1–71,000,000)</td><td class="xxxx-borders">200,000 (1–71,000,000)</td><td class="xxxx-borders">50,500 (1–71,000,000)</td><td class="xxxr-borders">156,000 (1–71,000,000)</td></tr><tr data-type="row"><td class="xxlx-borders hanging13 shading">Log<sub>10</sub> scale</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging23" data-xml-align="left">No. of patients</td><td class="xxxx-borders">84</td><td class="xxxx-borders">83</td><td class="xxxx-borders">167</td><td class="xxxx-borders">91</td><td class="xxxr-borders">258</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging23 shading" data-xml-align="left">Mean viral load — log<sub>10</sub> copies/ml</td><td class="xxxx-borders shading">5.04±2.495</td><td class="xxxx-borders shading">5.00±2.527</td><td class="xxxx-borders shading">5.02±2.503</td><td class="xxxx-borders shading">4.67±2.366</td><td class="xxxr-borders shading">4.90±2.457</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging23" data-xml-align="left">Median viral load (range) — log<sub>10</sub> copies/ml</td><td class="xxxx-borders">5.41 (0.0–7.9)</td><td class="xxxx-borders">5.29 (0.0–7.9)</td><td class="xxxx-borders">5.30 (0.0–7.9)</td><td class="xxxx-borders">4.70 (0.0–7.9)</td><td class="xxxr-borders">5.19 (0.0–7.9)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging03 shading" data-xml-align="left">Positive baseline qualitative RT-PCR — no. (%)<a href="#core-t1fn6" role="doc-noteref">‖</a></td><td class="xxxx-borders shading">73 (79)</td><td class="xxxx-borders shading">74 (82)</td><td class="xxxx-borders shading">147 (81)</td><td class="xxxx-borders shading">81 (87)</td><td class="xxxr-borders shading">228 (83)</td></tr><tr data-type="row"><td class="xxlx-borders hanging03">Baseline serum C-reactive protein level</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13 shading" data-xml-align="left">No. of patients</td><td class="xxxx-borders shading">87</td><td class="xxxx-borders shading">86</td><td class="xxxx-borders shading">173</td><td class="xxxx-borders shading">92</td><td class="xxxr-borders shading">265</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13" data-xml-align="left">Mean level — mg/liter</td><td class="xxxx-borders">11.1±28.1</td><td class="xxxx-borders">12.2±20.0</td><td class="xxxx-borders">11.7±24.4</td><td class="xxxx-borders">21.5±43.5</td><td class="xxxr-borders">15.1±32.6</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13 shading" data-xml-align="left">Median level (range) — mg/liter</td><td class="xxxx-borders shading">3.0 (0.2–239.7)</td><td class="xxxx-borders shading">4.8 (0.1–138.7)</td><td class="xxxx-borders shading">3.7 (0.1–239.7)</td><td class="xxxx-borders shading">4.8 (0.1–232.0)</td><td class="xxxr-borders shading">4.1 (0.1–239.7)</td></tr><tr data-type="row"><td class="xxlx-borders hanging03">Baseline serum antibody status — no. (%)</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13 shading" data-xml-align="left">Negative</td><td class="xxxx-borders shading">41 (45)</td><td class="xxxx-borders shading">39 (43)</td><td class="xxxx-borders shading">80 (44)</td><td class="xxxx-borders shading">33 (35)</td><td class="xxxr-borders shading">113 (41)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13" data-xml-align="left">Positive</td><td class="xxxx-borders">37 (40)</td><td class="xxxx-borders">39 (43)</td><td class="xxxx-borders">76 (42)</td><td class="xxxx-borders">47 (51)</td><td class="xxxr-borders">123 (45)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13 shading" data-xml-align="left">Unknown<a href="#core-t1fn7" role="doc-noteref">**</a></td><td class="xxxx-borders shading">14 (15)</td><td class="xxxx-borders shading">12 (13)</td><td class="xxxx-borders shading">26 (14)</td><td class="xxxx-borders shading">13 (14)</td><td class="xxxr-borders shading">39 (14)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging03" data-xml-align="left">Median time from symptom onset to randomization (range) — days</td><td class="xxxx-borders">3.5 (0–7)</td><td class="xxxx-borders">3.0 (0–8)</td><td class="xxxx-borders">3.0 (0–8)</td><td class="xxxx-borders">3.0 (0–8)</td><td class="xxxr-borders">3.0 (0–8)</td></tr><tr data-xml-align="center" data-type="row"><td class="xblx-borders hanging03 shading" data-xml-align="left">At least one risk factor for hospitalization — no. (%)<a href="#core-t1fn8" role="doc-noteref">††</a></td><td class="xbxx-borders shading">57 (62)</td><td class="xbxx-borders shading">61 (68)</td><td class="xbxx-borders shading">118 (65)</td><td class="xbxx-borders shading">58 (62)</td><td class="xbxr-borders shading">176 (64)</td></tr></tbody></table></div><figcaption><div class="notes"><div role="doc-footnote" data-has="label"><div class="label">*</div><div id="core-t1fn1" role="paragraph" data-to-manipulate="true">Plus–minus values are means ±SD. Percentages may not total 100 because of rounding. RT-PCR denotes reverse-transcriptase polymerase chain reaction.</div></div><div role="doc-footnote" data-has="label"><div class="label">†</div><div id="core-t1fn2" role="paragraph" data-to-manipulate="true">The interquartile range (IQR) is defined as quartile 1 to quartile 3.</div></div><div role="doc-footnote" data-has="label"><div class="label">‡</div><div id="core-t1fn3" role="paragraph" data-to-manipulate="true">Race and ethnic group were reported by the patients.</div></div><div role="doc-footnote" data-has="label"><div class="label">§</div><div id="core-t1fn4" role="paragraph" data-to-manipulate="true">The body-mass index is the weight in kilograms divided by the square of the height in meters.</div></div><div role="doc-footnote" data-has="label"><div class="label">¶</div><div id="core-t1fn5" role="paragraph" data-to-manipulate="true">Obesity is defined as a body-mass index of greater than 30.</div></div><div role="doc-footnote" data-has="label"><div class="label">‖</div><div id="core-t1fn6" role="paragraph" data-to-manipulate="true">A positive result was defined as a viral load greater than or equal to the lower limit of detection (714 copies per milliliter [2.85 log<sub>10</sub> copies per milliliter]).</div></div><div role="doc-footnote" data-has="label"><div class="label">**</div><div id="core-t1fn7" role="paragraph" data-to-manipulate="true">An unknown serum antibody status indicates that the status could not be evaluated or that the results were borderline.</div></div><div role="doc-footnote" data-has="label"><div class="label">††</div><div id="core-t1fn8" role="paragraph" data-to-manipulate="true">Risk factors for hospitalization include an age of more than 50 years, obesity, cardiovascular disease (including hypertension), chronic lung disease (including asthma), chronic metabolic disease (including diabetes), chronic kidney disease (including receipt of dialysis), chronic liver disease, and immunocompromise (immunosuppression or receipt of immunosuppressants).</div></div></div></figcaption></a><figcaption><div class="caption">Demographic and Baseline Medical Characteristics.<a href="#core-t1fn1" role="doc-noteref">*</a></div></figcaption></figure><div class="external-links"><a class="pill__to-original" href="#t1"><i class="icon-return" aria-hidden="true"></i><span>Go to Table</span></a><a class="open-in-viewer" href="#t1" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2035002_t1.jpg"><span>Open in Viewer</span><i class="icon-expand" aria-hidden="true"></i></a></div></div><div id="core-t2"><figure class="table"><a class="open-in-viewer" href="#t2" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2035002_t2.jpg"><div class="graphic-wrap" data-presentation="suppressed-in-viewer"><img src="/cms/10.1056/NEJMoa2035002/asset/94e47e11-9f70-43f6-bd7d-7a955e75f701/assets/images/large/nejmoa2035002_t2.jpg" height="3323" width="2615" loading="lazy"></div><div class="table-wrap catalyst-standard" data-presentation="suppressed-in-flow"><table data-shading="custom"><thead><tr class="head1" data-type="row head1"><th class="txlx-borders" data-xml-align="left">End Point</th><th class="txxx-borders" colspan="3"><span>REGN-COV2</span></th><th class="txxr-borders">Placebo</th></tr><tr class="head2" data-type="row head2"><td class="xxlx-borders">&nbsp;</td><th class="xxxx-borders">2.4 g</th><th class="xxxx-borders">8.0 g</th><th class="xxxx-borders">Combined</th><th class="xxxr-borders">&nbsp;</th></tr></thead><tbody><tr data-type="row"><td class="xxlx-borders hanging04 shading"><b>Time-weighted average change in viral load from day 1 through day 7</b><a href="#core-t2fn2" role="doc-noteref">†</a></td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-type="row"><td class="xxlx-borders hanging04">Modified full analysis set<a href="#core-t2fn3" role="doc-noteref">‡</a></td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders" data-xml-align="center">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging14" data-xml-align="left">No. of patients</td><td class="xxxx-borders">70</td><td class="xxxx-borders">73</td><td class="xxxx-borders">143</td><td class="xxxr-borders">78</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging14" data-xml-align="left">Least-squares mean change — log<sub>10</sub> copies/ml</td><td class="xxxx-borders">−1.60±0.14</td><td class="xxxx-borders">−1.90 ±0.14</td><td class="xxxx-borders">−1.74±0.11</td><td class="xxxr-borders">−1.34±0.13</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging24" data-xml-align="left">95% CI</td><td class="xxxx-borders">−1.87 to −1.32</td><td class="xxxx-borders">−2.18 to −1.62</td><td class="xxxx-borders">−1.95 to −1.53</td><td class="xxxr-borders">−1.60 to −1.08</td></tr><tr data-type="row"><td class="xxlx-borders hanging14">Difference vs. placebo at day 7 — log<sub>10</sub> copies/ml</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging24" data-xml-align="left">Least-squares mean</td><td class="xxxx-borders">−0.25±0.18</td><td class="xxxx-borders">−0.56±0.18</td><td class="xxxx-borders">−0.41±0.15</td><td class="xxxr-borders" data-xml-align="left">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging24" data-xml-align="left">95% CI</td><td class="xxxx-borders">−0.60 to 0.10</td><td class="xxxx-borders">−0.91 to −0.21</td><td class="xxxx-borders">−0.71 to −0.10</td><td class="xxxr-borders" data-xml-align="left">&nbsp;</td></tr><tr data-type="row"><td class="xxlx-borders hanging04 shading">Baseline serum antibody status: negative</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading" data-xml-align="center">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging14 shading" data-xml-align="left">No. of patients</td><td class="xxxx-borders shading">34</td><td class="xxxx-borders shading">35</td><td class="xxxx-borders shading">69</td><td class="xxxr-borders shading">28</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging14 shading" data-xml-align="left">Least-squares mean change — log<sub>10</sub> copies/ml</td><td class="xxxx-borders shading">−1.89±0.18</td><td class="xxxx-borders shading">−1.96±0.18</td><td class="xxxx-borders shading">−1.94±0.13</td><td class="xxxr-borders shading">−1.37±0.20</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging24 shading" data-xml-align="left">95% CI</td><td class="xxxx-borders shading">−2.24 to −1.53</td><td class="xxxx-borders shading">−2.33 to −1.60</td><td class="xxxx-borders shading">−2.20 to −1.67</td><td class="xxxr-borders shading">−1.76 to −0.98</td></tr><tr data-type="row"><td class="xxlx-borders hanging14 shading">Difference vs. placebo at day 7 — log<sub>10</sub> copies/ml</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging24 shading" data-xml-align="left">Least-squares mean</td><td class="xxxx-borders shading">−0.52±0.26</td><td class="xxxx-borders shading">−0.60±0.26</td><td class="xxxx-borders shading">−0.56±0.23</td><td class="xxxr-borders shading" data-xml-align="left">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging24 shading" data-xml-align="left">95% CI</td><td class="xxxx-borders shading">−1.04 to 0.00</td><td class="xxxx-borders shading">−1.12 to −0.08</td><td class="xxxx-borders shading">−1.02 to −0.11</td><td class="xxxr-borders shading" data-xml-align="left">&nbsp;</td></tr><tr data-type="row"><td class="xxlx-borders hanging04">Baseline serum antibody status: positive</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders" data-xml-align="center">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging14" data-xml-align="left">No. of patients</td><td class="xxxx-borders">27</td><td class="xxxx-borders">29</td><td class="xxxx-borders">56</td><td class="xxxr-borders">37</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging14" data-xml-align="left">Least-squares mean change — log<sub>10</sub> copies/ml</td><td class="xxxx-borders">−1.24±0.19</td><td class="xxxx-borders">−1.63±0.20</td><td class="xxxx-borders">−1.45±0.13</td><td class="xxxr-borders">−1.24±0.16</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging24" data-xml-align="left">95% CI</td><td class="xxxx-borders">−1.61 to −0.86</td><td class="xxxx-borders">−2.03 to −1.24</td><td class="xxxx-borders">−1.71 to −1.18</td><td class="xxxr-borders">−1.55 to −0.93</td></tr><tr data-type="row"><td class="xxlx-borders hanging14">Difference vs. placebo at day 7, log<sub>10</sub> copies/ml</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging24" data-xml-align="left">Least-squares mean</td><td class="xxxx-borders">0.00±0.24</td><td class="xxxx-borders">−0.39±0.25</td><td class="xxxx-borders">−0.21±0.20</td><td class="xxxr-borders" data-xml-align="left">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging24" data-xml-align="left">95% CI</td><td class="xxxx-borders">−0.48 to 0.49</td><td class="xxxx-borders">−0.89 to 0.11</td><td class="xxxx-borders">−0.62 to 0.20</td><td class="xxxr-borders" data-xml-align="left">&nbsp;</td></tr><tr data-type="row"><td class="xxlx-borders hanging04 shading">Baseline serum antibody status: unknown<a href="#core-t2fn4" role="doc-noteref">§</a></td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading" data-xml-align="center">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging14 shading" data-xml-align="left">No. of patients</td><td class="xxxx-borders shading">9</td><td class="xxxx-borders shading">9</td><td class="xxxx-borders shading">18</td><td class="xxxr-borders shading">13</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging14 shading" data-xml-align="left">Least-squares mean change — log<sub>10</sub> copies/ml</td><td class="xxxx-borders shading">−0.95±0.56</td><td class="xxxx-borders shading">−1.98±0.60</td><td class="xxxx-borders shading">−1.43±0.44</td><td class="xxxr-borders shading">−1.49±0.63</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging24 shading" data-xml-align="left">95% CI</td><td class="xxxx-borders shading">−2.12 to 0.22</td><td class="xxxx-borders shading">−3.22 to −0.73</td><td class="xxxx-borders shading">−2.34 to −0.51</td><td class="xxxr-borders shading">−2.79 to − 0.19</td></tr><tr data-type="row"><td class="xxlx-borders hanging14 shading">Difference vs. placebo at day 7 — log<sub>10</sub> copies/ml</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging24 shading" data-xml-align="left">Least-squares mean</td><td class="xxxx-borders shading">0.54±0.84</td><td class="xxxx-borders shading">−0.49±0.86</td><td class="xxxx-borders shading">0.06±0.76</td><td class="xxxr-borders shading" data-xml-align="left">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging24 shading" data-xml-align="left">95% CI</td><td class="xxxx-borders shading">−1.20 to 2.28</td><td class="xxxx-borders shading">−2.27 to 1.30</td><td class="xxxx-borders shading">−1.51 to 1.63</td><td class="xxxr-borders shading" data-xml-align="left">&nbsp;</td></tr><tr data-type="row"><td class="xxlx-borders hanging04"><b>At least one Covid-19–related, medically attended visit within 29 days</b><a href="#core-t2fn5" role="doc-noteref">¶</a></td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-type="row"><td class="xxlx-borders hanging04 shading">Full analysis set</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading" data-xml-align="center">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging14 shading" data-xml-align="left">No. of patients</td><td class="xxxx-borders shading">92</td><td class="xxxx-borders shading">90</td><td class="xxxx-borders shading">182</td><td class="xxxr-borders shading">93</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging14 shading" data-xml-align="left">Patients with ≥1 visit within 29 days — no. (%)</td><td class="xxxx-borders shading">3 (3)</td><td class="xxxx-borders shading">3 (3)</td><td class="xxxx-borders shading">6 (3)</td><td class="xxxr-borders shading">6 (6)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging24 shading" data-xml-align="left">Difference vs. placebo — percentage points</td><td class="xxxx-borders shading">−3</td><td class="xxxx-borders shading">−3</td><td class="xxxx-borders shading">−3</td><td class="xxxr-borders shading" data-xml-align="left">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging34 shading" data-xml-align="left">95% CI</td><td class="xxxx-borders shading">−18 to 11</td><td class="xxxx-borders shading">−18 to 11</td><td class="xxxx-borders shading">−16 to 9</td><td class="xxxr-borders shading" data-xml-align="left">&nbsp;</td></tr><tr data-type="row"><td class="xxlx-borders hanging04">Baseline serum antibody status: negative</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders" data-xml-align="center">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging14" data-xml-align="left">No. of patients</td><td class="xxxx-borders">41</td><td class="xxxx-borders">39</td><td class="xxxx-borders">80</td><td class="xxxr-borders">33</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging14" data-xml-align="left">Patients with ≥1 visit within 29 days — no. (%)</td><td class="xxxx-borders">2 (5)</td><td class="xxxx-borders">3 (8)</td><td class="xxxx-borders">5 (6)</td><td class="xxxr-borders">5 (15)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging24" data-xml-align="left">Difference vs. placebo — percentage points</td><td class="xxxx-borders">−10</td><td class="xxxx-borders">−8</td><td class="xxxx-borders">−9</td><td class="xxxr-borders" data-xml-align="left">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging34" data-xml-align="left">95% CI</td><td class="xxxx-borders">−32 to 13</td><td class="xxxx-borders">−30 to 16</td><td class="xxxx-borders">−29 to 11</td><td class="xxxr-borders" data-xml-align="left">&nbsp;</td></tr><tr data-type="row"><td class="xxlx-borders hanging04 shading">Baseline serum antibody status: positive</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading" data-xml-align="center">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging14 shading" data-xml-align="left">No. of patients</td><td class="xxxx-borders shading">37</td><td class="xxxx-borders shading">39</td><td class="xxxx-borders shading">76</td><td class="xxxr-borders shading">47</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging14 shading" data-xml-align="left">Patients with ≥1 visit within 29 days — no. (%)</td><td class="xxxx-borders shading">1 (3)</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">1 (1)</td><td class="xxxr-borders shading">1 (2)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging24 shading" data-xml-align="left">Difference vs. placebo — percentage points</td><td class="xxxx-borders shading">1</td><td class="xxxx-borders shading">−2</td><td class="xxxx-borders shading">−1</td><td class="xxxr-borders shading" data-xml-align="left">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging34 shading" data-xml-align="left">95% CI</td><td class="xxxx-borders shading">−21 to 22</td><td class="xxxx-borders shading">−23 to 19</td><td class="xxxx-borders shading">−19 to 17</td><td class="xxxr-borders shading" data-xml-align="left">&nbsp;</td></tr><tr data-type="row"><td class="xxlx-borders hanging04">Baseline serum antibody status: unknown<a href="#core-t2fn4" role="doc-noteref">§</a></td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders" data-xml-align="center">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging14" data-xml-align="left">No. of patients</td><td class="xxxx-borders">14</td><td class="xxxx-borders">12</td><td class="xxxx-borders">26</td><td class="xxxr-borders">13</td></tr><tr data-xml-align="center" data-type="row"><td class="xblx-borders hanging14" data-xml-align="left">Patients with ≥1 visit within 29 days — no. (%)</td><td class="xbxx-borders">0</td><td class="xbxx-borders">0</td><td class="xbxx-borders">0</td><td class="xbxr-borders">0</td></tr></tbody></table></div><figcaption><div class="notes"><div role="doc-footnote" data-has="label"><div class="label">*</div><div id="core-t2fn1" role="paragraph" data-to-manipulate="true">Plus–minus values are least-squares means ±SE. Covid-19 denotes coronavirus disease 2019.</div></div><div role="doc-footnote" data-has="label"><div class="label">†</div><div id="core-t2fn2" role="paragraph" data-to-manipulate="true">The time-weighted average change in viral load was based on an analysis-of-covariance model with treatment group, risk factor, and baseline serum antibody status as fixed effects and baseline viral load and treatment group–by–baseline viral load as covariates. Confidence intervals were not adjusted for multiplicity.</div></div><div role="doc-footnote" data-has="label"><div class="label">‡</div><div id="core-t2fn3" role="paragraph" data-to-manipulate="true">The modified full analysis set excluded patients who tested negative for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) by qualitative reverse-transcriptase polymerase chain reaction at baseline.</div></div><div role="doc-footnote" data-has="label"><div class="label">§</div><div id="core-t2fn4" role="paragraph" data-to-manipulate="true">An unknown serum antibody status indicates that the status could not be evaluated or that the results were borderline.</div></div><div role="doc-footnote" data-has="label"><div class="label">¶</div><div id="core-t2fn5" role="paragraph" data-to-manipulate="true">Confidence intervals for the difference (REGN-COV2 minus placebo) were based on the exact method and were not adjusted for multiplicity.</div></div></div></figcaption></a><figcaption><div class="caption">Key Virologic and Clinical End Points.<a href="#core-t2fn1" role="doc-noteref">*</a></div></figcaption></figure><div class="external-links"><a class="pill__to-original" href="#t2"><i class="icon-return" aria-hidden="true"></i><span>Go to Table</span></a><a class="open-in-viewer" href="#t2" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2035002_t2.jpg"><span>Open in Viewer</span><i class="icon-expand" aria-hidden="true"></i></a></div></div><div id="core-t3"><figure class="table"><a class="open-in-viewer" href="#t3" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2035002_t3.jpg"><div class="graphic-wrap" data-presentation="suppressed-in-viewer"><img src="/cms/10.1056/NEJMoa2035002/asset/2fe99bb1-da2e-469d-9589-8b11f161d50f/assets/images/large/nejmoa2035002_t3.jpg" height="1171" width="1999" loading="lazy"></div><div class="table-wrap catalyst-standard" data-presentation="suppressed-in-flow"><table data-shading="custom"><thead><tr class="head1" data-type="row head1"><th class="txlx-borders" data-xml-align="left">Event</th><th class="txxx-borders" colspan="3"><span>REGN-COV2</span></th><th class="txxr-borders">Placebo<br>(N=93)</th></tr><tr class="head2" data-type="row head2"><td class="xxlx-borders">&nbsp;</td><th class="xxxx-borders">2.4 g<br>(N=88)</th><th class="xxxx-borders">8.0 g<br>(N=88)</th><th class="xxxx-borders">Combined<br>(N=176)</th><th class="xxxr-borders">&nbsp;</th></tr><tr class="head3" data-type="row head3"><td class="xxlx-borders">&nbsp;</td><th class="xxxr-borders" colspan="4"><span>number of patients (percent)</span></th></tr></thead><tbody><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02 shading" data-xml-align="left">Any serious adverse event</td><td class="xxxx-borders shading">1 (1)</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">1 (1)</td><td class="xxxr-borders shading">2 (2)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02" data-xml-align="left">Any adverse event of special interest<a href="#core-t3fn1" role="doc-noteref">*</a></td><td class="xxxx-borders">0</td><td class="xxxx-borders">2 (2)</td><td class="xxxx-borders">2 (1)</td><td class="xxxr-borders">2 (2)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02 shading" data-xml-align="left">Any serious adverse event of special interest<a href="#core-t3fn1" role="doc-noteref">*</a></td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">0</td><td class="xxxr-borders shading">0</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02" data-xml-align="left">Grade ≥2 infusion-related reaction within 4 days</td><td class="xxxx-borders">0</td><td class="xxxx-borders">2 (2)</td><td class="xxxx-borders">2 (1)</td><td class="xxxr-borders">1 (1)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02 shading" data-xml-align="left">Grade ≥2 hypersensitivity reaction within 29 days</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">1 (1)</td><td class="xxxx-borders shading">1 (1)</td><td class="xxxr-borders shading">2 (2)</td></tr><tr data-type="row"><td class="xxlx-borders hanging02">Adverse events that occurred or worsened during the observation period<a href="#core-t3fn2" role="doc-noteref">†</a></td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders" data-xml-align="center">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Grade 3 or 4 event</td><td class="xxxx-borders shading">1 (1)</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">1 (1)</td><td class="xxxr-borders shading">1 (1)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Event that led to death</td><td class="xxxx-borders">0</td><td class="xxxx-borders">0</td><td class="xxxx-borders">0</td><td class="xxxr-borders">0</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Event that led to withdrawal from the trial</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">0</td><td class="xxxr-borders shading">0</td></tr><tr data-xml-align="center" data-type="row"><td class="xblx-borders hanging12" data-xml-align="left">Event that led to infusion interruption<a href="#core-t3fn1" role="doc-noteref">*</a></td><td class="xbxx-borders">0</td><td class="xbxx-borders">1 (1)</td><td class="xbxx-borders">1 (1)</td><td class="xbxr-borders">1 (1)</td></tr></tbody></table></div><figcaption><div class="notes"><div role="doc-footnote" data-has="label"><div class="label">*</div><div id="core-t3fn1" role="paragraph" data-to-manipulate="true">Events were grade 2 or higher hypersensitivity reactions or infusion-related reactions.</div></div><div role="doc-footnote" data-has="label"><div class="label">†</div><div id="core-t3fn2" role="paragraph" data-to-manipulate="true">Events listed here were not present at baseline or were an exacerbation of a preexisting condition that occurred during the observation period, which is defined as the time from administration of REGN-COV2 or placebo to the last study visit.</div></div></div></figcaption></a><figcaption><div class="caption">Serious Adverse Events and Adverse Events of Special Interest in the Safety Population.</div></figcaption></figure><div class="external-links"><a class="pill__to-original" href="#t3"><i class="icon-return" aria-hidden="true"></i><span>Go to Table</span></a><a class="open-in-viewer" href="#t3" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2035002_t3.jpg"><span>Open in Viewer</span><i class="icon-expand" aria-hidden="true"></i></a></div></div></div></div><div id="core-collateral-share" role="tabpanel" data-core-tabs="core-collateral-share" tabindex="-1" aria-labelledby="pane-core-collateral-share"><header><h2 id="pane-core-collateral-share"><i class="icon-share" aria-hidden="true"></i>Share</h2><button data-close="collateral" aria-label="Close"><i class="icon-close"></i></button></header><h3>Share</h3><div class="section--wrapper"><section><h4>CONTENT LINK</h4><div id="share-self"><p data-id="article-share-self-link" class="share-self__source">https://www.nejm.org/doi/full/10.1056/NEJMoa2035002</p><button data-id="article-share-access" aria-label="CONTENT LINK" class="share-self__action btn btn--inverse"><i aria-hidden="true" class="icon-copy-o"></i><span>Copy Link</span></button><div aria-live="polite" class="share-self__status"><p class="share-self__success"><i aria-hidden="true" class="icon-check_circle"></i><span>Copied!</span></p><p class="share-self__failed"><i aria-hidden="true" class="icon-x_btnclose"></i><span>Copying failed.</span></p></div></div></section><section data-location="share_tools_article"><h4>Share</h4><div class="share-buttons a2a a2a_kit" style="line-height: 16px;"><a href="/#facebook" aria-label="Share on Facebook" data-id="article-share-facebook" rel="nofollow noopener" role="link" target="_blank" title="Share on Facebook" class="btn btn--facebook a2a_button_facebook" data-interactiontype="social"><i aria-hidden="true" class="icon-facebook"></i><span>Facebook</span></a><a href="/#twitter" aria-label="Share on X (formerly Twitter)" data-id="article-share-twitter" rel="nofollow noopener" role="link" target="_blank" title="Share on X (formerly Twitter)" class="btn btn--twitter a2a_button_twitter" data-interactiontype="social"><i aria-hidden="true" class="icon-twitter"></i><span>X (formerly Twitter)</span></a><a href="/#linkedin" aria-label="Share on LinkedIn" data-id="article-share-linkedin" rel="nofollow noopener" role="link" target="_blank" title="Share on LinkedIn" class="btn btn--linkedin a2a_button_linkedin" data-interactiontype="social"><i aria-hidden="true" class="icon-linkedin"></i><span>LinkedIn</span></a><a href="/#email" aria-label="Share on email" data-id="article-share-email" rel="nofollow noopener" role="link" target="_blank" title="Share on email" class="btn btn--email a2a_button_email" data-interactiontype="content_email_click"><i aria-hidden="true" class="icon-mail"></i><span>email</span></a><a href="/#bluesky" aria-label="Share on Bluesky" data-id="article-share-bluesky" rel="nofollow noopener" role="link" target="_blank" title="Share on Bluesky" class="btn btn--bluesky a2a_button_bluesky" data-interactiontype="social"><i aria-hidden="true" class="icon-bluesky"></i><span>Bluesky</span></a></div></section></div></div><div data-location="references_article" id="core-collateral-references" role="tabpanel" aria-labelledby="pane-core-collateral-references" data-core-tabs="core-collateral-references" tabindex="-1"><header><h2 id="pane-core-collateral-references"><i aria-hidden="true" class="icon-references"></i>References</h2><button data-close="collateral" aria-label="Close"><i class="icon-close"></i></button></header><h3>References</h3><div role="list" class="section--wrapper"><div role="listitem" data-has="label"><div class="label">1.</div><div id="core-r1" class="citations"><div class="citation"><div class="citation-content">Zhu N, Zhang D, Wang W, et al. A novel coronavirus from patients with pneumonia in China, 2019. <em>N Engl J Med</em> 2020;382:727-733.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r1"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="/servlet/linkout?suffix=e_1_3_5_2_2&amp;dbid=4&amp;doi=10.1056%2FNEJMoa2035002&amp;key=10.1056%2FNEJMoa2001017&amp;site=mms-site" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/31978945/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000517119800008" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=A+novel+coronavirus+from+patients+with+pneumonia+in+China%2C+2019.&amp;publication_year=2020&amp;journal=N+Engl+J+Med&amp;pages=727-733&amp;doi=10.1056%2FNEJMoa2001017&amp;pmid=31978945" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">2.</div><div id="core-r2" class="citations"><div class="citation"><div class="citation-content">Gudbjartsson DF, Helgason A, Jonsson H, et al. Spread of SARS-CoV-2 in the Icelandic population. <em>N Engl J Med</em> 2020;382:2302-2315.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r5"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="/servlet/linkout?suffix=e_1_3_5_3_2&amp;dbid=4&amp;doi=10.1056%2FNEJMoa2035002&amp;key=10.1056%2FNEJMoa2006100&amp;site=mms-site" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/32289214/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000541151500010" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Spread+of+SARS-CoV-2+in+the+Icelandic+population.&amp;publication_year=2020&amp;journal=N+Engl+J+Med&amp;pages=2302-2315&amp;doi=10.1056%2FNEJMoa2006100&amp;pmid=32289214" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">3.</div><div id="core-r3" class="citations"><div class="citation"><div class="citation-content">Lavezzo E, Franchin E, Ciavarella C, et al. Suppression of a SARS-CoV-2 outbreak in the Italian municipality of Vo’. <em>Nature</em> 2020;584:425-429.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r5"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1038/s41586-020-2488-1" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/32604404/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000556239500001" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Suppression+of+a+SARS-CoV-2+outbreak+in+the+Italian+municipality+of+Vo%E2%80%99.&amp;publication_year=2020&amp;journal=Nature&amp;pages=425-429&amp;doi=10.1038%2Fs41586-020-2488-1&amp;pmid=32604404" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">4.</div><div id="core-r4" class="citations"><div class="citation"><div class="citation-content">Lee S, Kim T, Lee E, et al. Clinical course and molecular viral shedding among asymptomatic and symptomatic patients with SARS-CoV-2 infection in a community treatment center in the Republic of Korea. <em>JAMA Intern Med</em> 2020;180:1447-1452.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r5"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1001/jamainternmed.2020.3862" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/32780793/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000604965700009" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Clinical+course+and+molecular+viral+shedding+among+asymptomatic+and+symptomatic+patients+with+SARS-CoV-2+infection+in+a+community+treatment+center+in+the+Republic+of+Korea.&amp;publication_year=2020&amp;journal=JAMA+Intern+Med&amp;pages=1447-1452&amp;doi=10.1001%2Fjamainternmed.2020.3862&amp;pmid=32780793" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">5.</div><div id="core-r5" class="citations"><div class="citation"><div class="citation-content">Oran DP, Topol EJ. Prevalence of asymptomatic SARS-CoV-2 infection: a narrative review. <em>Ann Intern Med</em> 2020;173:362-367.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r5"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.7326/M20-3012" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/32491919/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000567080900010" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Prevalence+of+asymptomatic+SARS-CoV-2+infection%3A+a+narrative+review.&amp;publication_year=2020&amp;journal=Ann+Intern+Med&amp;pages=362-367&amp;doi=10.7326%2FM20-3012&amp;pmid=32491919" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">6.</div><div id="core-r6" class="citations"><div class="citation"><div class="citation-content">Goyal P, Choi JJ, Pinheiro LC, et al. Clinical characteristics of Covid-19 in New York City. <em>N Engl J Med</em> 2020;382:2372-2374.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r8"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="/servlet/linkout?suffix=e_1_3_5_7_2&amp;dbid=4&amp;doi=10.1056%2FNEJMoa2035002&amp;key=10.1056%2FNEJMc2010419&amp;site=mms-site" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/32302078/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000541151500019" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Clinical+characteristics+of+Covid-19+in+New+York+City.&amp;publication_year=2020&amp;journal=N+Engl+J+Med&amp;pages=2372-2374&amp;doi=10.1056%2FNEJMc2010419&amp;pmid=32302078" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">7.</div><div id="core-r7" class="citations"><div class="citation"><div class="citation-content">Guan WJ, Ni ZY, Hu Y, et al. Clinical characteristics of coronavirus disease 2019 in China. <em>N Engl J Med</em> 2020;382:1708-1720.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r8"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="/servlet/linkout?suffix=e_1_3_5_8_2&amp;dbid=4&amp;doi=10.1056%2FNEJMoa2035002&amp;key=10.1056%2FNEJMoa2002032&amp;site=mms-site" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/32109013/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000531351300014" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Clinical+characteristics+of+coronavirus+disease+2019+in+China.&amp;publication_year=2020&amp;journal=N+Engl+J+Med&amp;pages=1708-1720&amp;doi=10.1056%2FNEJMoa2002032&amp;pmid=32109013" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">8.</div><div id="core-r8" class="citations"><div class="citation"><div class="citation-content">Richardson S, Hirsch JS, Narasimhan M, et al. Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York City area. <em>JAMA</em> 2020;323:2052-2059.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r8"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1001/jama.2020.6775" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/32320003/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000538023900036" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Presenting+characteristics%2C+comorbidities%2C+and+outcomes+among+5700+patients+hospitalized+with+COVID-19+in+the+New+York+City+area.&amp;publication_year=2020&amp;journal=JAMA&amp;pages=2052-2059&amp;doi=10.1001%2Fjama.2020.6775&amp;pmid=32320003" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">9.</div><div id="core-r9" class="citations"><div class="citation"><div class="citation-content">Blanco-Melo D, Nilsson-Payant BE, Liu WC, et al. Imbalanced host response to SARS-CoV-2 drives development of COVID-19. <em>Cell</em> 2020;181(5):1036-1045.e9.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r9"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/j.cell.2020.04.026" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/32416070/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000537399500011" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Imbalanced+host+response+to+SARS-CoV-2+drives+development+of+COVID-19.&amp;publication_year=2020&amp;journal=Cell&amp;pages=1036-1045.e9&amp;doi=10.1016%2Fj.cell.2020.04.026&amp;pmid=32416070" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">10.</div><div id="core-r10" class="citations"><div class="citation"><div class="citation-content">Regeneron and Sanofi provide update on Kevzara® (sarilumab) phase 3 U.S. trial in COVID-19 patients. Regeneron, July 2, 2020 (<a href="https://investor.regeneron.com/news-releases/news-release-details/regeneron-and-sanofi-provide-update-kevzarar-sarilumab-phase-3">https://investor.regeneron.com/news-releases/news-release-details/regeneron-and-sanofi-provide-update-kevzarar-sarilumab-phase-3</a>).</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r13"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Regeneron+and+Sanofi+provide+update+on+Kevzara%C2%AE+%28sarilumab%29+phase+3+U.S.+trial+in+COVID-19+patients&amp;publication_year=2020" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">11.</div><div id="core-r11" class="citations"><div class="citation"><div class="citation-content">Roche provides an update on the phase III COVACTA Trial of Actemra/RoActemra in hospitalized patients with severe COVID-19 associated pneumonia. Roche, July 29, 2020 (<a href="https://www.roche.com/media/releases/med-cor-2020-07-29.htm">https://www.roche.com/media/releases/med-cor-2020-07-29.htm</a>).</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r13"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Roche+provides+an+update+on+the+phase+III+COVACTA+Trial+of+Actemra%2FRoActemra+in+hospitalized+patients+with+severe+COVID-19+associated+pneumonia.&amp;publication_year=2020" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">12.</div><div id="core-r12" class="citations"><div class="citation"><div class="citation-content">Rosas I, Bräu N, Waters M, et al. Tocilizumab in hospitalized patients with COVID-19 pneumonia. August 27, 2020 (<a href="https://www.medrxiv.org/content/10.1101/2020.08.27.20183442v2">https://www.medrxiv.org/content/10.1101/2020.08.27.20183442v2</a>). preprint.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r13"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Tocilizumab+in+hospitalized+patients+with+COVID-19+pneumonia.&amp;publication_year=2020" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">13.</div><div id="core-r13" class="citations"><div class="citation"><div class="citation-content">RECOVERY Collaborative Group. Dexamethasone in hospitalized patients with Covid-19 — preliminary report. <em>N Engl J Med</em>.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r13"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="/servlet/linkout?suffix=e_1_3_5_14_2&amp;dbid=4&amp;doi=10.1056%2FNEJMoa2035002&amp;key=10.1056%2FNEJMoa2021436&amp;site=mms-site" target="_blank">Crossref</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000623807600009" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Dexamethasone+in+hospitalized+patients+with+Covid-19+%E2%80%94+preliminary+report.&amp;journal=N+Engl+J+Med&amp;doi=10.1056%2FNEJMoa2021436" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">14.</div><div id="core-r14" class="citations"><div class="citation"><div class="citation-content">Wölfel R, Corman VM, Guggemos W, et al. Virological assessment of hospitalized patients with COVID-2019. <em>Nature</em> 2020;581:465-469.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r14-core" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1038/s41586-020-2196-x" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/32235945/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000535223600001" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Virological+assessment+of+hospitalized+patients+with+COVID-2019.&amp;publication_year=2020&amp;journal=Nature&amp;pages=465-469&amp;doi=10.1038%2Fs41586-020-2196-x&amp;pmid=32235945" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r14-core" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r14-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] high viral titers in hospitalized patients, </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r20" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] against SARS-CoV-2 and viral loads. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">15.</div><div id="core-r15" class="citations"><div class="citation"><div class="citation-content">Baum A, Fulton BO, Wloga E, et al. Antibody cocktail to SARS-CoV-2 spike protein prevents rapid mutational escape seen with individual antibodies. <em>Science</em> 2020;369:1014-1018.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r15-core" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1126/science.abd0831" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/32540904/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000562436800055" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Antibody+cocktail+to+SARS-CoV-2+spike+protein+prevents+rapid+mutational+escape+seen+with+individual+antibodies&amp;publication_year=2020&amp;journal=Science&amp;pages=1014-1018&amp;doi=10.1126%2Fscience.abd0831&amp;pmid=32540904" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r15-core" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r16" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] enzyme 2 (ACE2) receptor. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r15-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] mutants seen with either single antibody. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">16.</div><div id="core-r16" class="citations"><div class="citation"><div class="citation-content">Hansen J, Baum A, Pascal KE, et al. Studies in humanized mice and convalescent humans yield a SARS-CoV-2 antibody cocktail. <em>Science</em> 2020;369:1010-1014.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r16"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1126/science.abd0827" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/32540901/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000562436800054" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Studies+in+humanized+mice+and+convalescent+humans+yield+a+SARS-CoV-2+antibody+cocktail&amp;publication_year=2020&amp;journal=Science&amp;pages=1010-1014&amp;doi=10.1126%2Fscience.abd0827&amp;pmid=32540901" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">17.</div><div id="core-r17" class="citations"><div class="citation"><div class="citation-content">Simões EAF, Forleo-Neto E, Geba GP, et al. Suptavumab for the prevention of medically attended respiratory syncytial virus infection in preterm infants. <em>Clin Infect Dis</em> 2020 September 8 (Epub ahead of print).</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r17"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1093/cid/ciaa951" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/32897368/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000735309500119" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Suptavumab+for+the+prevention+of+medically+attended+respiratory+syncytial+virus+infection+in+preterm+infants.&amp;publication_year=2020&amp;journal=Clin+Infect+Dis&amp;doi=10.1093%2Fcid%2Fciaa951&amp;pmid=32897368" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">18.</div><div id="core-r18" class="citations"><div class="citation"><div class="citation-content">Baum A, Ajithdoss D, Copin R, et al. REGN-COV2 antibodies prevent and treat SARS-CoV-2 infection in rhesus macaques and hamsters. <em>Science</em> 2020;370:1110-1115.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r18"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1126/science.abe2402" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/33037066/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000595345600056" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=REGN-COV2+antibodies+prevent+and+treat+SARS-CoV-2+infection+in+rhesus+macaques+and+hamsters.&amp;publication_year=2020&amp;journal=Science&amp;pages=1110-1115&amp;doi=10.1126%2Fscience.abe2402&amp;pmid=33037066" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">19.</div><div id="core-r19" class="citations"><div class="citation"><div class="citation-content">Regeneron’s COVID-19 outpatient trial prospectively demonstrates that REGN-COV2 antibody cocktail significantly reduced virus levels and need for further medical attention. Regeneron, October 28, 2020 (<a href="https://investor.regeneron.com/news-releases/news-release-details/regenerons-covid-19-outpatient-trial-prospectively-demonstrates">https://investor.regeneron.com/news-releases/news-release-details/regenerons-covid-19-outpatient-trial-prospectively-demonstrates</a>).</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r19"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Regeneron%E2%80%99s+COVID-19+outpatient+trial+prospectively+demonstrates+that+REGN-COV2+antibody+cocktail+significantly+reduced+virus+levels+and+need+for+further+medical+attention.&amp;publication_year=2020" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">20.</div><div id="core-r20" class="citations"><div class="citation"><div class="citation-content">Wellinghausen N, Plonné D, Voss M, Ivanova R, Frodl R, Deininger S. SARS-CoV-2-IgG response is different in COVID-19 outpatients and asymptomatic contact persons. <em>J Clin Virol</em> 2020;130:104542-104542.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r20"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/j.jcv.2020.104542" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/32707511/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000571737600012" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=SARS-CoV-2-IgG+response+is+different+in+COVID-19+outpatients+and+asymptomatic+contact+persons.&amp;publication_year=2020&amp;journal=J+Clin+Virol&amp;pages=104542-104542&amp;doi=10.1016%2Fj.jcv.2020.104542&amp;pmid=32707511" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">21.</div><div id="core-r21" class="citations"><div class="citation"><div class="citation-content">Tenforde MW, Kim SS, Lindsell CJ, et al. Symptom duration and risk factors for delayed return to usual health among outpatients with COVID-19 in a multistate health care systems network — United States, March–June 2020. <em>MMWR Morb Mortal Wkly Rep</em> 2020;69:993-998.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r21"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.15585/mmwr.mm6930e1" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/32730238/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000554866700003" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Symptom+duration+and+risk+factors+for+delayed+return+to+usual+health+among+outpatients+with+COVID-19+in+a+multistate+health+care+systems+network+%E2%80%94+United+States%2C+March%E2%80%93June+2020.&amp;publication_year=2020&amp;journal=MMWR+Morb+Mortal+Wkly+Rep&amp;pages=993-998&amp;doi=10.15585%2Fmmwr.mm6930e1&amp;pmid=32730238" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">22.</div><div id="core-r22" class="citations"><div class="citation"><div class="citation-content">Magleby R, Westblade LF, Trzebucki A, et al. Impact of SARS-CoV-2 viral load on risk of intubation and mortality among hospitalized patients with coronavirus disease 2019. <em>Clin Infect Dis</em> 2020 June 30 (Epub ahead of print).</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r22"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1093/cid/ciaa851" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/32603425/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000735309500093" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Impact+of+SARS-CoV-2+viral+load+on+risk+of+intubation+and+mortality+among+hospitalized+patients+with+coronavirus+disease+2019.&amp;publication_year=2020&amp;journal=Clin+Infect+Dis&amp;doi=10.1093%2Fcid%2Fciaa851&amp;pmid=32603425" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">23.</div><div id="core-r23" class="citations"><div class="citation"><div class="citation-content">Joyner MJ, Senefeld JW, Klassen SA, et al. Effect of convalescent plasma on mortality among hospitalized patients with COVID-19: initial three-month experience. August 12, 2020. preprint.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r24"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/32817978/" target="_blank">PubMed</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Effect+of+convalescent+plasma+on+mortality+among+hospitalized+patients+with+COVID-19%3A+initial+three-month+experience.&amp;publication_year=2020&amp;pmid=32817978" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">24.</div><div id="core-r24" class="citations"><div class="citation"><div class="citation-content">Li L, Zhang W, Hu Y, et al. Effect of convalescent plasma therapy on time to clinical improvement in patients with severe and life-threatening COVID-19: a randomized clinical trial. <em>JAMA</em> 2020;324:460-470.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r24"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1001/jama.2020.10044" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/32492084/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000561261900017" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Effect+of+convalescent+plasma+therapy+on+time+to+clinical+improvement+in+patients+with+severe+and+life-threatening+COVID-19%3A+a+randomized+clinical+trial.&amp;publication_year=2020&amp;journal=JAMA&amp;pages=460-470&amp;doi=10.1001%2Fjama.2020.10044&amp;pmid=32492084" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">25.</div><div id="core-r25" class="citations"><div class="citation"><div class="citation-content">Chen P, Nirula A, Heller B, et al. SARS-CoV-2 neutralizing antibody LY-CoV555 in outpatients with Covid-19. <em>N Engl J Med</em> 2021;384:229-237.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r25"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="/servlet/linkout?suffix=e_1_3_5_26_2&amp;dbid=4&amp;doi=10.1056%2FNEJMoa2035002&amp;key=10.1056%2FNEJMoa2029849&amp;site=mms-site" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/33113295/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000613533100008" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=SARS-CoV-2+neutralizing+antibody+LY-CoV555+in+outpatients+with+Covid-19.&amp;publication_year=2021&amp;journal=N+Engl+J+Med&amp;pages=229-237&amp;doi=10.1056%2FNEJMoa2029849&amp;pmid=33113295" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">26.</div><div id="core-r26" class="citations"><div class="citation"><div class="citation-content">Mulangu S, Dodd LE, Davey RT Jr, et al. A randomized, controlled trial of Ebola virus disease therapeutics. <em>N Engl J Med</em> 2019;381:2293-2303.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r26"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="/servlet/linkout?suffix=e_1_3_5_27_2&amp;dbid=4&amp;doi=10.1056%2FNEJMoa2035002&amp;key=10.1056%2FNEJMoa1910993&amp;site=mms-site" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/31774950/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000505221600004" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=A+randomized%2C+controlled+trial+of+Ebola+virus+disease+therapeutics.&amp;publication_year=2019&amp;journal=N+Engl+J+Med&amp;pages=2293-2303&amp;doi=10.1056%2FNEJMoa1910993&amp;pmid=31774950" target="_blank">Google Scholar</a></div></div></div></div></div></div></div></div><aside data-core-aside="right-rail">



        
        <div id="DTM_Position_MedRectangle" class="ad">
 <!--emptycomment-->
</div>




        
        <div class="ng-page_layout-sidebarSpacing"></div>










    
    
        <div data-widget-def="relatedArticlesWidget" data-widget-id="8206d5cd-cb8c-4ff9-8c46-3d22e0dee215" data-location="recirc_curatedRelated_article">
        



        
        <div class="ng-related-articles"><h3 class="ng-subsection-title"><span class="ng-subsection-title_text">Related articles</span></h3><ul class="ng-related-articles_list"><li class="ng-related-articles_item"><div class="issue-item issue-item_sm"><div class="issue-item_meta"><ul class="issue-item_meta-list clearfix"><li class="issue-item_meta-item"><a href="/browse/nejm-article-type/editorial" class="issue-item_type">Editorial</a></li><li class="issue-item_meta-item"><span class="issue-item_date">Jan 20, 2021</span></li></ul></div><div class="issue-item_row"><div class="issue-item_left"><div class="issue-item_content clearfix"><h4 class="issue-item_title"><a href="/doi/full/10.1056/NEJMe2034495" data-interactiontype="article_recirculation_click" class="issue-item_title-link animation-underline">Monoclonal Antibodies to Disrupt Progression of Early Covid-19 Infection</a></h4><div class="issue-item_authors-and-text"><span class="issue-item_authors">M.S. Cohen</span></div></div></div></div></div></li><li class="ng-related-articles_item"><div class="issue-item issue-item_sm"><div class="issue-item_meta"><ul class="issue-item_meta-list clearfix"><li class="issue-item_meta-item"><a href="/browse/nejm-article-type/original-article" class="issue-item_type">Original Article</a></li><li class="issue-item_meta-item"><span class="issue-item_date">Oct 28, 2020</span></li></ul></div><div class="issue-item_row"><div class="issue-item_left"><div class="issue-item_content clearfix"><h4 class="issue-item_title"><a href="/doi/full/10.1056/NEJMoa2029849" data-interactiontype="article_recirculation_click" class="issue-item_title-link animation-underline">SARS-CoV-2 Neutralizing Antibody LY-CoV555 in Outpatients with Covid-19</a></h4><div class="issue-item_authors-and-text"><span class="issue-item_authors">P. Chen and Others</span></div></div></div></div></div></li></ul></div>

        </div>
    





        
        <div class="ng-page_layout-sidebarSpacing"></div>




        
        <div id="nejm_jobs" class="nejm_jobs"> <!-- top red rectangle --><div id="nejm-widget" class="nejm-widget" style="display: block;"><div class="nejm-widget_logo">	<a target="nejm-win" href="https://www.nejmcareercenter.org/?query=fjw">		<img alt="CareerCenter" src="https://apps1.nejmcareercenter.org/images/nejmCCID-JobsWidget.gif" width="140" height="36">	</a></div><div class="nejm-widget_cont"> <!-- content --><div class="nejm-widget_title">PHYSICIAN JOBS</div><div class="nejm-widget_date">June 10, 2025</div><div class="nejm-widget_item"><div><span> Presque Isle, Maine</span></div><div><span>Obstetrics &amp; Gynecology</span></div><div><a target="nejm-job-win" onmouseover="jlho(this);" onmouseout="jlou(this);" href="https://www.nejmcareercenter.org/job/886432/ob-gyn-physician-full-time-or-part-time-schedule-available-/?query=fjwp&amp;rid=3625">OB/GYN Physician - Full-Time or Part-Time Schedule Available!</a></div></div><div class="nejm-widget_item"><div><span> Manchester, New Hampshire</span></div><div><span>Psychiatry</span></div><div><a target="nejm-job-win" onmouseover="jlho(this);" onmouseout="jlou(this);" href="https://www.nejmcareercenter.org/job/889101/outpatient-psychiatrist-hybrid-elliot-health-manchester-nh-1-hour-to-boston-/?query=fjwp&amp;rid=484217">Outpatient Psychiatrist "Hybrid" - Elliot Health, Manchester, NH (1 Hour to Boston)</a></div></div><div class="nejm-widget_item"><div><span> California</span></div><div><span>Anesthesiology</span></div><div><a target="nejm-job-win" onmouseover="jlho(this);" onmouseout="jlou(this);" href="https://www.nejmcareercenter.org/job/891429/anesthesiology-monterey-ca-coastal-ca-1099-model-800k-income-potential/?query=fjwf&amp;rid=5263">Anesthesiology | Monterey, CA - Coastal CA | 1099 Model - 800k Income Potential</a></div></div><div class="nejm-widget_item"><div><span> San Francisco, California</span></div><div><span>Family Medicine</span></div><div><a target="nejm-job-win" onmouseover="jlho(this);" onmouseout="jlou(this);" href="https://www.nejmcareercenter.org/job/889218/physician-family-medicine-internal-medicine-san-francisco-ca-/?query=fjwf&amp;rid=845672">Physician, Family Medicine / Internal Medicine (San Francisco, CA)</a></div></div><div class="nejm-widget_item"><div><span> Fort Worth, Texas</span></div><div><span>Neonatal / Perinatal Medicine</span></div><div><a target="nejm-job-win" onmouseover="jlho(this);" onmouseout="jlou(this);" href="https://www.nejmcareercenter.org/job/883493/neonatologist-fort-worth-tx/?query=fjwf&amp;rid=49812">Neonatologist - Fort Worth, TX</a></div></div><div class="nejm-widget_item"><div><span> Seattle, Washington State</span></div><div><span>Dermatology</span></div><div><a target="nejm-job-win" onmouseover="jlho(this);" onmouseout="jlou(this);" href="https://www.nejmcareercenter.org/job/881627/dermatology-physician-north-seattle-wa/?query=fjwf&amp;rid=220874">Dermatology Physician - North Seattle, WA</a></div></div></div> <!-- content --> <!-- footer --></div> <!-- nejm-widget --></div><script src="https://apps1.nejmcareercenter.org/?width=300&amp;sp=all"></script>




        
        <div class="ng-page_layout-sidebarSpacing"></div>










    
    
        <div data-widget-def="literatumAd" data-widget-id="001e4aa7-b6fe-4b21-9d5b-5bde81227c67" id="ad-article-right-rail-300x250-1">
        



        
        



    
        <div class="pb-house-message adplaceholder exists">
            <a href="/action/clickThrough?id=128720&amp;url=https%3A%2F%2Fstore.nejm.org%2Fsignup%2Fnejmai%2Fregister%2Faifallpdf24%3Fpromo%3DOAFQF4NA%26query%3Dcm-rr%26utm_source%3Dnejm%26utm_medium%3Dcm%26utm_campaign%3Daifallpdf24&amp;loc=%2Fdoi%2Ffull%2F10.1056%2FNEJMoa2035002&amp;pubId=41289801&amp;placeholderId=101337&amp;productId=1007" target="_blank"><img src="/sda/128720/NEJ-AI-Fall24-300x250---002.jpg" width="300" height="250"></a>
            
        </div>
    

    

    



        </div>
    





        
        <div class="ng-page_layout-sidebarSpacing"></div>




        
        <script src="https://widgets.nejm.org/onepub-widgets/loader/webcomponents-loader.js" async="" nonce="94d6670fb4c0f1da-SJC">
<script src="https://widgets.nejm.org/onepub-widgets/loader/polyfill-support.js"  nonce="94d6670fb4c0f1da-SJC"></script>
<script src="https://widgets.nejm.org/onepub-widgets/more-like-this.js" type="module" nonce="94d6670fb4c0f1da-SJC"></script>

<more-like-this class="onepub-widget" dataid="onepub-more-like-this" collections="catalyst-article, clinician-article, evidence-article, nejm-ai-article, nejm-article" headertitle="More Like This" maxitems="5"><!----><div class="more-like-this onepub-more-like-this_"><!--?lit$181050630$--><onepub-fonts><wc-fetch></wc-fetch><!--?lit$181050630$--><div class="mlt-wrapper"><div class="mlt-header-container"><div class="mlt-header-content-left"><div class="mlt-header-title-container"><span class="mlt-header-title">More Like This</span></div><!--?lit$181050630$--></div></div><div class="mlt-body"><!--?lit$181050630$--><!----><div class="mlt-article-container"><div class="mlt-article-container-header"><a data-location="recirc_Semantic" class="mlt-article-type nejm" href="https://www.nejm.org/browse/nejm-article-type/original-article" target="_self"><!--?lit$181050630$-->Original Article</a> <span class="mlt-article-site-label"><!--?lit$181050630$-->NEJM</span> <span class="mlt-article-pubdate"><!--?lit$181050630$-->Jun 09, 2022</span></div><div class="mlt-article-title"><a data-location="recirc_Semantic" href="https://www.nejm.org/doi/full/10.1056/NEJMoa2118946?query=recirc_Semantic" target="_self">Protection and Waning of Natural and Hybrid Immunity to SARS-CoV-2</a></div><div class="mlt-article-authors"><!--?lit$181050630$-->Y. Goldberg and Others</div></div><!----><!----><div class="mlt-article-container"><div class="mlt-article-container-header"><a data-location="recirc_Semantic" class="mlt-article-type nejm" href="https://www.nejm.org/browse/nejm-article-type/original-article" target="_self"><!--?lit$181050630$-->Original Article</a> <span class="mlt-article-site-label"><!--?lit$181050630$-->NEJM</span> <span class="mlt-article-pubdate"><!--?lit$181050630$-->Mar 31, 2022</span></div><div class="mlt-article-title"><a data-location="recirc_Semantic" href="https://www.nejm.org/doi/full/10.1056/NEJMoa2118691?query=recirc_Semantic" target="_self">Protection against SARS-CoV-2 after Covid-19 Vaccination and Previous Infection</a></div><div class="mlt-article-authors"><!--?lit$181050630$-->V. Hall and Others</div></div><!----><!----><div class="mlt-article-container"><div class="mlt-article-container-header"><a data-location="recirc_Semantic" class="mlt-article-type nejm" href="https://www.nejm.org/browse/nejm-article-type/original-article" target="_self"><!--?lit$181050630$-->Original Article</a> <span class="mlt-article-site-label"><!--?lit$181050630$-->NEJM</span> <span class="mlt-article-pubdate"><!--?lit$181050630$-->Nov 18, 2021</span></div><div class="mlt-article-title"><a data-location="recirc_Semantic" href="https://www.nejm.org/doi/full/10.1056/NEJMoa2107934?query=recirc_Semantic" target="_self">Early Treatment for Covid-19 with SARS-CoV-2 Neutralizing Antibody Sotrovimab</a></div><div class="mlt-article-authors"><!--?lit$181050630$-->A. Gupta and Others</div></div><!----><!----><div class="mlt-article-container"><div class="mlt-article-container-header"><a data-location="recirc_Semantic" class="mlt-article-type nejm" href="https://www.nejm.org/browse/nejm-article-type/correspondence" target="_self"><!--?lit$181050630$-->Correspondence</a> <span class="mlt-article-site-label"><!--?lit$181050630$-->NEJM</span> <span class="mlt-article-pubdate"><!--?lit$181050630$-->Feb 22, 2024</span></div><div class="mlt-article-title"><a data-location="recirc_Semantic" href="https://www.nejm.org/doi/full/10.1056/NEJMc2400160?query=recirc_Semantic" target="_self">More on Pre–Covid-19, SARS-CoV-2–Negative MIS-C</a></div><div class="mlt-article-authors"><!--?lit$181050630$--></div></div><!----><!----><div class="mlt-article-container"><div class="mlt-article-container-header"><a data-location="recirc_Semantic" class="mlt-article-type nejm" href="https://www.nejm.org/browse/nejm-article-type/correspondence" target="_self"><!--?lit$181050630$-->Correspondence</a> <span class="mlt-article-site-label"><!--?lit$181050630$-->NEJM</span> <span class="mlt-article-pubdate"><!--?lit$181050630$-->Nov 30, 2023</span></div><div class="mlt-article-title"><a data-location="recirc_Semantic" href="https://www.nejm.org/doi/full/10.1056/NEJMc2307574?query=recirc_Semantic" target="_self">Pre–Covid-19, SARS-CoV-2–Negative Multisystem Inflammatory Syndrome in Children</a></div><div class="mlt-article-authors"><!--?lit$181050630$--></div></div><!----></div><div class="mlt-footer"></div></div></onepub-fonts><style>:host{display:block}@keyframes fadeIn{0%{opacity:0}100%{opacity:1}}.more-like-this{max-width:25rem}.more-like-this *{font-variant-numeric:lining-nums}.mlt-wrapper{animation:fadeIn 1s}.mlt-header-container{border-bottom:#4d4d4d solid .0625rem;border-top:#4d4d4d solid .125rem}.mlt-header-title{color:#1a1a1a;display:block;font-family:var(--sans-serif);font-size:1rem;font-weight:700;letter-spacing:.02rem;line-height:1.5rem;padding-bottom:.94rem;padding-top:.94rem;text-transform:uppercase}.mlt-header-description{color:#333;display:block;font-family:ff-scala-sans-pro;font-size:.75rem;letter-spacing:.05rem;margin-top:-.5rem;padding-bottom:1rem;text-transform:uppercase}.mlt-article-container{border-bottom:#e5e5e5 solid .0625rem;margin-top:1.38rem}.mlt-article-container-header{font-family:var(--sans-serif);font-size:.6875rem;letter-spacing:.04em;line-height:1.125rem;margin:0 0 1rem;text-transform:uppercase}.mlt-article-type{font-weight:700;line-height:1.25rem;letter-spacing:.04rem;text-decoration:none}.mlt-article-type:hover{text-decoration:underline}.nejm{color:#f30}.nejm-ai{color:#006197}.nejm-catalyst{color:#5708a6}.nejm-evidence{color:#69a323}.mlt-article-site-label::after,.mlt-article-type::after{border-right:1px solid #e5e5e5;content:'';display:inline;padding:.1875rem .375rem .125rem 0;margin:0 .375rem 0 0}.mlt-article-pubdate{color:#666;font-style:normal;font-weight:700;line-height:1.25rem;letter-spacing:.04em}.mlt-article-authors{color:#666;font-family:var(--sans-serif);font-size:1rem;font-style:normal;font-weight:400;letter-spacing:normal;line-height:1.5rem;margin-bottom:1.38rem}.mlt-article-site-label{color:#666;font-style:normal;font-weight:700;letter-spacing:.04em}.mlt-article-title{margin-bottom:.5rem}.mlt-article-title>a{background-image:linear-gradient(#f30,#f30);background-position:0 90%;background-repeat:no-repeat;background-size:0 0;color:#1a1a1a;font-family:var(--quadraat-web);font-size:1.25rem;font-style:normal;font-weight:700;letter-spacing:normal;line-height:1.8rem;margin:1.5rem 0 .35rem 0;text-decoration:none;transition:background .25s ease-in-out}.mlt-article-title>a:hover{background-position:0 98%;background-size:100% .125rem;text-decoration:none}.skeleton-card{box-shadow:0 0 4px 1px rgba(0,0,0,.1);margin:1rem 0;padding:1rem}</style></div></more-like-this>




        
        <div><div class="pb-dropzone" data-pb-dropzone="col-0" title="col-0"></div></div>










    
    
        <div data-widget-def="UX3HTMLWidget" data-widget-id="ad06db99-f228-4c92-9ad7-c4ae0fdbdbf1" id="bc-web-rec">
        



        
        <!-- BlueConic TEST empty HTML widget with DIV wrapper with id=bc-web-rec -->

        </div>
    

</aside></article><div data-extent="article-wrapper"><div class="core-container"></div><div class="after-credits"><div class="core-container"><a href="/doi/pdf/10.1056/NEJMoa2035002?download=true" id="downloadPdfUrl" data-doi="10.1056/NEJMoa2035002" data-behavior="trackDownloadEvent" data-interactiontype="article_tools_download_pdf" data-multimedia-type="Article PDF" data-multimedia-filename="nejmoa2035002.pdf"><span>Download PDF</span></a></div></div></div><script id="axel-publication-metadata" type="application/json">{"doi":"10.1056/NEJMoa2035002"}
</script><script type="text/javascript" data-ot-ignore="data-ot-ignore" defer="defer" src="https://static.addtoany.com/menu/page.js" class="optanon-category-C0004 ot-vscat-C0004"></script><div class="articles-nav"></div><template id="figure_nav_template"><nav><a href="#" title="Open in viewer" class="open-in-viewer"><i aria-hidden="true" class="icon-expand"></i></a></nav></template><template id="fv_panel_template" data-sharesocial="Share"><div class="fv__panel js--hidden"><div class="fv__panel__text"><div class="fv__panel__contentTitle"></div><div class="fv__panel__contentText"></div></div></div></template>
<template id="fv_directory_template" data-overlay="View figure"><div class="fv__directory"><div class="fv__header"><nav class="tab__nav"></nav><a href="#" title="Close figure viewer" class="fv__close"><i aria-hidden="true" class="icon-close"></i></a></div><div class="fv__content tab__content"></div></div></template><template id="fv_directory_tabItem_template" data-figures="Figures" data-others="Others" data-tables="Tables"><button role="tab" data-toggle="tab" class="tab__nav__item"></button></template>
<template id="fv_lightbox_template" data-sr-back="Go to figure location within the article" data-sr-closealt="Close" data-sr-download="Toggle download panel" data-sr-download-pptx="Download PPT" data-sr-info="Toggle information panel" data-sr-panel="Close panel" data-sr-share="Toggle share panel" data-sr-zoom="Zoom" data-text-close="Back to article" data-text-nav-figures="All figures" data-text-nav-others="All others" data-text-nav-tables="All tables" data-text-viewall="View all material" data-title-back="Back to article" data-title-closealt="Close" data-title-download="Download" data-title-download-pptx="Download PPT" data-title-info="Info" data-title-share="Share" data-title-zoom="Zoom"></template>
<template id="fv_toolbar_template"><div class="fv__toolbar__info"><strong class="fv__toolbar__contentTitle uppercase"></strong><p class="fv__toolbar__contentText"></p></div></template><template id="toCitationLink" data-citation="Citation" data-footnote="Footnote"><div class="to-citation__wrapper"><a class="to-citation"><i aria-hidden="true" class="icon-return"></i><span>Go to</span></a></div></template><template id="toCitationButton" data-citation="Citation" data-footnote="Footnote"><div class="to-citation__wrapper"><button class="to-citation"><i aria-hidden="true" class="icon-return"></i><span>Go to</span></button></div></template><template id="toCitationAccordion" data-collapse-citation="Hide Citations" data-expand-citation="Show Citations" data-collapse-footnote="Hide Footnotes" data-expand-footnote="Show Footnotes"><div class="to-citation__wrapper"><button aria-controls="aria-controls" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="data-expand-title" data-collapsed-title="data-collapsed-title" class="accordion__toggle__title"></span></button><div role="menu" aria-label="links" class="to-citation__accordion no-separator"><ul></ul></div></div></template><template id="toCitationAccordionItem"><li><a class="to-citation"><i aria-hidden="true" class="icon-return"></i><span></span></a></li></template><template id="citations_truncate_template"><div class="citations-truncation"><button data-label-expand="Show all references" data-label-collapse="Show fewer" data-label-remaining="references remaining" class="btn btn--secondary"><span>Show all references</span></button></div></template><template id="collateral_texts_template" data-references="References" data-figure="Go to Figure" data-media="Go to Media" data-more="More" data-original="Go to original" data-table="Go to Table" data-inviewer="Open in Viewer" data-allinviewer="Open all in viewer"><svg data-tags="copyright" viewBox="0 0 24 24"><path d="M12 20.016q3.281 0 5.648-2.368T20.016 12t-2.368-5.648T12 3.984 6.352 6.352 3.984 12t2.368 5.648T12 20.016zm0-18q4.125 0 7.055 2.93T21.985 12t-2.93 7.055T12 21.985t-7.055-2.93T2.015 12t2.93-7.055T12 2.015zm-.14 7.125q-1.876 0-1.876 2.718v.282q0 2.718 1.875 2.718.704 0 1.172-.398t.469-1.008h1.781q0 1.172-1.031 2.063-.984.843-2.39.843-1.876 0-2.86-1.125t-.984-3.093v-.282q0-1.921.937-3 1.125-1.265 2.906-1.265 1.547 0 2.438.89.984.985.984 2.297H13.5q0-.328-.14-.61-.235-.468-.329-.562-.469-.468-1.172-.468z"></path></svg><span>Request permissions</span><i aria-hidden="true" class="icon-open_in_new"></i></template><template id="collapsible_authors_template"><button aria-expanded="false" data-expandable="all" data-label-expand="Expand All" data-label-collapse="Collapse All" class="collateral-contributors-control"><span>Expand All</span></button></template>
<template id="collapsible_tables_collapse_template"><div class="collapsible-figure-btn__wrapper expanded"><button aria-expanded="true" class="btn collapsible-figure-btn btn--inverse"><i aria-hidden="true" class="icon-arrow-up"></i><span class="text-uppercase">Collapse</span></button></div></template>
<template id="collapsible_tables_expand_template"><div class="collapsible-figure-btn__wrapper collapsed"><button aria-expanded="false" class="btn collapsible-figure-btn btn--inverse"><i aria-hidden="true" class="icon-arrow-down"></i><span class="text-uppercase">Expand Table</span></button></div></template><template id="authorsAffiliationsLink"><a href="#tab-contributors" class="to-authors-affiliations">Authors Info &amp; Affiliations</a></template>

        <div role="navigation" aria-label="Sticky Navigation" class="st-header"><div class="st-header__content"><div class="st-header__item st-header__menu"></div><div class="st-header__current st-header__item"><div class="st-header__label">Now Reading:</div><div class="st-header__title">REGN-COV2, a Neutralizing Antibody Cocktail, in Outpatients with Covid-19</div></div><div class="st-header__share st-header__item"><div class="share-dropblock dropdown"><a id="sticky-header-dropBlock" href="#" role="button" data-toggle="dropdown" aria-haspopup="true" aria-expanded="false" class="dropdown-toggle"><span title="" data-toggle="tooltip" data-trigger="hover" data-original-title="Share options"><span class="sr-only">Share</span><i aria-hidden="true" class="icon-share"></i></span></a><div aria-labelledby="sticky-header-dropBlock" data-location="share_tools_article" class="dropdown-menu"><ul class="rlist--inline a2a a2a_kit" style="line-height: 16px;"><li><a href="/#facebook" aria-label="Share on Facebook" data-id="article-share-facebook" rel="nofollow noopener" role="link" target="_blank" title="Share on Facebook" class="btn btn--facebook a2a_button_facebook" data-interactiontype="social"><i aria-hidden="true" class="icon-facebook"></i></a></li><li><a href="/#twitter" aria-label="Share on X (formerly Twitter)" data-id="article-share-twitter" rel="nofollow noopener" role="link" target="_blank" title="Share on X (formerly Twitter)" class="btn btn--twitter a2a_button_twitter" data-interactiontype="social"><i aria-hidden="true" class="icon-twitter"></i></a></li><li><a href="/#linkedin" aria-label="Share on LinkedIn" data-id="article-share-linkedin" rel="nofollow noopener" role="link" target="_blank" title="Share on LinkedIn" class="btn btn--linkedin a2a_button_linkedin" data-interactiontype="social"><i aria-hidden="true" class="icon-linkedin"></i></a></li><li><a href="/#email" aria-label="Share on email" data-id="article-share-email" rel="nofollow noopener" role="link" target="_blank" title="Share on email" class="btn btn--email a2a_button_email" data-interactiontype="content_email_click"><i aria-hidden="true" class="icon-mail"></i></a></li><li><a href="/#bluesky" aria-label="Share on Bluesky" data-id="article-share-bluesky" rel="nofollow noopener" role="link" target="_blank" title="Share on Bluesky" class="btn btn--bluesky a2a_button_bluesky" data-interactiontype="social"><i aria-hidden="true" class="icon-bluesky"></i></a></li></ul></div></div></div><div class="st-header__nav st-header__item"><div class="content-navigation"><a href="/doi/full/10.1056/NEJMoa2029849" aria-label="Previous article" aria-disabled="false" class="content-navigation__prev"><div aria-hidden="true" class="content-navigation__hint"><div class="content-navigation__hint__content"><h6>PREVIOUS ARTICLE</h6><div>SARS-CoV-2 Neutralizing Antibody LY-CoV555 in Outpatients with Covid-19</div></div></div><i aria-hidden="true" class="icon-arrow-left"></i><span>Previous</span></a><a href="/doi/full/10.1056/NEJMoa2031054" aria-label="Next article" aria-disabled="false" class="content-navigation__next"><div aria-hidden="true" class="content-navigation__hint"><div class="content-navigation__hint__content"><h6>NEXT ARTICLE</h6><div>CRISPR-Cas9 Gene Editing for Sickle Cell Disease and β-Thalassemia</div></div></div><span>Next</span><i aria-hidden="true" class="icon-arrow-right"></i></a></div></div></div><div class="st-header__track"><div id="progress-tracker" class="st-header__tracker" style="width: 0px;"></div></div></div><div class="fv figureViewer js--has-focus-mode"><div class="fv__directory" data-core-tabs="default" style="display: flex;"><div class="fv__header"><nav class="tab__nav" role="tablist"><button role="tab" data-toggle="tab" class="tab__nav__item active" aria-controls="#tab-pane-figures" aria-selected="true">Figures</button><button role="tab" data-toggle="tab" class="tab__nav__item" aria-controls="#tab-pane-tables" tabindex="-1" aria-selected="false">Tables</button></nav><a href="#" title="Close figure viewer" class="fv__close"><i aria-hidden="true" class="icon-close"></i></a></div><div class="fv__content tab__content"><div class="tab__pane fv__list fv__list--figures" id="tab-pane-figures" aria-label="All figures" tabindex="0" role="tabpanel"><div class="fv__item"><a class="fv__open-item fv__item__view fv__fit" href="#fv-f1" data-type="figures" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa2035002_f1.jpg"><img src="/cms/10.1056/NEJMoa2035002/asset/4eef3f7d-a00a-46f4-9759-44174e57e4cc/assets/images/large/nejmoa2035002_f1.jpg" height="2120" width="2640" aria-labelledby="f1" loading="lazy"><span class="fv__fit--overlay"><span>View figure</span></span></a><div class="fv__item__title">Figure 1</div><div class="fv__item__description"><figcaption><div class="caption">Screening, Randomization, and Treatment.</div><div class="notes"><div role="doc-footnote">One patient underwent randomization in error, and Regeneron requested that the patient withdraw from the trial. Four patients in the low-dose REGN-COV2 group withdrew consent: one patient could not participate in the follow-up period, one patient could not have blood drawn and an intravenous line placed, and two patients withdrew consent with no additional information available. Three patients in the high-dose REGN-COV2 group withdrew consent: one patient could not participate in the follow-up period, one patient could not have blood drawn and an intravenous line placed, and one withdrew consent with no additional information available.</div></div></figcaption></div></div><div class="fv__item"><a class="fv__open-item fv__item__view fv__fit" href="#fv-f2" data-type="figures" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa2035002_f2.jpg"><img src="/cms/10.1056/NEJMoa2035002/asset/6dfe3683-c06a-498e-b72e-63041484af8e/assets/images/large/nejmoa2035002_f2.jpg" height="2016" width="2640" aria-labelledby="f2" loading="lazy"><span class="fv__fit--overlay"><span>View figure</span></span></a><div class="fv__item__title">Figure 2</div><div class="fv__item__description"><figcaption><div class="caption">SARS-CoV-2 Viral Load over Time.</div><div class="notes"><div role="doc-footnote">Shown is the change in mean viral load (in log<sub>10</sub> copies per milliliter) from baseline at each visit through day 7 in the overall population (modified full analysis set, which excluded patients who tested negative for severe acute respiratory syndrome coronavirus 2 [SARS-CoV-2] by qualitative reverse-transcriptase polymerase chain reaction at baseline) and in groups defined according to baseline antibody status and baseline viral load. 𝙸 bars in Panel C indicate the standard error. The least-squares mean difference between the groups in the time-weighted average change in viral load (TWA LS mean) from baseline through day 7, expressed as log<sub>10</sub> copies per milliliter, was based on analysis-of-covariance models with treatment group, risk factor, and baseline antibody status as fixed effects and baseline viral load and treatment group–by–baseline viral load as covariates. The lower limit of detection (dashed line) is 714 copies per milliliter (2.85 log<sub>10</sub> copies per milliliter).</div></div></figcaption></div></div></div><div class="tab__pane fv__list fv__list--tables" id="tab-pane-tables" aria-label="All tables" tabindex="-1" role="tabpanel"><div class="fv__item"><a class="fv__open-item fv__item__view" href="#fv-t1" data-type="tables" data-interactiontype="multimedia_click" data-multimedia-type="Table"><i class="icon-tables"></i></a><div class="fv__item__title">Table 1</div><div class="fv__item__description"><figcaption><div class="caption">Demographic and Baseline Medical Characteristics.<a href="#fv-t1fn1" role="doc-noteref">*</a></div></figcaption></div></div><div class="fv__item"><a class="fv__open-item fv__item__view" href="#fv-t2" data-type="tables" data-interactiontype="multimedia_click" data-multimedia-type="Table"><i class="icon-tables"></i></a><div class="fv__item__title">Table 2</div><div class="fv__item__description"><figcaption><div class="caption">Key Virologic and Clinical End Points.<a href="#fv-t2fn1" role="doc-noteref">*</a></div></figcaption></div></div><div class="fv__item"><a class="fv__open-item fv__item__view" href="#fv-t3" data-type="tables" data-interactiontype="multimedia_click" data-multimedia-type="Table"><i class="icon-tables"></i></a><div class="fv__item__title">Table 3</div><div class="fv__item__description"><figcaption><div class="caption">Serious Adverse Events and Adverse Events of Special Interest in the Safety Population.</div></figcaption></div></div></div></div></div></div><div class="references-pop-up fade" aria-hidden="true"><div class="references-pop-up__heading text-dark d-flex align-items-center"><div class="references-pop-up__title flex-grow-1">Reference <span class="references-pop-up__heading-number">1</span></div><a class="references-pop-up__close text-dark" href="#" title="close pop-up" tabindex="-1" aria-hidden="true"><i class="icon-close" aria-hidden="true"></i></a></div><div class="references-pop-up__items citations to-citation__accordion external-links"></div></div></main>
    

</div>

                    
                        



        
        <div class="ng-page_layout ng-page_layout-fullWidth"><div class="container-fluid"><div class="row"><div class="col-12">



        
        




        
        <div class="ng-page_layout-contentSpacing"></div>










    
    
        <div data-widget-def="oneSearchMultiSearch" data-widget-id="778b3ad8-1a8d-43d8-8196-63b03df4a138" data-location="recirc_inIssue_bottom_article">
        



        
        <div class="os-ms os-ms-more-from-issue"><h3 class="ng-subsection-title"><a href="/toc/nejm/384/3" class="ng-subsection-title_link animation-icon-shift"><span class="ng-subsection-title_text">More from Vol. 384 No. 3</span><span class="ng-subsection-title_icon"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#arrows-longArrowRight"></use></svg></span></span></a></h3><ul class="os-ms-more-from-issue_list"><li class="os-ms-more-from-issue_item"><div class="issue-item issue-item_sm"><div class="issue-item_meta"><ul class="issue-item_meta-list clearfix"><li class="issue-item_meta-item"><a href="/browse/nejm-article-type/original-article" class="issue-item_type">Original Article</a></li><li class="issue-item_meta-item"><span class="issue-item_date">Jan 21, 2021</span></li><li class="issue-item_meta-item"><span class="issue-item_free">FREE</span></li></ul></div><div class="issue-item_row"><div class="issue-item_left"><div class="issue-item_content clearfix"><h4 class="issue-item_title"><a href="/doi/full/10.1056/NEJMoa2028220" data-interactiontype="article_recirculation_click" class="issue-item_title-link animation-underline">Polypill with or without Aspirin in Persons without Cardiovascular Disease</a></h4><div class="issue-item_authors-and-text"><span class="issue-item_authors">S. Yusuf and Others</span></div></div></div></div></div></li><li class="os-ms-more-from-issue_item"><div class="issue-item issue-item_sm"><div class="issue-item_meta"><ul class="issue-item_meta-list clearfix"><li class="issue-item_meta-item"><a href="/browse/nejm-article-type/original-article" class="issue-item_type">Original Article</a></li><li class="issue-item_meta-item"><span class="issue-item_date">Jan 21, 2021</span></li><li data-toggle="tooltip" data-original-title="Video" class="issue-item_meta-item"><span role="img" aria-label="Video" tabindex="0" class="issue-item_video"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#tooltip-video"></use></svg></span></span></li><li data-toggle="tooltip" data-original-title="Visual Abstract" class="issue-item_meta-item"><span role="img" aria-label="Visual Abstract" tabindex="0" class="issue-item_visualAbstract"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#tooltip-visual"></use></svg></span></span></li><li class="issue-item_meta-item"><span class="issue-item_free">FREE</span></li></ul></div><div class="issue-item_row"><div class="issue-item_left"><div class="issue-item_content clearfix"><h4 class="issue-item_title"><a href="/doi/full/10.1056/NEJMoa2029392" data-interactiontype="article_recirculation_click" class="issue-item_title-link animation-underline">Post-Transcriptional Genetic Silencing of <em>BCL11A</em> to Treat Sickle Cell Disease</a></h4><div class="issue-item_authors-and-text"><span class="issue-item_authors">E.B. Esrick and Others</span></div></div></div></div></div></li><li class="os-ms-more-from-issue_item"><div class="issue-item issue-item_sm"><div class="issue-item_meta"><ul class="issue-item_meta-list clearfix"><li class="issue-item_meta-item"><a href="/browse/nejm-article-type/original-article" class="issue-item_type">Original Article</a></li><li class="issue-item_meta-item"><span class="issue-item_date">Jan 21, 2021</span></li><li data-toggle="tooltip" data-original-title="Video" class="issue-item_meta-item"><span role="img" aria-label="Video" tabindex="0" class="issue-item_video"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#tooltip-video"></use></svg></span></span></li><li class="issue-item_meta-item"><span class="issue-item_free">FREE</span></li></ul></div><div class="issue-item_row"><div class="issue-item_left"><div class="issue-item_content clearfix"><h4 class="issue-item_title"><a href="/doi/full/10.1056/NEJMoa2031054" data-interactiontype="article_recirculation_click" class="issue-item_title-link animation-underline">Brief Report: CRISPR-Cas9 Gene Editing for Sickle Cell Disease and β-Thalassemia</a></h4><div class="issue-item_authors-and-text"><span class="issue-item_authors">H. Frangoul and Others</span></div></div></div></div></div></li></ul></div>

        </div>
    

</div></div></div></div>

                    
                        



        
        <div class="ng-page_layout-bottomAd"><div class="container-fluid"><div class="row"><div class="col-12">









    
    
        <div data-widget-def="literatumAd" data-widget-id="7e022d0d-4a48-44a7-af66-033cf5c13eb8" id="ad-article-bottom-FULLx320-1">
        



        
        



    
        <div class="pb-house-message adplaceholder exists">
            <!-- START: Circulation Footer 3 -->
<aside class="g-cta-subscribe">
	<style>
.bads_footer-banner24-ONJQNRF1{background:url(/pb-assets/contextual_messaging/footer-yel-background-2x-1513629627453.jpg) center center no-repeat;padding:20px;display:block;margin:0;min-height:inherit;background-size:cover;text-decoration:none!important;color:#1a1a1a;text-align:left}.bads_footer-banner24-ONJQNRF1 .g-cta-subscribe__title{font-size:42px;line-height:44px;letter-spacing:.2px;margin:0 0 20px;font-family:ff-quadraat-web-pro,sans-serif;font-weight:600}.bads_footer-banner24-ONJQNRF1-inner{max-width:1300px;margin:0 auto}.bads_footer-banner24-ONJQNRF1-inner .g-cta-subscribe__actions .a-btn{width:130px;padding-left:12px}.bads_footer-banner24-ONJQNRF1-inner .g-cta-subscribe__login{position:static;color:#000;font-size:18px;line-height:27px;border:0}.bads_footer-banner24-ONJQNRF1-inner .g-cta-subscribe__actions{margin:20px 0 20px 0;list-style-type:none;padding:0}.bads_footer-banner24-ONJQNRF1-inner .g-cta-subscribe__login a{color:#0a68ad}.bads_clearfix:after{visibility:hidden;display:block;font-size:0;content:" ";clear:both;height:0}.bads_clearfix{display:block}.bads_footer-banner24-ONJQNRF1-inner .bads_subs-btn{float:left;width:50%;padding:30px 0}.bads_footer-banner24-ONJQNRF1-inner .bads_device-img{float:left;padding-left:30px;width:50%}.bads_footer-banner24-ONJQNRF1 .bads_device-img>img{display:block;max-width:100%;height:auto}.bads_footer-banner24-ONJQNRF1 .bads_h5{font-size:18px;text-transform:uppercase;line-height:24px;font-weight:600;margin:-15px 0 0;letter-spacing:.2px}@media only screen and (max-width:480px){.bads_footer-banner24-ONJQNRF1-inner .bads_device-img,.bads_footer-banner24-ONJQNRF1-inner .bads_subs-btn{width:100%;float:none}.bads_footer-banner24-ONJQNRF1-inner .bads_device-img{padding-left:0}.bads_footer-banner24-ONJQNRF1 .g-cta-subscribe__title{font-size:20px;line-height:27px;margin-bottom:10px}.bads_footer-banner24-ONJQNRF1-inner .bads_subs-btn{padding-top:0;padding-bottom:0}.bads_footer-banner24-ONJQNRF1{height:auto}.bads_footer-banner24-ONJQNRF1-inner .g-cta-subscribe__actions{margin:0 0 12px;list-style-type:none}.bads_footer-banner24-ONJQNRF1-inner .g-cta-subscribe__login{line-height:25px;font-size:15px;margin-bottom:10px}.bads_footer-banner24-ONJQNRF1 .bads_device-img{width:280px!important;margin:0 auto}.bads_footer-banner24-ONJQNRF1 .bads_h5{margin:0 0 3px;font-size:14px}}@media only screen and (min-width:480px) and (max-width:1024px){.bads_footer-banner24-ONJQNRF1 .g-cta-subscribe__title{font-size:20px;line-height:30px;margin-bottom:15px}.bads_footer-banner24-ONJQNRF1-inner .bads_subs-btn{padding:0}.bads_footer-banner24-ONJQNRF1-inner .g-cta-subscribe__login{font-size:14px}.bads_footer-banner24-ONJQNRF1 .bads_h5{font-size:13px;margin-top:0}}@media only screen and (min-width:1025px) and (max-width:1200px){.bads_footer-banner24-ONJQNRF1-inner .bads_subs-btn{padding:10px 0}.bads_footer-banner24-ONJQNRF1 .bads_h5{margin:0 0 5px}}@media only screen and (min-width:1401px){.bads_footer-banner24-ONJQNRF1 .bads_device-img>img{float:right}}
	</style>
	<div class="bads_footer-banner24-ONJQNRF1">
	  <div class="bads_footer-banner24-ONJQNRF1-inner bads_clearfix">
		 <div class="bads_subs-btn">
			<p class="g-cta-subscribe__title">Tap into groundbreaking research and clinically relevant insights</p>
			<ul class="g-cta-subscribe__actions">
				<li class="g-cta-subscribe__actions-primary">
				  <a href="/action/clickThrough?id=127716&amp;url=%2Faction%2FstoreProxy%3Faction%3Dsubscribe%26url%3Dhttps%253A%252F%252Fwww.nejm.org%252Fdoi%252Ffull%252F10.1056%252FNEJMoa2035002%26promo%3DONFQNRF1&amp;loc=%2Fdoi%2Ffull%2F10.1056%2FNEJMoa2035002&amp;pubId=41289801&amp;placeholderId=101336&amp;productId=1035" class="ng-btn_primary ng-btn_iconRight"><span class="ng-btn_text">Subscribe </span><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#arrows-longArrowRight"></use></svg></span></a>
				</li>
			</ul>
			<p class="g-cta-subscribe__login">Already a subscriber? <a href="/action/clickThrough?id=127716&amp;url=%2Faction%2FstoreProxy%3Faction%3Dactivate%26url%3Dhttps%253A%252F%252Fwww.nejm.org%252Fdoi%252Ffull%252F10.1056%252FNEJMoa2035002%26promo%3DONFQANR4&amp;loc=%2Fdoi%2Ffull%2F10.1056%2FNEJMoa2035002&amp;pubId=41289801&amp;placeholderId=101336&amp;productId=1035">Activate</a> your online access.</p>
		 </div>

		<div class="bads_device-img">
		   <img src="/sda/127716/footer-devices-2x.png" alt="Devices">
		</div>
	   </div>
	</div>
</aside>
<!--/END: Circulation Footer 3 -->
            
        </div>
    

    

    



        </div>
    

</div></div></div></div>

                    
                        



        
        <footer class="ng-footer footer__top" style="position: relative;"><div data-location="footer" class="ng-footer_columns"><div class="container-fluid"><div class="row"><div class="col-lg-4 col-md-6 col-sm-12 ng-footer_column"><div class="row"><div class="col-6 ng-footer_column-nested">



        
        <h4 class="ng-footer_column-title">ARTICLE CATEGORIES</h4>
<ul class="ng-footer_column-list">
    <li class="ng-footer_column-list-item">
        <a href="/browse/nejm-article-category/research" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Research</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/browse/nejm-article-category/review" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Reviews</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/browse/nejm-article-category/clinical-cases" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Clinical Cases</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/browse/nejm-article-category/perspective" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Perspective</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/browse/nejm-article-category/commentary" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Commentary</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/browse/nejm-article-category/other" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Other</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/medical-article-index" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Browse all Articles</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/toc/nejm/current" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Current Issue</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/loi/nejm" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Issue Index</span></a></li>
</ul>
</div><div class="col-6 ng-footer_column-nested">



        
        <h4 class="ng-footer_column-title">RESOURCES</h4>
<ul class="ng-footer_column-list">
    <li class="ng-footer_column-list-item"><a href="/author-center/home" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Authors &amp; Reviewers</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/author-center/home" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Submit a Manuscript</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/products-and-services" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Subscribers</span></a></li>
    <li class="ng-footer_column-list-item"><a href="https://tools.ovid.com/ovidtools/nejm.html" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Institutional Administrators</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/media" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Media</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/how-to-advertise" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Advertisers</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/information-for-subscription-agents" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Agents</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/permissions" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Permissions &amp; Licensing</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/reprints" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Reprints</span></a></li>
    <li class="ng-footer_column-list-item"><a href="https://www.nejmcareercenter.org" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">NEJM CareerCenter</span></a>
    </li>
</ul>
</div></div></div><div class="col-lg-4 col-md-6 col-sm-12 ng-footer_column"><div class="row"><div class="col-6 ng-footer_column-nested">



        
        <h4 class="ng-footer_column-title" aria-label="About us">ABOUT US</h4>
<ul class="ng-footer_column-list">
    <li class="ng-footer_column-list-item"><a href="/about-nejm/about-nejm" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">About NEJM</span></a></li>
    <li class="ng-footer_column-list-item"><a href="https://www.nejmgroup.org/" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">NEJM Group</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/products-and-services" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Products &amp; Services</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/editors-and-publishers" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Editors &amp; Publishers</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/advertising-policies" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Advertising Policies</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/contact-nejm" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text" aria-label="Contact us">Contact Us</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/frequently-asked-questions?#Accessibility" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Accessibility</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/frequently-asked-questions" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">FAQs</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/help" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Help</span></a></li>
    <li class="ng-footer_column-list-item"><a href="mailto:sitefeedback@nejm.org" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Site Feedback</span></a></li>
</ul>
</div><div class="col-6 ng-footer_column-nested">



        
        <h4 class="ng-footer_column-title">SUBSCRIPTIONS</h4>
<ul class="ng-footer_column-list">
    <li class="ng-footer_column-list-item"><a href="/action/storeProxy?action=subscribe&amp;promo=ONF4NRS3" class="ng-footer_column-link animation-underline ro-mode_disabled"><span class="ng-footer_column-link-text">Subscribe</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/action/storeProxy?action=renew&amp;product=nejm&amp;promo=ONFLNRR3&amp;prc=ONFARN52" class="ng-footer_column-link animation-underline ro-mode_disabled"><span class="ng-footer_column-link-text">Renew</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/action/storeProxy?action=activate&amp;promo=ONFLNAA1" class="ng-footer_column-link animation-underline ro-mode_disabled"><span class="ng-footer_column-link-text">Activate Subscription</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/action/storeProxy?action=register&amp;promo=ONFLNRC4" class="ng-footer_column-link animation-underline ro-mode_disabled"><span class="ng-footer_column-link-text">Create Account</span></a></li>
    <li class="ng-footer_column-list-item"><a href="https://myaccount.nejm.org" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Manage Account</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/action/storeProxy?action=paybill&amp;product=nejm&amp;promo=BNFLPBA1" class="ng-footer_column-link animation-underline ro-mode_disabled"><span class="ng-footer_column-link-text">Pay Bill</span></a></li>
    <li class="ng-footer_column-list-item"><a href="https://www.wolterskluwer.com/en/solutions/ovid/nejm-complete-collection" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Institutional Sales</span></a></li>    
    <li class="ng-footer_column-list-item"><a href="https://myaccount.nejm.org/special-content" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Special Content</span></a></li>
</ul>
</div></div></div><div class="col-lg-4 col-md-12 ng-footer_column"><div class="row"><div class="col-6 ng-footer_column-nested">



        
        <h4 class="ng-footer_column-title">STAY CONNECTED</h4>
<ul class="ng-footer_column-list">
    <li class="ng-footer_column-list-item"><a href="https://myaccount.nejm.org/emails?section=NEJM" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Email Alerts</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/action/storeProxy?action=register&amp;promo=ONFLNRC3" class="ng-footer_column-link animation-underline ro-mode_disabled"><span class="ng-footer_column-link-text">Create Account</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/products-and-services" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Apps</span></a></li>
    <li class="ng-footer_column-list-item"><a href="https://www.nejmcareercenter.org" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">NEJM CareerCenter</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/rss-feed/" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Podcasts</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/rss-feed/" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">RSS Feed</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/institutional-access" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Remote Access</span></a></li>
</ul>
</div><div class="col-6 ng-footer_column-nested">



        
        <h4 class="ng-footer_column-title" aria-label="Follow us">FOLLOW US</h4>
<ul class="ng-footer_column-list">
<li class="ng-footer_column-list-item"><a href="https://www.facebook.com/TheNewEnglandJournalofMedicine" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-icon"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#social-facebook"></use></svg></span></span><span class="ng-footer_column-link-text">Facebook</span></a></li>
<li class="ng-footer_column-list-item"><a href="https://twitter.com/nejm" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-icon"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#social-twitter"></use></svg></span></span><span class="ng-footer_column-link-text">X (formerly Twitter)</span></a></li>
<li class="ng-footer_column-list-item"><a href="https://www.instagram.com/nejm/" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-icon"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#social-instagram"></use></svg></span></span><span class="ng-footer_column-link-text">Instagram</span></a></li>
<li class="ng-footer_column-list-item"><a href="https://www.youtube.com/user/NEJMvideo" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-icon"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#social-youtube"></use></svg></span></span><span class="ng-footer_column-link-text">Youtube</span></a></li>
<li class="ng-footer_column-list-item"><a href="https://www.linkedin.com/company/nejm-group" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-icon"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#social-linkedin"></use></svg></span></span><span class="ng-footer_column-link-text">LinkedIn</span></a></li>
<li class="ng-footer_column-list-item"><a href="https://bsky.app/profile/nejm.org" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-icon"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#social-bluesky"></use></svg></span></span><span class="ng-footer_column-link-text">Bluesky</span></a></li>
<li class="ng-footer_column-list-item"><a href="https://www.tiktok.com/@nejm.org" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-icon"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#social-tiktok"></use></svg></span></span><span class="ng-footer_column-link-text">TikTok</span></a></li>
</ul>
</div></div></div></div></div></div><div data-location="footer" class="ng-footer_journals"><div class="container-fluid"><div class="row"><div class="col-12">



        
        <h4 class="ng-footer_journals-label">JOURNALS</h4>
<ul class="ng-footer_journals-list">
<li class="ng-footer_journals-item"><a href="https://www.nejm.org/" target="_blank" rel="noopener" class="ng-footer_journals-link">The New England Journal of Medicine</a></li>
<li class="ng-footer_journals-item"><a href="https://catalyst.nejm.org/" target="_blank" rel="noopener" class="ng-footer_journals-link">NEJM Catalyst Innovations in Care Delivery</a></li>
<li class="ng-footer_journals-item"><a href="https://evidence.nejm.org/" target="_blank" rel="noopener" class="ng-footer_journals-link">NEJM Evidence</a></li>
<li class="ng-footer_journals-item"><a href="https://ai.nejm.org/" target="_blank" rel="noopener" class="ng-footer_journals-link">NEJM AI</a></li>
</ul>
</div></div></div></div><div data-location="legal" class="ng-footer_bottom"><div class="container-fluid"><div class="row"><div class="col-lg-7 col-md-6 ng-footer_bottom-left">



        
        <p>Copyright © 2025 <a href="https://www.massmed.org/" target="_blank" rel="noopener" class="ng-footer_bottom-link"><b>Massachusetts Medical Society</b></a>. All rights reserved, including those for text and data mining, AI training, and similar technologies. Electronic ISSN 1533-4406. Print ISSN 0028-4793.The content of this site is intended for health care professionals.</p>
</div><div class="col-lg-5 col-md-6 ng-footer_bottom-right">



        
        <style>
  #teconsent a {
    color: #666;
    text-decoration: none;
  }
  #teconsent a:hover {
    color: #666;
    text-decoration: underline;
  }
</style>
<ul class="ng-footer_bottom-list">
<li class="ng-footer_bottom-list-item"><a href="https://www.nejmgroup.org/legal/copyright-information.htm" target="_blank" rel="noopener" class="ng-footer_bottom-link">Copyright</a></li>
<li class="ng-footer_bottom-list-item"><a href="https://www.nejmgroup.org/legal/terms-of-use.htm" target="_blank" rel="noopener" class="ng-footer_bottom-link">Terms</a></li>
<li class="ng-footer_bottom-list-item"><a href="https://www.nejmgroup.org/legal/privacy-policy.htm" target="_blank" rel="noopener" class="ng-footer_bottom-link">Privacy Policy</a></li>
<li class="ng-footer_bottom-list-item"><span id="teconsent" consent="undefined" aria-label="Open Cookie Preferences Modal" role="complementary"><a role="link" id="icon-id03889386391562246" tabindex="0" lang="en" aria-haspopup="dialog" aria-label="Cookie Preferences, opens a dedicated popup modal window" class="truste_cursor_pointer">Cookie Preferences</a></span></li>
</ul>
<a href="https://www.nejmgroup.org/" title="NEJM Group" target="_blank" rel="noopener" class="ng-footer_logo-link"><img src="/specs/products/mms-nextgen/mms/releasedAssets/images/other-images/logo_group.svg" alt="NEJM Group logo" class="ng-footer_logo" loading="lazy" width="103" height="40"></a>
</div></div></div></div><div data-show-after="400" class="back-to-top back-to-top--align-right  "><button data-snap="footer__top" class="back-to-top__action position-relative p-0 m-0 border-0 d-flex flex-column align-items-center justify-content-center"><svg viewBox="0 0 36 36" class="position-relative"><path d="M18 2.0845 a 15.9155 15.9155 0 0 1 0 31.831 a 15.9155 15.9155 0 0 1 0 -31.831" class="back-to-top__action__ring-bg"></path><path d="M18 2.0845 a 15.9155 15.9155 0 0 1 0 31.831 a 15.9155 15.9155 0 0 1 0 -31.831" stroke-dasharray="0, 100" class="back-to-top__action__ring"></path></svg><span class="back-to-top__action-icon position-absolute d-flex"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#arrows-up"></use></svg></span></span><span class="sr-only">Back to top</span></button></div></footer>

                    
                        



        
        <!-- TrustArc: Banner -->
<div id="consent_blackbar"><style>  #consent_blackbar{    position:relative;    width:100%;    z-index: 999999;  }    #trustarc-banner-overlay {  background-color: rgb(0, 0, 0);   opacity: 0.3;   position: fixed;   z-index: 1000000;   width: 100%;  height: 100%;   top: 0px;   left: 0px;   overflow: hidden;}.truste-title {  /*font-family: "Source Sans Pro", sans-serif;  font-size: 23px;  font-style: normal;  font-stretch: normal;*/  color: #222;  margin-bottom: 20px;  text-align: center;/*  font-weight:bold;*/}.truste-footer {  margin: 0 auto;      }.truste-left {  margin: 0px 0px 15px 15px;/*font-family: "Source Sans Pro", sans-serif;  font-size: 14px;    */}.truste-banner { margin: 0 auto; }.truste-messageColumn {/*font-family: "Source Sans Pro", sans-serif;  font-size: 14px;*/  color: #666666;  margin: 0px;}#truste-consent-button, #truste-consent-required {    background-color: #FF1E00;    color: #F2F1F1;    padding: 5px 10px;    border: 1px solid #FF1E00;    border-radius: 0px;    cursor: pointer;    text-transform:uppercase;/*    font-family: "Source Sans Pro",sans-serif;    font-size: 15px;*/  }      #truste-show-consent {    background-color: #FF1E00;    color: #F2F1F1;    border: 1px solid #FF1E00;    padding: 5px 10px;    border-radius: 0px;    cursor: pointer;    text-transform:uppercase;/*    font-family: "Source Sans Pro",sans-serif;    font-size: 15px;*/  }div.truste-consent-track-class {  position: fixed;  z-index:9999999;   background: #666;   border: 1px solid #333;    /*padding: 10px 60px;*/    bottom:0px;    right:0px;    left:0px;    margin: 10px;}.truste-left {  margin: 0;}div.text-content {  display: flex;  flex-direction: column;  align-self: baseline;}#truste-consent-text {    /*font-family: "Source Sans Pro", sans-serif;    font-size: 16px;*/    color: #fff;    margin: 15px 0px;}.truste-footer {  padding-top: 15px;}#truste-consent-content {  margin: 0 auto;    padding: 0 10px;    max-width: 1366px;}.truste-consent-footer {  display: none;}.flex-container {  display: block;  align-items: center;  justify-content: space-between;}#truste-consent-buttons {  float: right;  margin: 10px 5px 10px 0px;}#truste-show-consent { background: #F30 !important;}#truste-consent-button, #truste-consent-required { background: #F30 !important; } /* MEDIA QUERIES */  @media screen and (max-width: 500px) {  #truste-consent-track {    padding: 5px 20px;  }  }@media screen and (max-width: 375px) {  .truste-buttonsColumn {    float: none;    margin: 0;  }  #truste-consent-button, #truste-consent-required, #truste-show-consent {    width: 100%;    margin-bottom: 5px;  }          #truste-consent-buttons {  float: none;  margin: 10px 0px 10px 0px;	}}</style><div id="truste-consent-track" style="display: block; opacity: 1;">  <div id="trustarc-banner-overlay"></div>  <div class="truste-consent-track-class">    <div id="truste-consent-content" class="truste-banner">        <div class="flex-container">          <div class="text-content">            <div id="truste-consent-text" class="truste-messageColumn">This site uses cookies and related technologies, as described in our privacy policy, for purposes that may include site operation, analytics, enhanced user experience, or advertising. You may choose to consent to our use of these technologies, or manage your own preferences.                       </div>          </div>          <div id="truste-consent-buttons" class="truste-buttonsColumn">            <button id="truste-show-consent" aria-haspopup="dialog">Manage Settings</button>      <button id="truste-consent-button">Accept</button>      <!-- <button id="truste-consent-required">Decline All</button> -->          </div>        </div>                <div style="clear:both;"></div>    </div>  </div></div><!--emptycomment--></div>
<!-- /TrustArc: Banner -->

                    
                        



        
        <link rel="stylesheet" href="https://cssjs.nejm.org/mmsWidgets.css"><script nonce="94d6670fb4c0f1da-SJC" type="text/javascript" src="https://cssjs.nejm.org/mmsWidgets.js"></script><script nonce="94d6670fb4c0f1da-SJC" type="text/javascript">var litSSO = {
    "ucid": null,
    "accessToken": null,
    "authState": null
};

var loginUri = '/action/doSsoLogin';
var logoutUri = '/action/doLogout';

displayAuthenticatedMessage();

mmsWidgets.init({
    clientId: 'qsra7g4d6jwdsgn3zbe6udp6r6278mr9',
    origin: 'NEJM',
    xdReceiver: 'http://www.nejm.org/pb-assets/sso/xd.html',
    isFullPageSignIn: isSignInPage(),
    debug: true,

    onReady: function (e) {
        console.log('<<<<<<<<<< client: received onReady event.');
        $("A.litSsoLogin").click(function (e) {
            if (!$(e.currentTarget).hasClass("noMd") || $(e.currentTarget).parents(".header_sm-login").length === 0) {
                mmsWidgets.signIn(e);
                return false;
            }
        });
        $("A.litSsoLogout").click(function (e) {
            mmsWidgets.signOut(e);
            return false;
        });
        $("A.litSsoCreate").click(function (e) {
            mmsWidgets.showRegModal(e);
            return false;
        });
        $("A.litSsoSubscribe").click(function (e) {
            if (!$(e.currentTarget).hasClass("noMd") || $(e.currentTarget).parents(".header_sm-login").length === 0)
                location.assign(e.currentTarget.href);
            return false;
        });
        if (window.doSSOLogin) {
            window.setTimeout(function () {
                mmsWidgets.signIn();
            }, 500);
        }
        ;
    },
    onLoginSuccess: function (e) {
        console.log('<<<<<<<<<< client: received onLoginSuccess event.' + JSON.stringify(e));

        const redirectUrl = getRedirectUri(window.location.search, location.href.replace(window.location.origin, ""));
        document.cookie = "skipSso=; expires=; path=/";
        if (!litSSO.ucid || e.ucid != litSSO.ucid || !litSSO.accessToken || e.accessToken != litSSO.accessToken) {
            location.assign(loginUri + "?ucid=" + e.profile.ucid
                + "&accessToken=" + e.accessToken
                + "&authState=" + e.authState
                + "&email=" + encodeURIComponent(e.profile.email)
                + "&givenNames=" + e.profile.givenName
                + "&surname=" + e.profile.familyName
                + "&redirectUri=" + redirectUrl
                + "&uccLastUpdatedDate=" + encodeURIComponent(e.profile.uccLastUpdatedDate)
                + "&rememberMe=" + e.rememberMe);
        }
    },
    onAuthStateReady: function (e) {
        console.log('<<<<<<<<<< client: received onAuthStateReady event.' + JSON.stringify(e))

        var isMmsSsoAuthenticated = (e.authState && e.authState !== "anonymous" && e.authState !== "lead" && e.ucid && e.accessToken) ? true : false;
        var isLitSsoAuthenticated = (litSSO.ucid && litSSO.accessToken && litSSO.authState) ? true : false;
        console.log('           isMmsSsoAuthenticated=' + isMmsSsoAuthenticated + ', isLitSsoAuthenticated=' + isLitSsoAuthenticated);

        if (isMmsSsoAuthenticated) {
            if (!isLitSsoAuthenticated || litSSO.ucid != e.ucid) {
                if (window.skipSso)
                    document.cookie = "skipSso=" + encodeURIComponent(e.ucid) + "; expires=; path=/";

                if (!window.skipSso && document.cookie.indexOf("skipSso=" + encodeURIComponent(e.ucid)) == -1) {
                    location.assign(loginUri + "?ucid=" + e.profile.ucid
                        + "&accessToken=" + e.accessToken
                        + "&authState=" + e.authState
                        + "&email=" + encodeURIComponent(e.profile.email)
                        + "&givenNames=" + e.profile.givenName
                        + "&surname=" + e.profile.familyName
                        + "&redirectUri=" + location.href.replace(window.location.origin, "")
                        + "&uccLastUpdatedDate=" + encodeURIComponent(e.profile.uccLastUpdatedDate)
                        + "&rememberMe=" + e.rememberMe);
                } else
                    console.log('**** client: Skip SSO ****');
            } else if (e.accessToken !== litSSO.accessToken)
                updateLitSession(e.ucid, e.accessToken);
        } else if (isLitSsoAuthenticated)
            location.assign(logoutUri + "?redirectUri=" + encodeURIComponent(location.href.replace(window.location.origin, "")));

        if (document.getElementById("ssoerr-ucid"))
            document.getElementById("ssoerr-ucid").innerHTML = e.ucid;

    },
    onRegistrationSuccess: function (e) {
        console.log('<<<<<<<<<< client: received onRegistrationSuccess event.' + JSON.stringify(e))
        document.cookie = "skipSso=; expires=; path=/";
        var uccLastUpdatedDate = '1812-01-01 00:00:00.1 +0000';
        location.assign(loginUri + "?ucid=" + e.profile.ucid
            + "&accessToken=" + e.accessToken
            + "&authState=" + e.authState
            + "&email=" + encodeURIComponent(e.profile.email)
            + "&givenNames=" + e.profile.givenName
            + "&surname=" + e.profile.familyName
            + "&redirectUri=" + location.href.replace(window.location.origin, "")
            + "&uccLastUpdatedDate=" + encodeURIComponent(uccLastUpdatedDate)
            + "&rememberMe=" + e.rememberMe);
    },
    onLogoutSuccess: function (e) {
        console.log('<<<<<<<<<< client: received onLogoutSuccess event.' + JSON.stringify(e))

        document.cookie = "skipSso=; expires=; path=/";
        location.assign(logoutUri);
    },
});

function updateLitSession(ucid, accessToken) {
    $.ajax({
        method: "GET",
        url: "/action/doSsoSessionUpdate",
        data: {ucid: ucid, accessToken: accessToken},
        success: function (callData, textStatus) {
            console.log("Session accessToken updated")
            litSSO.accessToken = accessToken
        },
        error: function (jqXHR, textStatus, errorThrown) {
            alert("Your website session has expired and will now be reset.")
            console.log("Session update failed: " + jqXHR.responseText)
            location.assign(logoutUri + "?redirectUri=" + encodeURIComponent(location.href.replace(window.location.origin, "")));
        }
    });
}

function getRedirectUri(location, fallback) {
    const urlParams = new URLSearchParams(location);
    const uriUrlParam = urlParams.get('uri');
    if (uriUrlParam)
        return encodeURIComponent(uriUrlParam);
    else
        return encodeURIComponent(fallback);
}

function isSignInPage() {
    return document.querySelector('meta[name="pbContext"]').content.indexOf("customPage:string:/sign-in") > -1;
}

function displayAuthenticatedMessage() {
    if (isSignInPage()) {
        var div = document.getElementById('authMsg');
        if ("" === "PersonUser") {
            div.innerHTML += "You are already signed in to " + window.location.origin.replace("https://", "").replace("www.", "") + ". If you would like to sign in with a different email address, please use the form below.";
        } else {
            div.innerHTML = '';
        }
    }
}</script>

                    
                
            </div>
        </div><iframe name="trustarc_notice" id="trustarcNoticeFrame" title="Trustarc Cross-Domain Consent Frame" src="https://consent.trustarc.com/get?name=crossdomain.html&amp;domain=nejm.com" style="display: none;"></iframe><script src="https://consent.trustarc.com/asset/notice.js/v/v1.7-1576" async="async" crossorigin="" importance="high" nonce="94d6670fb4c0f1da-SJC"></script>
        


        
        

            <script src="/products/mms-nextgen/mms/releasedAssets/js/build.lazyload.bundle-c8c4e7d20884f81951fb.js" nonce="94d6670fb4c0f1da-SJC"></script>

        <script src="/products/mms-nextgen/mms/releasedAssets/js/main.bundle-3819a02ec7bc2aca01ec.js" nonce="94d6670fb4c0f1da-SJC"></script>
        


<div id="adModal" tabindex="-1" aria-labelledby="exampleModalCenterTitle" class="ng-modal modal" style="display: none;" aria-hidden="true">
    <div role="document" class="ng-modal_dialog modal-dialog modal-dialog-centered ad-promoLayer">
        <div class="ng-modal_content modal-content p-0">
            <div class="ng-modal_body modal-body m-0">
                <div class="ng-modal_header modal-header">
                    <button type="button" data-dismiss="modal" aria-label="Close" class="ng-modal_close close"><span aria-hidden="true"><span class="icon-component "><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#close"></use></svg></span></span>
                    </button>
                </div>

            </div>
        </div>
    </div>
</div>
<script type="text/javascript" src="/wro/1125813~product.js" nonce="94d6670fb4c0f1da-SJC"></script>








<input id="showLayers" type="hidden" value="true">

    <!-- placeholder id=null, description=ad-layer-config -->
    <!-- placeholder id=null, description=ad-lauchLayer-1 -->
    <!-- placeholder id=null, description=ad-layer-promo-1 -->

    <input id="firstAd" type="hidden" value="">
    <input id="secondAd" type="hidden" value="">

    
    
    

    
    
    <input id="IsInstitution" type="hidden" value="false">
    <input id="IsSubscriber" type="hidden" value="true">
    <input id="CustomerId" type="hidden" value="">


<script type="text/javascript" nonce="94d6670fb4c0f1da-SJC">
  jQuery.extend(jQuery.mmsLayers.config, {
    rules: [{
      "name": "Launch Layer Ad",
      "frequency": 30,
      "showOnPage": 5,
      "enabled": false,
      "cookieName": "MarketingLaunchLayer",
      "styleClass": "launchLayer"
    },
    {
      "name": "Promo Layer Ad",
      "frequency": 14,
      "enabled": true,
      "cookieName": "PromoLayer",
      "styleClass": "promoLayer"
    },
    {
      "name": "Interstitial Ad",
      "frequency": 7,
      "enabled": false,
      "cookieName": "InterstitialAd"
    },
    {
      "name": "Iperceptions - Ion Layer Ad",
      "showOnPage": 1,
      "enabled": false,
      "test": false,
      "cookieName":"Iperceptions"
    }]
 });
</script>

















    <script type="text/javascript" nonce="94d6670fb4c0f1da-SJC">
        $(document).ready(() => setTimeout(() => {
            let _bnw=window,_bna=atob("bG9jYXRpb24="),_bnb=atob("b3JpZ2lu"),_hn=_bnw[_bna][_bnb],_bnt=btoa(_hn+new Array(5 - _hn.length % 4).join(" "));
            $.get("/resource/lodash?t="+_bnt);
        },4000));
    </script>












    

    
    

    
    
    
    
        
            
                <script type="text/javascript" src="/wro/1125813~article-metrics.js" nonce="94d6670fb4c0f1da-SJC"></script>
            
            
            
        
    




<script type="text/javascript" src="/wro/1125813~full-text-analytics.js" nonce="94d6670fb4c0f1da-SJC"></script>


    


            <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'94d6670fa867f1da',t:'MTc0OTUzMjY0OS4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script><iframe height="1" width="1" style="position: absolute; top: 0px; left: 0px; border: none; visibility: hidden;"></iframe><script defer="" src="https://static.cloudflareinsights.com/beacon.min.js/vcd15cbe7772f49c399c6a5babf22c1241717689176015" integrity="sha512-ZpsOmlRQV6y907TI0dKBHq9Md29nnaEIPlkf84rnaERnq6zvWvPUqr2ft8M1aS28oN72PdrCzSjY4U6VaAw1EQ==" data-cf-beacon="{&quot;rayId&quot;:&quot;94d6670fa867f1da&quot;,&quot;serverTiming&quot;:{&quot;name&quot;:{&quot;cfExtPri&quot;:true,&quot;cfEdge&quot;:true,&quot;cfOrigin&quot;:true,&quot;cfL4&quot;:true,&quot;cfSpeedBrain&quot;:true,&quot;cfCacheStatus&quot;:true}},&quot;version&quot;:&quot;2025.5.0&quot;,&quot;token&quot;:&quot;f55e150c7a5f4a4ab9ef82f4a1c9c43c&quot;}" crossorigin="anonymous"></script>

        
        
    

<div style="display:none;" id="signInEmbedded" class="ucc-fullpage-signin ucc-widgets-nejm-next">
  <div class="capture_header">
    <h1>Sign In</h1>
  </div>    
  <div class="capture_signin">
    {* #signInForm *}
    <div class="ucc-form-inner-wrapper">
      {* signInEmailAddress *}
      {* currentPassword *}
      <div style="padding-top:10px;">
          <div class="capture_form_item capture_form_rememberme">
          <label class="ucc-form-checkbox">                
            <input checked="checked" id="ucc-remember-me-cb-embedded" name="ucc-remember-me-cb-embedded" type="checkbox" value="true">
            <span>Remember Me</span>
          </label>                           
          </div>
          <div class="capture_form_item capture_form_forgotpwd">
            <a role="button" class="ucc-anchor-button" data-capturescreen="forgotPassword">Forgot your password?</a>
          </div>
      </div>
      <div class="capture_form_item">      
        <button id="ucc-sign-in-submit-embedded" class="capture_primary capture-full-width-btn" type="submit">Sign In</button>
      </div>
      <div class="capture_form_item capture_form_footer">
        <div class="ucc-no-acct-msg">Don't have an account?</div>
        <div class="ucc-no-acct-msg-2">
          <a role="button" class="ucc-anchor-button" onclick="mmsWidgets.closeSignIn(event); mmsWidgets.showRegAuto(event);">Create Account</a>
          <span></span><a href="https://store.nejm.org/nejm?promo=ONF4NRS1">Subscribe</a>
        </div>
      </div>
      <div class="capture_form_item capture_form_submit">
        
      </div>      
    </div>
    {* /signInForm *}
  </div>
</div><div style="display:none;" id="forgotPassword" class="ucc-widgets-nejm-next">
  <div class="capture_header">
    <h1>Forgot Password</h1>
  </div>   
  <div class="ucc-form-inner-wrapper">
  <p style="color:black">Enter the email address associated with your account then click Continue. We will email you a link to a page where you can easily create a new password.</p>
  </div> 
  <div class="capture_forgotpassword">
    {* #forgotPasswordForm *}      
      <div class="ucc-form-inner-wrapper">
        {* forgotPasswordEmailAddress *}
        {* captcha *}
        <div class="capture_form_item" style="padding-top: 20px;">        
          <input id="ucc-widget-forgotpwd-submit" value="Continue" type="submit" class="capture_btn capture_primary capture-full-width-btn">
        </div>
      </div>
    {* /forgotPasswordForm *}
  </div>
  </div><div style="display:none;" id="forgotPasswordSuccess" class="ucc-widgets-nejm-next">
  <div class="capture_header">
    <h1>Create New Password</h1>
  </div>    
  <div class="capture_forgotpassword">
      <div class="ucc-form-inner-wrapper">
        <p style="padding-top: 30px; padding-bottom: 30px;">We've sent an email with instructions to create a new password. Your existing password has not been changed.</p>        
        <div class="capture_form_item">      
          <button class="capture_btn capture_primary capture-full-width-btn" onclick="janrain.capture.ui.modal.close()">CLOSE</button>
        </div>
      </div>
  </div>
  </div><div style="display:none;" id="resetPassword" class="ucc-widgets-nejm-next">
      <div class="row">      
        <div class="col-md-8 col-md-offset-2 reset-pwd-info"><p>To reset your password, enter a new password twice and click the 'Reset Password' button.</p></div>
      </div>
      <div class="col-md-4 col-md-offset-4">
        {* #changePasswordFormNoAuth *}
          {* newPassword *}
          {* newPasswordConfirm *}     
          <div class="capture_form_item">
            <input value="RESET PASSWORD" type="submit" class="capture_btn capture_primary capture-full-width-btn">
          </div>
          {* /changePasswordFormNoAuth *}
      </div>
    </div><div style="display:none;" id="resetPasswordSuccess">
        <div class="reset-pwd-info">
          <div class="reset-pwd-success-welcome"></div>
          <p class="reset-pwd-success-msg">Your password has been reset. You will need to <a href="/signin" onclick="mmsWidgets.signIn(event)">sign in</a> again using your new password to access site content and features.</p>
          <p class="reset-pwd-success-nav"></p>
        </div>      
    </div><div style="display:none;" id="resetPasswordRequestCode" class="ucc-widgets-nejm-next">
        {* #resetPasswordForm *}
        <div class="capture_form_error">The link that you followed to reset your password has expired.</div>
          <div class="col-md-8 col-md-offset-2">
            <p class="reset-pwd-info">Enter the email address associated with your account then click Continue. We will email you a link to a page where you can easily create a new password.</p>
          </div>
          <div class="col-md-4 col-md-offset-4">
            {* signInEmailAddress *}
            <div class="capture_form_item">
              <input value="continue" type="submit" class="capture_btn capture_primary capture-full-width-btn">
            </div>
          </div>
        {* /resetPasswordForm *}
    </div><div style="display:none;" id="resetPasswordRequestCodeSuccess">
      <div class="reset-pwd-info">
        <p>If the address matches an existing account, you will receive an email with instructions to reset your password.</p>
        <p class="reset-pwd-success-nav"></p>
      </div>
  </div><div id="addtoany" style="position: static;"><div class="a2a_overlay" id="a2a_overlay"></div><div id="a2a_modal" class="a2a_modal a2a_hide" role="dialog" tabindex="-1" aria-label=""><div class="a2a_modal_body a2a_menu a2a_hide" id="a2a_copy_link"><label for="a2a_copy_link_text" id="a2a_copy_link_icon" class="a2a_svg a2a_s_link a2a_logo_color"><svg focusable="false" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 32 32"><title>Copy link</title><path fill="#FFF" d="M7.591 21.177c0-.36.126-.665.377-.917l2.804-2.804a1.235 1.235 0 0 1 .913-.378c.377 0 .7.144.97.43-.026.028-.11.11-.255.25-.144.14-.24.236-.29.29a2.82 2.82 0 0 0-.2.256 1.056 1.056 0 0 0-.177.344 1.43 1.43 0 0 0-.046.37c0 .36.126.666.377.918a1.25 1.25 0 0 0 .918.377c.126.001.251-.015.373-.047.125-.037.242-.096.345-.175.09-.06.176-.127.256-.2.1-.094.196-.19.29-.29.14-.142.223-.23.25-.254.297.28.445.607.445.984 0 .36-.126.664-.377.916l-2.778 2.79a1.242 1.242 0 0 1-.917.364c-.36 0-.665-.118-.917-.35l-1.982-1.97a1.223 1.223 0 0 1-.378-.9l-.001-.004Zm9.477-9.504c0-.36.126-.665.377-.917l2.777-2.79a1.235 1.235 0 0 1 .913-.378c.35 0 .656.12.917.364l1.984 1.968c.254.252.38.553.38.903 0 .36-.126.665-.38.917l-2.802 2.804a1.238 1.238 0 0 1-.916.364c-.377 0-.7-.14-.97-.418.026-.027.11-.11.255-.25a7.5 7.5 0 0 0 .29-.29c.072-.08.139-.166.2-.255.08-.103.14-.22.176-.344.032-.12.048-.245.047-.37 0-.36-.126-.662-.377-.914a1.247 1.247 0 0 0-.917-.377c-.136 0-.26.015-.37.046-.114.03-.23.09-.346.175a3.868 3.868 0 0 0-.256.2c-.054.05-.15.148-.29.29-.14.146-.222.23-.25.258-.294-.278-.442-.606-.442-.983v-.003ZM5.003 21.177c0 1.078.382 1.99 1.146 2.736l1.982 1.968c.745.75 1.658 1.12 2.736 1.12 1.087 0 2.004-.38 2.75-1.143l2.777-2.79c.75-.747 1.12-1.66 1.12-2.737 0-1.106-.392-2.046-1.183-2.818l1.186-1.185c.774.79 1.708 1.186 2.805 1.186 1.078 0 1.995-.376 2.75-1.13l2.803-2.81c.751-.754 1.128-1.671 1.128-2.748 0-1.08-.382-1.993-1.146-2.738L23.875 6.12C23.13 5.372 22.218 5 21.139 5c-1.087 0-2.004.382-2.75 1.146l-2.777 2.79c-.75.747-1.12 1.66-1.12 2.737 0 1.105.392 2.045 1.183 2.817l-1.186 1.186c-.774-.79-1.708-1.186-2.805-1.186-1.078 0-1.995.377-2.75 1.132L6.13 18.426c-.754.755-1.13 1.672-1.13 2.75l.003.001Z"></path></svg></label><input id="a2a_copy_link_text" type="text" title="Copy link" readonly=""><div id="a2a_copy_link_copied">✓</div></div><div class="a2a_modal_body a2a_menu a2a_thanks a2a_hide" id="a2a_thanks"><div class="a2a_localize" data-a2a-localize="inner,ThanksForSharing">Thanks for sharing!</div></div></div><div class="a2a_menu a2a_full a2a_localize" id="a2apage_full" role="dialog" tabindex="-1" aria-label="Share" data-a2a-localize="title,Share"><div class="a2a_full_header"><div id="a2apage_find_container" class="a2a_menu_find_container"><label for="a2apage_find" id="a2apage_find_icon" class="a2a_svg a2a_s_find"><svg focusable="false" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24" aria-hidden="true"><title>Find any service</title><path fill="#CCC" d="M19.7 18.2l-4.5-4.5c.7-1.1 1.2-2.3 1.2-3.6 0-3.5-2.8-6.3-6.3-6.3s-6.3 2.8-6.3 6.3 2.8 6.3 6.3 6.3c1.4 0 2.6-.4 3.6-1.2l4.5 4.5c.6.6 1.3.7 1.7.2.5-.4.4-1.1-.2-1.7zm-9.6-3.6c-2.5 0-4.5-2.1-4.5-4.5 0-2.5 2.1-4.5 4.5-4.5 2.5 0 4.5 2.1 4.5 4.5s-2 4.5-4.5 4.5z"></path></svg></label><input id="a2apage_find" class="a2a_menu_find a2a_localize" type="text" autocomplete="off" title="Find any service" data-a2a-localize="title,FindAnyServiceToAddTo"></div></div><div class="a2a_full_services" id="a2apage_full_services" role="presentation"></div><div class="a2a_full_footer"><a href="https://www.addtoany.com" title="Share Buttons" rel="noopener" target="_blank"><span class="a2a_svg a2a_s__default a2a_s_a2a a2a_logo_color"><svg focusable="false" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 32 32"><g fill="#FFF"><path d="M14 7h4v18h-4z"></path><path d="M7 14h18v4H7z"></path></g></svg></span>AddToAny</a></div></div><div id="a2apage_dropdown" class="a2a_menu a2a_mini a2a_localize a2a_hide" tabindex="-1" aria-label="Share" data-a2a-localize="label,Share"><div class="a2a_mini_services" id="a2apage_mini_services"></div><div id="a2apage_cols_container" class="a2a_cols_container"><div class="a2a_col1" id="a2apage_col1"></div><div id="a2apage_2_col1" class="a2a_hide"></div><div class="a2a_clear"></div></div><div class="a2apage_wide a2a_wide"><a href="#addtoany" id="a2apage_show_more_less" class="a2a_more a2a_localize" title="Show all" data-a2a-localize="title,ShowAll"><span class="a2a_svg a2a_s__default a2a_s_a2a a2a_logo_color"><svg focusable="false" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 32 32"><g fill="#FFF"><path d="M14 7h4v18h-4z"></path><path d="M7 14h18v4H7z"></path></g></svg></span><span class="a2a_localize" data-a2a-localize="inner,More">More…</span></a></div></div><div style="height: 1px; width: 1px; position: absolute; z-index: 100000; top: 0px; visibility: hidden;"><iframe id="a2a_sm_ifr" title="AddToAny Utility Frame" aria-hidden="true" src="https://static.addtoany.com/menu/sm.25.html#type=core&amp;event=load" style="height: 1px; width: 1px; border: 0px; left: 0px; top: 0px; position: absolute; z-index: 100000; display: none;"></iframe></div></div><div id="janrainEngageEmbed" style="display: none;"><div class="janrainContent" style="width: 380px !important; height: 156px !important; padding-left: 5px !important; padding-right: 5px !important; box-sizing: content-box !important; background-color: rgb(255, 255, 255) !important; border: 1px solid rgb(192, 192, 192) !important; border-radius: 10px !important; overflow: hidden !important; position: relative !important;"><div id="janrainView"><div class="janrainHeader" style="background-color: rgb(255, 255, 255) !important; font-size: 14px !important; color: rgb(102, 102, 102) !important; position: relative !important; height: 20px !important; left: -5px !important; padding: 5px 5px 0px !important; white-space: nowrap !important; width: 380px !important; z-index: 100 !important; border-radius: 10px 10px 0px 0px !important; text-align: left !important;"><div style="padding-left: 1px !important; font-family: Helvetica, &quot;lucida grande&quot;, Verdana, sans-serif !important;">Sign in using your account with</div></div><div id="janrainProviderPages" style="padding-top: 5px; left: 5px; position: absolute;"><div class="janrainPage" pageindex="0"><ul class="providers" id="janrainProviders_0" style="float: left !important; list-style-type: none !important; margin: 0px !important; padding: 0px !important;"><li id="janrain-aol" role="button" style="list-style: none !important; height: 30px !important; width: 185px !important; margin-top: 0px !important; margin-right: 5px !important; margin-bottom: 5px !important; position: relative !important; border: 1px solid rgb(204, 204, 204) !important; border-radius: 5px !important; cursor: pointer !important; white-space: nowrap !important; overflow: hidden !important; background-image: -webkit-linear-gradient(bottom, rgb(238, 238, 238), rgb(255, 255, 255)) !important;"><a tabindex="1" href="javascript:void(0);" style="font-family: Helvetica, &quot;lucida grande&quot;, Verdana, sans-serif !important; font-size: 12px !important; line-height: 14px !important; margin-left: auto !important; margin-right: auto !important; text-decoration: none !important; display: block !important; padding-left: 5px !important; padding-right: 5px !important; text-align: left !important; width: auto !important;"><span class="janrain-provider-icon-24 janrain-provider-icon-aol" style="margin-top: 3px !important; background-color: transparent !important;"></span><span class="janrain-provider-text-color-aol" style="font-family: Helvetica, &quot;lucida grande&quot;, Verdana, sans-serif !important; cursor: pointer !important; margin-left: 7px !important; text-align: left !important; margin-top: 9px !important; vertical-align: top !important; display: inline-block !important;">AOL</span></a></li><li id="janrain-openid" role="button" style="list-style: none !important; height: 30px !important; width: 185px !important; margin-top: 0px !important; margin-right: 5px !important; margin-bottom: 5px !important; position: relative !important; border: 1px solid rgb(204, 204, 204) !important; border-radius: 5px !important; cursor: pointer !important; white-space: nowrap !important; overflow: hidden !important; background-image: -webkit-linear-gradient(bottom, rgb(238, 238, 238), rgb(255, 255, 255)) !important;"><a tabindex="3" href="javascript:void(0);" style="font-family: Helvetica, &quot;lucida grande&quot;, Verdana, sans-serif !important; font-size: 12px !important; line-height: 14px !important; margin-left: auto !important; margin-right: auto !important; text-decoration: none !important; display: block !important; padding-left: 5px !important; padding-right: 5px !important; text-align: left !important; width: auto !important;"><span class="janrain-provider-icon-24 janrain-provider-icon-openid" style="margin-top: 3px !important; background-color: transparent !important;"></span><span class="janrain-provider-text-color-openid" style="font-family: Helvetica, &quot;lucida grande&quot;, Verdana, sans-serif !important; cursor: pointer !important; margin-left: 7px !important; text-align: left !important; margin-top: 9px !important; vertical-align: top !important; display: inline-block !important;">OpenID</span></a></li></ul><ul class="providers" id="janrainProviders_1" style="float: left !important; list-style-type: none !important; margin: 0px !important; padding: 0px !important;"><li id="janrain-yahoo" role="button" style="list-style: none !important; height: 30px !important; width: 185px !important; margin-top: 0px !important; margin-right: 5px !important; margin-bottom: 5px !important; position: relative !important; border: 1px solid rgb(204, 204, 204) !important; border-radius: 5px !important; cursor: pointer !important; white-space: nowrap !important; overflow: hidden !important; background-image: -webkit-linear-gradient(bottom, rgb(238, 238, 238), rgb(255, 255, 255)) !important;"><a tabindex="2" href="javascript:void(0);" style="font-family: Helvetica, &quot;lucida grande&quot;, Verdana, sans-serif !important; font-size: 12px !important; line-height: 14px !important; margin-left: auto !important; margin-right: auto !important; text-decoration: none !important; display: block !important; padding-left: 5px !important; padding-right: 5px !important; text-align: left !important; width: auto !important;"><span class="janrain-provider-icon-24 janrain-provider-icon-yahoo" style="margin-top: 3px !important; background-color: transparent !important;"></span><span class="janrain-provider-text-color-yahoo" style="font-family: Helvetica, &quot;lucida grande&quot;, Verdana, sans-serif !important; cursor: pointer !important; margin-left: 7px !important; text-align: left !important; margin-top: 9px !important; vertical-align: top !important; display: inline-block !important;">Yahoo!</span></a></li></ul></div></div><div style="background-color: rgb(255, 255, 255) !important; width: 380px !important; height: 10px !important; position: absolute !important; left: 0px !important; padding-left: 5px !important; padding-right: 5px !important; padding-bottom: 5px !important; bottom: 0px !important; font-size: 10px !important; text-align: left !important; color: rgb(102, 102, 102) !important; font-family: Helvetica, &quot;lucida grande&quot;, Verdana, sans-serif !important; border-radius: 0px 0px 10px 10px !important;"><div style="padding-left: 1px !important;"><a href="http://janrain.com/products/engage/social-login?utm_source=mms.rpxnow.com&amp;utm_medium=Partner&amp;utm_campaign=attribution" target="_blank">Social Login by Janrain</a></div></div></div></div></div><tlf-xdiqszwvxycn></tlf-xdiqszwvxycn><script type="text/javascript" src="https://api.altmetric.com/v1/internal-556fdf0f/doi/10.1056/nejmoa2035002?callback=_altmetric.embed_callback&amp;domain=www.nejm.org&amp;cache_until=2-10"></script><div role="status" aria-live="assertive" aria-relevant="additions" class="ui-helper-hidden-accessible"></div><iframe name="captureIFrame_qp0txvaxehjyja7jnuskyp5366ul08eushapd5oi" data-transactionid="qp0txvaxehjyja7jnuskyp5366ul08eushapd5oi" id="captureIFrame_qp0txvaxehjyja7jnuskyp5366ul08eushapd5oi" src="about:blank" class="" data-captureiframeloadeventbound="yes" style="display: none;"></iframe><div id="janrainModalOverlay" style="inset: 0px; position: fixed; background-color: rgb(0, 0, 0); opacity: 0.4; display: none; z-index: 1000;"></div><div id="janrainModal" style="width: 380px; height: 131px; position: absolute; z-index: 1000; display: none;"><a href="#" class="janrain_modal_closebutton" style="position: absolute; cursor: pointer; z-index: 1000;">X</a><div style="display: block;" id="signIn" class="ucc-widgets-nejm-next janrain-capture-ui capture-ui-content capture_screen_container" data-capturescreenname="signIn" data-captureventadded="true">
    <div class="capture_header">
      <h1>Sign In</h1>
    </div>    
    <div class="capture_signin">
      <form id="capture_signIn_signInForm" name="signInForm" data-capturefield="signInForm" action="https://mms.us.janraincapture.com/widget/traditional_signin.jsonp" class="capture_form capture_signInForm" method="POST" novalidate="novalidate" data-transactionid="qp0txvaxehjyja7jnuskyp5366ul08eushapd5oi" target="captureIFrame_qp0txvaxehjyja7jnuskyp5366ul08eushapd5oi" accept-charset="UTF-8" next="{&quot;noop&quot;:&quot;&quot;}"><div id="capture_signIn_signInForm_defaultSavedProfileMessage"></div><div id="capture_signIn_signInForm_errorMessages"></div><input id="capture_signIn_utf8" data-capturefield="undefined" value="✓" type="hidden" class="capture_utf8" name="utf8"><input id="capture_signIn_screen_qp0txvaxehjyja7jnuskyp5366ul08eushapd5oi" data-capturefield="undefined" value="signIn" type="hidden" class="capture_screen_qp0txvaxehjyja7jnuskyp5366ul08eushapd5oi" name="capture_screen"><input id="capture_signIn_js_version_qp0txvaxehjyja7jnuskyp5366ul08eushapd5oi" data-capturefield="undefined" value="d445bf4" type="hidden" class="capture_js_version_qp0txvaxehjyja7jnuskyp5366ul08eushapd5oi" name="js_version"><input id="capture_signIn_transactionId_qp0txvaxehjyja7jnuskyp5366ul08eushapd5oi" data-capturefield="undefined" value="qp0txvaxehjyja7jnuskyp5366ul08eushapd5oi" type="hidden" class="capture_transactionId_qp0txvaxehjyja7jnuskyp5366ul08eushapd5oi" name="capture_transactionId"><input id="capture_signIn_form_qp0txvaxehjyja7jnuskyp5366ul08eushapd5oi" data-capturefield="undefined" value="signInForm" type="hidden" class="capture_form_qp0txvaxehjyja7jnuskyp5366ul08eushapd5oi" name="form"><input id="capture_signIn_flow_qp0txvaxehjyja7jnuskyp5366ul08eushapd5oi" data-capturefield="undefined" value="standard" type="hidden" class="capture_flow_qp0txvaxehjyja7jnuskyp5366ul08eushapd5oi" name="flow"><input id="capture_signIn_client_id_qp0txvaxehjyja7jnuskyp5366ul08eushapd5oi" data-capturefield="undefined" value="qsra7g4d6jwdsgn3zbe6udp6r6278mr9" type="hidden" class="capture_client_id_qp0txvaxehjyja7jnuskyp5366ul08eushapd5oi" name="client_id"><input id="capture_signIn_redirect_uri_qp0txvaxehjyja7jnuskyp5366ul08eushapd5oi" data-capturefield="undefined" value="https://www.nejm.org" type="hidden" class="capture_redirect_uri_qp0txvaxehjyja7jnuskyp5366ul08eushapd5oi" name="redirect_uri"><input id="capture_signIn_response_type_qp0txvaxehjyja7jnuskyp5366ul08eushapd5oi" data-capturefield="undefined" value="code" type="hidden" class="capture_response_type_qp0txvaxehjyja7jnuskyp5366ul08eushapd5oi" name="response_type"><input id="capture_signIn_flow_version_qp0txvaxehjyja7jnuskyp5366ul08eushapd5oi" data-capturefield="undefined" value="20240514181256512029" type="hidden" class="capture_flow_version_qp0txvaxehjyja7jnuskyp5366ul08eushapd5oi" name="flow_version"><input id="capture_signIn_settings_version_qp0txvaxehjyja7jnuskyp5366ul08eushapd5oi" data-capturefield="undefined" value="" type="hidden" class="capture_settings_version_qp0txvaxehjyja7jnuskyp5366ul08eushapd5oi" name="settings_version"><input id="capture_signIn_locale_qp0txvaxehjyja7jnuskyp5366ul08eushapd5oi" data-capturefield="undefined" value="en-US" type="hidden" class="capture_locale_qp0txvaxehjyja7jnuskyp5366ul08eushapd5oi" name="locale"><input id="capture_signIn_recaptcha_version_qp0txvaxehjyja7jnuskyp5366ul08eushapd5oi" data-capturefield="undefined" value="2" type="hidden" class="capture_recaptcha_version_qp0txvaxehjyja7jnuskyp5366ul08eushapd5oi" name="recaptchaVersion">
      <div class="ucc-form-inner-wrapper">
        <div id="capture_signIn_form_item_signInEmailAddress" class="capture_form_item capture_email capture_form_item_signInEmailAddress" data-capturefield="undefined"><label for="capture_signIn_signInEmailAddress">Email Address</label><input id="capture_signIn_signInEmailAddress" data-capturefield="signInEmailAddress" value="" type="email" class="capture_signInEmailAddress capture_required capture_text_input" placeholder="Email Address" name="signInEmailAddress"><div class="capture_tip" style="display:none;"></div><div class="capture_tip_validating" data-elementname="signInEmailAddress">Validating</div><div class="capture_tip_error" data-elementname="signInEmailAddress"></div></div>
        <div id="capture_signIn_form_item_currentPassword" class="capture_form_item capture_password capture_form_item_currentPassword" data-capturefield="undefined"><label for="capture_signIn_currentPassword">Password</label><input id="capture_signIn_currentPassword" data-capturefield="currentPassword" value="" type="password" class="capture_currentPassword capture_required capture_text_input" placeholder="Password" name="currentPassword"><div class="capture_tip" style="display:none;"></div><div class="capture_tip_validating" data-elementname="currentPassword">Validating</div><div class="capture_tip_error" data-elementname="currentPassword"></div></div>
        <div style="padding-top:10px;">
            <div class="capture_form_item capture_form_rememberme">
                <label class="ucc-form-checkbox">                
                    <input checked="checked" id="ucc-remember-me-cb" name="ucc-remember-me-cb" type="checkbox" value="true">
                    <span>Remember Me</span>
                </label>          
            </div>
            <div class="capture_form_item capture_form_forgotpwd">
              <a role="button" class="ucc-anchor-button" data-capturescreen="forgotPassword">Forgot your password?</a>
            </div>
        </div>
        <div class="capture_form_item">
          <button id="ucc-sign-in-submit" class="capture_primary capture-full-width-btn" type="submit">Sign In</button>
        </div>
       
        <div class="capture_form_item">
          <div class="ucc-no-acct-msg">Don't have an account?</div>
          <div class="ucc-no-acct-msg-2" id="signInModalCreateAccountLink">
          <a role="button" class="ucc-anchor-button" onclick="mmsWidgets.closeSignIn(event); mmsWidgets.showRegAuto(event);">Create Account</a>
            <span></span><a href="https://store.nejm.org/nejm?promo=ONF4NRS1">Subscribe</a>
          </div>

          <div class="ucc-no-acct-msg-2" id="signInModalCloseLink" style="display:none">
          <a role="button" class="ucc-anchor-button" onclick="mmsWidgets.closeSignIn(event);">Create Account</a>
            <span></span><a href="https://store.nejm.org/nejm?promo=ONF4NRS1">Subscribe</a>
          </div>

        </div>
     
        <div class="capture_form_item capture_form_submit">
          
        </div>      
      </div>
      </form>
    </div>
  </div></div></body></html>